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Abstract 
Background -Vascular smooth muscle forms the media layer of blood 
vessels and is responsible for maintaining total peripheral resistance, an 
integral factor in blood pressure. Relaxation of vascular smooth muscle, which 
increases vessel lumen diameter and decreases resistance, is brought about 
by a decrease in cytoplasmic Ca2+ and/or a decrease in the Ca2+ sensitivity of 
contractile proteins. Relaxation can be initiated by vasoactive transmitters 
working via the activation of G-protein coupled receptors; with the downstream 
effects being attributed to the action of numerous signalling mediators.  
Exchange protein directly activated by cAMP (Epac), a major effector for the 
second messenger 3'-5'-cyclic adenosine monophosphate (cAMP), has 
recently been shown to be involved in a novel vascular relaxation pathway that 
increases the frequency of localised Ca2+ release from intracellular stores in 
vascular smooth muscle.  
Methods – Multiple biochemical techniques such as immunoblotting 
and immunoprecipitation were used to assess cellular signalling pathways 
involved in Epac activation. Patch clamping was used in the whole cell format 
to record the electrical currents regulated by Epac activation. 
Results - In immunoblots of rat mesenteric artery lysates, pretreatment 
with 8-(4-chloro-phenylthio)-2´-O-methyladenosine-3´, 5’-cyclic 
monophosphate-AM (8-pCPT-AM), a selective Epac activating cAMP 
analogue, induced phosphorylation of calcium/calmodulin-dependent kinase 2 
(CaMKII) at position Thr286/7, an autophosphorylation site that indicates 
CaMKII activation. Epac activation preferentially induced auto-phosphorylation 
of specific CaMKII gamma (g) isoform/s, as shown by CamKIIg and CamKII 
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delta (d) isoform knock out mice.  In whole-cell recordings from isolated rat 
mesenteric artery myocytes, inhibition of CaMKII reversed the increase in 
STOC frequency and amplitude induced by 8-pCPT-AM. Epac-induced 
CaMKII activation is probably initiated by inositol 1, 4, 5-trisphosphate (IP3)-
mobilized Ca2+: 8-pCPT-AM failed to induce CaMKII activation following 
intracellular Ca2+ store depletion and inhibition of IP3 receptors blocked both 
8-pCPT-AM-mediated CaMKII phosphorylation and STOC activity.  
Conclusion - Epac-mediated STOC activity occurs via activation of 
specific isoforms of CaMKII activated by IP3-mediated Ca2+ release and is 
driven by changes in the underlying kinetic behaviour of RyR channels. To our 
knowledge, this is the first report of CaMKII initiating cellular activity linked to 
vasorelaxation and suggests novel roles for this Ca2+ and redox-sensing 
enzyme in the regulation of vascular tone and blood flow.  
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1 Introduction  
1.1 The Vasculature 
The vasculature in mammals is organised into three main types of blood 
vessel; arteries, capillaries and veins. The function of arteries is to deliver 
blood to organs in the body, and they fall into two general categories based on 
the size of their relaxed lumen. Conduit arteries possess a relaxed luminal 
diameter of >400µm and are responsible for absorption of pressure pulses 
produced by the pumping of the heart muscle (O’Rourke 1995). These arteries 
have a low ratio of wall thickness:diameter with large amounts of elastin and 
collagen and moderate amounts of vascular smooth muscle (Shadwick 1999). 
Resistance arteries possess a resting diameter ranging between 400µm and 
~100µm (Intengan & Schiffrin 2000; Schiffrin 1992). These arteries have a 
higher ratio of wall thickness:diameter and contain large amounts of muscle 
with lower levels of elastin and collagen compared to conduit arteries. 
Resistance arteries are the primary site of vascular resistance since 
contraction and relaxation of vascular smooth muscle within these vessels 
regulates lumen diameter and controls blood flow and distribution between and 
within tissues.  As blood pressure is proportional to cardiac output and 
peripheral vascular resistance, the resistance produced by vascular smooth 
muscle contraction controls blood pressure (Intengan & Schiffrin 2000). 
Resistance is determined using Poiseuille’s law, including parameters such as 
vessel length, vessel radius and blood viscosity (Sutera & Skalak 1993).  
Blood Pressure µ Cardiac Output x Total Peripheral Resistance 
  
22 
 After blood passes through large resistance arteries responsible for 
delivering blood to organs it drains into arterioles which, together with venules, 
control intracapillary pressure to keep capillaries open or closed (Gardner & 
Fox 2001). Capillaries are endothelial tubes with no nerve innervations and 
are key in allowing the movement of oxygen, nutrients and hormones to tissues 
via the extracellular fluid. After flowing through capillaries and then venules, 
blood enters veins which possess little muscle and are thought of as blood 
reservoirs. Veins, unlike arteries and capillaries, possess valves which inhibit 
retrograde flow of blood.  
1.1.1 Smooth Muscle Tone 
Vascular smooth muscle is categorised as tonic smooth muscle,  in that it has 
properties of slow and sustained contraction that may be maintained with 
minimal energy (Khalil 2010; Baker et al. 2003). This is compared to phasic 
smooth muscle, such as gastrointestinal and uterine smooth muscle, which 
produce phasic contractions and relaxations (Fisher 2010). The level of 
contraction experienced by an artery relative to its fully dilated state (referred 
to as vascular tone) is determined by the balance of vasodilating and 
vasoconstricting influences. 
As with other muscle, the contractile apparatus is made up of myosin motor 
proteins that induce contraction by moving along a framework of actin 
filaments.  Unlike skeletal and cardiac muscle, there is no regular, striated 
arrangement of actin and myosin (hence the name ‘smooth’ muscle), and actin 
and myosin bundles are found throughout the sarcoplasm.  These bundles are 
fastened to the cell membrane by adhesion densities and anchored within the 
cytoplasm by focal densities (Young 2006).  Smooth muscle cells also do not 
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possess the Ca2+-binding protein troponin that regulates contraction in striated 
muscle. Contraction is still triggered by elevation of intracellular Ca2+ (see 
Section 1.2), but Ca2+ instead binds to calmodulin.  The Ca2+-calmodulin 
complex then activates myosin light chain kinase (MLCK), which in turn 
phosphorylates the myosin heads, initiating interaction with actin.   
1.2 Mechanism of Contraction 
A rise in intracellular Ca2+ is one of the two methods of contraction in vascular 
smooth muscle, the other being Ca2+ sensitization (discussed below). The 
Ca2+ required for activation of MLCK is produced either through intracellular 
store Ca2+ release or through influx of extracellular Ca2+ via membrane Ca2+ 
channels, such as voltage-dependent Ca2+ channels (VDCCs), store-operated 
Ca2+ channels (SOCCs), receptor-operated Ca2+ channels (ROCCs) and 
stretch-activated Ca2+ channels (SACCs). 
This rise in intracellular Ca2+ concentration, either via influx or store release, is 
predominately mediated by activation of cell-surface receptors coupled to Gq-
type, heterotrimeric guanine nucleotide binding proteins (G proteins)  (Harnett 
& Biancani 2003). The a subunit of Gq is responsible for activation of 
phospholipase C (PLC); it hydrolyses phosphatidylinositol 4,5-bisphosphate 
(PIP2) to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These two 
signalling molecules are responsible for protein kinase C (PKC) mediated Ca2+ 
entry and IP3-mediated store Ca2+ release, respectively (Khalil 2010). 
Once activated by the binding of Ca2+-calmodulin, MLCK phosphorylates 
myosin heads at position 19, producing a conformational change. This allows 
myosin heads and actin to cycle through crossbridging, due to an increase in 
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actin-activated myosin MgATPase activity (Somlyo & Somlyo 1994; Gallagher 
et al. 1991) . Removal of this position 19 phosphorylation by myosin light chain 
phosphatase (MLCP) inhibits contraction (Figure 1.1).  
Alternative mechanisms of contraction exist that do not rely on an increase in 
intracellular Ca2+ and one of these is termed ‘Ca2+ sensitization’. Ca2+ 
sensitization involves the modulation of MLCP through the downstream kinase 
of Rho-A, Rho-A-associated protein kinase (ROCK). MLCP contains three 
distinct subunits, MYPT1, PP1c and M20 (Grassie et al. 2012). ROCK 
phosphorylates the MYPT1 subunit of MLCP at positions, T696 and T853, 
which inhibits MLCP thereby reducing the amount of dephosphorylation of 
myosin (i.e. inhibits MLCP leading to contraction). ROCK is not the only kinase 
to mediate Ca2+ sensitization. PKC phosphorylates PKC potentiated inhibitor 
17 kDa protein (CPI-17), which also decreases the activity of MLCP and is 
therefore procontractile (Somlyo & Somlyo 2003; Khalil 2010). 
A third mechanism of contraction has also been explored in the vasculature, 
involving the protein family of heat shock proteins. HSP27 has been shown to 
interact with tropomyosin and caldesmon (part of the thin filament) by addition 
of a vasoconstrictive agonist (Somara & Bitar 2004). In colonic smooth muscle, 
tropomyosin involvement in contraction has been shown. Phospho-HSP27 
(induced by acetylcholine) causes a sliding of tropomyosin, allowing myosin to 
bind actin (Somara & Bitar 2004). This dissociation of tropomyosin with actin 
is dependent on phosphorylated caldesmon (Somara & Bitar 2004; Bitar et al. 
1991; Somara & Bitar 2010). 
Therefore, in essence, vascular smooth muscle contraction is produced 
through two main mechanism: 1) increase in Ca2+ and 2) increase in Ca2+ 
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sensitivity. A number of endogenous hormones and signalling molecules 
which produce contraction are discussed below. 
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1.2.1 Endogenous vasoconstrictors 
Table 1.1- Summary of common endogenous vasoconstrictors including category/structure, target receptors, release site and mechanism of action. 
Vasoconstrictor Receptor Structure Release Site Mechanism of Action References 
Adrenaline a1 Catecholamine Nerves PLC/IP3/DAG (Wu et al. 1992) 
Angiotensin II AT1 Peptide Blood Stream PLC/IP3/DAG 
Intracellular alkalisation 
Increased [Na]I and decreased [Mg2+] 
inside the cell 
(Berk et al. 1987; Griendling et 
al. 1994; Griendling et al. 
1997; Touyz & Berry 2002; 
Wynne et al. 2009) 
In depth-review (Touyz & 
Schiffrin 2000) 
ATP  P2X/Y Nucleotide Paracrine/ 
Blood Stream 
Increase Ca2+ via P2X receptor 
VDCC/Ca2+-activated Cl- channel via 
P2Y 
(Mitchell et al. 2012; Liu et al. 
1989) 
Endothelin ETA Peptide Endothelium PLC/IP3/DAG 
ROCK 
(Schneider et al. 2007; 
Kedzierski & Yanagisawa 
2001; Inoue et al. 1989; Ivey et 
al. 2008; Klöckner & Isenberg 
1991) 
Neuropeptide Y NYP Y1 Peptide Nerves Potentiate adrenaline contraction (Na+ 
influx/Ca2+ mobilization/PLC activity) 
Adrenaline independent contraction via 
Ca2+ channels 
(Franco-Cereceda & Liska 
1998; Prieto et al. 2000; 
Wahlestedt et al. 1985) 
Thromboxane 
A2 
 Hormone Platelets/ 
Endothelium 
Gq/Ca2+ influx/Ca2+ sensitivity (caudal; 
not PKC) 
PKC/ROCK/Ca2+ mobilization 
(coronary) 
(Wilson et al. 2005; Grann et 
al. 2016; Ding & Murray 2005; 
Nobe & Paul 2001; Leung et 
al. 2010) 
Vasopressin V1 Hormone Blood Stream (produced in 
posterior pituitary gland) 
>µM PLC/IP3/DAG 
<µM PKC/VDCC 
(Henderson & Byron 2007; 
Nemenoff 1998) 
Summarised in Figure 1.
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1.2.2 Stretch/Pressure 
Stretch activated channels (SACs) exist in vascular smooth muscle cells. They 
are activated by elongation of the vascular smooth muscle i.e. stretching the 
membrane. Stretch is associated with increases in an inward cation current 
which produces depolarization of cells increasing VDCC mediated Ca2+ entry 
(Zou et al. 2002). SACs themselves conduct Ca2+ with these ions activating 
RyR causing Ca2+ induced Ca2+ release (Kirber et al. 2000; Gilbert et al. 2014). 
Also activation of large conductance Ca2+-activated K+ (BKCa) channels 
hyperpolarize the cell membrane and amplify the Ca2+ entry through SACs due 
to an increased electrochemical driving force for Ca2+ (Zou et al. 2002; Gilbert 
et al. 2014). 
Myogenic tone, produced by arterial pressure within an artery causing 
elongation of smooth muscle cells is pivotal to maintaining and controlling 
blood flow to organs. Specifically, it allows a baseline level of contraction which 
can be increased or decreased. Elegant studies by Osol et al. (2002) showed 
the development of myogenic tone at 60 mmHg in cerebral arteries (Osol et al. 
2002). In this study, stepwise increments (10mmHg) from a starting pressure 
of 20mmHg showed an initial increase in diameter, before an increase in Ca2+ 
and depolarization took place to produce contraction and development of tone 
at around 60 mmHg. Increasing this pressure up to ~160mmHg does not have 
any further effect on blood vessel diameter i.e. contraction counters the 
pressure and the vessel lumen diameter does not widen (Osol et al. 2002). 
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Figure 1.1- Endogenous vasoconstrictors in the vasculature. Many vasoconstrictors use GPCR and Nicotinic receptors to produce contraction in 
vascular smooth muscle cells. These pathways aim to increase Ca2+ or increase Ca2+ sensitivity of the contractile proteins. Many endogenous 
vasoconstrictors such as adrenaline, released from nerves, work by activating Gaq coupled receptors which activate phospholipase C to produce IP3 
and DAG, both capable of producing vasoconstriction. The endothelium also produces procontractile peptides such as Endothelin which works via 
GCPRs on smooth muscle cells. More complex vasocontractile pathways are present such as alkalinisation, decreasing cAMP and Mg2+ regulation.
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1.3 Mechanisms of Vasodilation 
Relaxation of vascular smooth muscle i.e. decreasing vascular tone, is the 
opposite to contraction in that pathways aim to reduce available cytoplasmic 
[Ca2+] and decrease Ca2+ sensitivity of the contractile apparatus. Reduction of 
available cytoplasmic [Ca2+] can be through sequestration of Ca2+ to 
intracellular stores, such as the sarcoplasmic reticulum, Ca2+ extrusion via 
plasma membrane Ca2+ ATPase or decreasing voltage-dependent Ca2+ entry 
(VDCC) (Khalil 2010). Inhibition of VDCC can be brought about by 
hyperpolarisation of the membrane, through the activation of outward K+ 
currents (Somlyo & Somlyo 1994). Receptor operated channels (ROCs) and 
store operated channels (SOCs) can be inhibited by removal of the stimulus 
i.e. receptor activation or recovery of Ca2+ load, respectively. Reduction of 
available Ca2+ removes the activation of MLCK produced through Ca2+/CaM 
and therefore limits contraction (Somlyo & Somlyo 2003). The other route of 
relaxation is that of decreasing Ca2+ sensitivity. Vasodilating hormones can 
produce an increase in activity of MLCP, therefore increasing the 
dephosphorylation of myosin light chain and limiting contraction (Somlyo & 
Somlyo 2003). Most of these mechanisms, which aim at reducing Ca2+ 
availability or Ca2+ sensitivity, are initiated by phosphorylation events mediated 
by cAMP-dependent protein kinase (protein kinase A, PKA). PKA is activated 
by 3'-5'-cyclic adenosine monophosphate (cAMP), a ubiquitous second 
messenger produced by the enzyme adenylyl cyclase following activation of 
Gs-coupled cell-surface receptors (Canaves & Taylor 2002; Taylor et al. 2004; 
Kim et al. 2005; Walsh et al. 1968; Rall et al. 1956). Phosphorylation targets 
of PKA in vasodilation, include ion channels, MLCP and heat shock proteins.  
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Indeed, many endogenous vasodilators responsible for maintaining the 
vascular tone of arteries work through PKA mediated signalling pathways and 
are summarised in Section 1.3.1 and Table 1.2. A number of endogenous 
vasodilators also utilise cGMP pathways, activating PKG and producing 
vasodilation through downstream phosphorylation of PKG targets. This is a 
common pathway by which nitric oxide produces relaxation, through activation 
of guanylyl cyclase increasing cGMP in smooth muscle cells. 
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1.3.1 Endogenous Vasodilator 
Table 1.2- Endogenous vasodilators summarising target receptor, type of structure, release site and mechanism of action. 
Vasorelaxant Receptor Structure Release Site Mechanism of Action References 
Adenosine A1/2 Hormone Cells 
cAMP/PKA (AT2) 
Decrease cAMP (AT1) 
cAMP/Ca2+/NO 
(Kleppisch & Nelson 1995; Dart & 
Standen 1993; K. T. Cheng et al. 2008; 
Karczewski et al. 1998) 
Adrenaline b2 Catecholamine Nerves 
cAMP/PKA in VSMC 
cAMP independent signalling 
cAMP/PKA/eNOS/NO in endothelium 
(Butt et al. 2000; Ferro et al. 2004; Queen 
& Ferro 2006; Tanaka et al. 2005) 
ATP Endothelial P2Y Nucleotide Platelets/Cells 
Ca2+/NO 
cAMP? 
(Mitchell et al. 2012; Shah et al. 2001; 
Kaiser et al. 2002) 
Calcitonin-gene 
related peptide CGRP1 Peptide Peptide 
cAMP/PKA in VSMC 
cAMP/PKA/eNOS/NO in endothelium 
(Y Hayabuchi, Dart, et al. 2001; Brain & 
Grant 2004) 
Endothelin Endothelial ETB Peptide 
Endotheliu
m NO production 
(Schneider et al. 2007; Kedzierski & 
Yanagisawa 2001; Filep et al. 1993; 
Pollock 2001; Kisanuki et al. 2010) 
Vasoactive 
intestinal 
polypeptide 
VDAC1/2 Peptide Nerves cAMP/PKA NO 
(Yang et al. 2008; Ergün & Oğülener 
2001; Henning & Sawmiller 2001; Severi 
et al. 2006; D’Amato et al. 1992) 
 Endothelial Derived Relaxant Factors (Reviewed Edwards 2010 (Edwards et al. 2010)) 
Nitric Oxide (EDRF) Guanylyl Cyclase (GC) N/A 
Endotheli
um 
NO released by endothelial cell acts on GC 
activating PKG 
(Murad et al. 1978; Palmer et al. 1987; 
Furchgott & Zawadzki 1980) 
Endothelial derived 
hyperpolarisng 
factor (EDHF) 
N/A N/A 
Extracellular K+ increase leads to 
hyperpolarization via Na+/K+ exchanger and 
Kir family. 
Spread of hyperpolarization from 
endothelial cells to VSMC via gap junctions. 
(Edwards et al. 1998; Richards et al. 
2001) 
 
(Garland et al. 2011; Yamamoto et al. 
1999; Sonkusare et al. 2012) 
11,12 epoxyeico- 
satrienoic acid 
(EET) 
TRPV4? Acid Activate TRPV4 increase Ca2+ sparks (Filosa et al. 2013; Earley et al. 2005; Earley et al. 2009) 
Prostacyclin IP receptors  cAMP/PKA (Karczewski et al. 1998; Parkington et al. 2004; Edwards et al. 2010) 
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1.3.2 Ca2+ Sparks 
Within smooth muscle cells an important caveat exists in regards to increases 
in Ca2+ producing contraction, whereby local releases of Ca2+ counter 
intuitively elicit relaxation (Nelson et al. 1995). These local releases of Ca2+ 
are termed “Ca2+ sparks” and can be up to 10µM in concentration (Jaggar et 
al. 2000; Nelson et al. 1995; Zhuge et al. 2002). In smooth muscle Ca2+ influx 
through VDCCs leads to an increase in Ca2+ store load, increasing the 
frequency of Ca2+ sparks (Essin et al. 2007; Collier et al. 2000; ZhuGe et al. 
1999). These Ca2+ sparks are produced by Ca2+ release from ryanodine-
sensitive Ca2+ release channels (RyRs) located on the sarcoplasmic reticulum 
(Vaithianathan et al. 2010). Ryanodine receptors are named due to their 
inhibition by the plant alkaloid ryanodine. Ca2+ sparks produce both contractile 
and relaxant effects by activating Ca2+ activated Cl- channels or Ca2+ activated 
K+ channels (BKCa) , respectively (ZhuGe et al. 1998).  These activations of 
BKCa channels are termed spontaneous transient outward currents, or STOCs 
(Jaggar et al. 1998). Importantly, these STOCs carrying a large outward 
current of K+, which leads to a hyperpolarisation of the cell membrane and a 
decrease in Ca2+ entry via VDCCs, lowering global [Ca2+], leading to 
vasorelaxation. Indeed inhibition of RyRs, with ryanodine, to pressurised 
arteries causes vasoconstriction showing the importance of STOCs in vascular 
tone regulation (Nelson et al. 1995). Ca2+ sparks and with them STOCs can 
be modulated by cAMP and cAMP-raising endogenous agonists, such as 
adenosine (Porter et al. 1998). STOC frequency is also increased by 
depolarisation, induced by elevations in pressure (Jaggar 2001). 
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1.3.3 Shear stress induced vasorelaxation 
Under shear stress, produced by the dragging force generated by blood flow, 
numerous pathways are involved in flow-induced vasodilation including the 
integrin pathway, which produces NO by PKA mediated or Akt mediated 
phosphorylation of eNOS (Boo et al. 2002; Dimmeler et al. 1999), prostacyclin 
release via cyclooxygenase (COX) or inhibition of Nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (Lu & Kassab 2011). The ion 
channel TRPV4 has also been shown to be flow sensitive; activation increases 
both the classical NO dependent vasodilation and the novel endothelial 
derived-hyperpolarising factor (EDHF) pathway (Filosa et al. 2013; Sonkusare 
et al. 2012; Mendoza et al. 2010).
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Figure 1.2- Endogenous Vasodilators. Numerous vasodilators use cAMP to activate PKA and cause relaxation, including Gs coupled GPCRs such as b 
adrenoceptors and calcitonin gene-related peptide receptor. cAMP can also activate PKG as depicted by the dotted line, as can cGMP activate PKA.   Many 
vasodilators use the endothelium as a source of Nitric Oxide to produce relaxation, such as muscarinic 3 receptors which increase Ca2+ in the endothelial cell 
and activates eNOS to produce NO. This NO can then increase cGMP and activate PKG or PKA (cross over annotated using dotted line). The rise in [Ca2+] in 
endothelial cells also activates Ca2+ activated K+ channels causing a hyperpolarisation of the cell which spreads to VSMC through gap junctions. The K+ “cloud” 
from such channels also causes hyperpolarisation through increasing the outward current K+ current of Inward-rectifying K+ channels such as Kir2
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1.4 cAMP Signalling Overview 
A common and generally conserved feature of vasorelaxant pathways 
is the use of the second messenger cAMP to convey the relaxant signal from 
cell-surface receptors to downstream effectors (Table 1.2 and Figure 1.2).  
1.4.1 History 
cAMP is a small, diffusible nucleotide first identified as an intracellular second 
messenger by Sutherland and Rall (Rall et al. 1956) in 1956, who suggested 
that a membrane-bound receptor must mediate the activation of liver 
phosphorylase in the cytoplasm by a heat stable factor. This was 
demonstrated by separating membrane and cytoplasmic fractions of the liver 
and treating the membrane fraction with adrenaline. Membranes were then 
removed by centrifugation and the soluble supernatant was added to the 
original cytoplasmic fraction. Addition of this supernatant increased 
phosphorylation of liver phosphorylase and gave the first indication that a 
soluble heat resistant messenger molecule was present (Rall et al. 1956). 
Later, research showed that this second messenger was cAMP and was 
produced from heart, liver and brain particulate fractions (Sutherland & Rall 
1958). Further research by Sutherland and Rall identified an enzyme 
(phosphodiesterase) that, particularly in brain homogenates, converted cAMP 
to 5’-AMP. These phosphodiesterases were inhibited by caffeine and 
dependent on Mg2+ (Sutherland & Rall 1958). Since its original discovery, the 
production (by adenylyl cyclases) and destruction (by phosphodiesterases) of 
cAMP has been extensively explored.  
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1.4.2 Adenylyl Cyclases 
Activation of Gs coupled receptors present in the membrane causes GTP 
recruitment and dissociation of the heterotrimeric G protein (a,b and g 
subunits). Gas produces an increase in cAMP through activation of adenylyl 
cyclase, which produces cAMP by converting ATP in the presence of Mg2+ into 
cAMP and pyrophosphate (Garrett & Grisham 2012).  Ten isoenzymes of 
adenylyl cyclase are known, 9 membrane bound and a single soluble isoform 
(sAC) (Hanoune & Defer 2001). Adenylyl cyclase isoenzymes are each 
regulated differently, for instance certain isoenzymes are inhibited by Ca2+ 
(AC5/6), whereas AC3 is inhibited by calcium/calmodulin-dependent protein 
kinase II (CaMKII) (Hayn et al. 2010; Hanoune & Defer 2001) (Table 1.3).  
 
Isoform Activators Inhibitors 
1 Gas, Fsk, Ca2+, PKC Gai 
2 Gas , Fsk, PKC Ca
2+, CaMKIV 
3 Gas , Fsk, Ca2+(in vitro), PKC Gai , CaMKII 
4 Gas , Fsk, PKC  
5 Gas , Fsk, PKC Gai, Ca2+, PKA 
6 Gas , Fsk Gai, Ca2+, PKC, PKA 
7 Gas , Fsk, PKC  
8 Gas , Fsk, Ca2+ Gai 
9 Gas , Fsk (weak) GaI, Calcineruin,  
Soluble Mn2+ , Ca2+, HCO3- (Tresguerres et 
al. 2011) 
 
Table 1.3- Adenylyl Cyclase regulation. Unless stated, data was taken from Hanoune 
and Defer (2001) (Hanoune & Defer 2001). Fsk denotes Forskolin a commonly used 
adenylyl cyclase activator. 
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Vascular smooth muscle expresses isoforms 3,5 and 6 as assessed by mRNA 
analysis and immunoblotting (Ostrom et al. 2002; Nelson et al. 2011); AC7 
expression has only been shown by mRNA analysis from freshly isolated aortic 
smooth muscle, with no confirmed protein expression available (Nelson et al. 
2011). However, in the same study knockdown of AC3/5/6 inhibited cAMP 
accumulation by 90% suggesting only a minor role for AC7.  Importantly, AC 
expression changes in culture, with AC2/8 mRNA detected in cells passaged 
3-6 (Nelson et al. 2011; Ostrom et al. 2002).  Overexpression of AC6 in rat 
aortic smooth muscle cells enhances both b1 and b2 adrenoceptor-mediated 
cAMP production, but did not affect basal cAMP (Ostrom et al. 2002). 
Furthermore, AC6 proved predominately responsible for the increase in KATP 
current induced by isoprenaline in freshly isolated aortic smooth muscle cells, 
with AC6 knockdown attenuating the evoked current (Nelson et al. 2011). AC3 
knockdown also produced a modest reduction in KATP currents. Surprisingly, 
knockdown of AC5, which shares a high homology to AC6, produced no effect 
on the KATP current. 
In pulmonary arterial smooth muscle cells AC 2/5/6 are the predominant 
isoenzymes, with AC3 expressed at lower levels (Jourdan et al. 2001). 
1.4.3 Phosphodiesterases 
Cyclic nucleotide phosphodiesterases are a family of enzymes that degrade 
the phosphodiester bond in cAMP and cGMP.  Twenty-one genes encode the 
11 known mammalian PDE families, with alternative mRNA splicing producing 
multiple variants (Maurice et al. 2014).  This produces a highly complex 
situation with almost 100 different PDE isozymes possible. These isoforms 
collectively produce a high level of control on cAMP, with small areas 
  
38 
containing a high concentration of cAMP, known as a cAMP “hotspots” 
(Maurice et al. 2014) (Figure 1.3).  
PDEs fall into three general groups based on their substrate specificity: PDEs 
4, 7 and 8 selectively hydrolyse cAMP; PDEs 5, 6 and 9 are cGMP-specific; 
and PDEs1-3,10 and 11 degrade both cAMP and cGMP (Maurice et al. 2014). 
PDE 1, 3, 4 and 5 are expressed in vascular myocytes (Komas, Lugnier, 
Andriantsitohaina, et al. 1991; Polson & Strada 1996) . PDE 2, 3 ,4 and 5 have 
been shown to be expressed in endothelium cells (Netherton & Maurice 2005).  
PDE 1 has been shown to be involved in vascular remodelling, where they 
have a role in the proliferative phenotypic smooth muscle cells i.e. dividing and 
growing. PDE 1 is also involved in vascular tone regulation in the contractile 
phenotype i.e. no growth, force generating phenotype. PDE1’s localisation is 
different in contractile and proliferative VSMCs, cytoplasmic in contractile and 
nuclear in proliferative cells. The role of PDE1A in contractile smooth muscle 
is to regulate myosin light chain kinase phosphorylation (Nagel et al. 2006). 
However, in proliferative VSMCs, PDE1A is involved in the cell cycle, whereby 
inhibition of PDE1 (total family inhibition) or knock down (PDE1A specific) 
decreases cell growth (Nagel et al. 2006). PDE1C expression levels increase 
after the phenotypic change from contractile to proliferative and this limits 
cAMP-mediated inhibition of proliferation (Rybalkin et al. 2002). Disease 
involvement of PDE1 in pulmonary hypertension has been shown whereby 
there is over 250-fold increase in PDE1C mRNA from idiopathic pulmonary 
artery hypertension patients pulmonary myocytes compared to control. Upon 
knockdown the disease associated increase in proliferation of vascular smooth 
muscle is decreased (Murray et al. 2007). PDE1A and 1C do not produce their 
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increase in cell proliferation via the same pathways, further showing 
compartmentalisation and the complexity of cAMP signalling (Nagel et al. 
2006; Growth et al. 2015; Chan & Yan 2011).  
PDE3, also known as cGMP-inhibited phosphodiesterase, is a low Km (i.e. high 
affinity) cAMP hydrolysing PDE shown to have an involvement in vascular 
tone. Inhibition of PDE3 in a number of vascular beds relaxes arteries by 
inducing leftward shift in the dose response curve to b-adrenergic agonists, 
such as isoprenaline (Lindgren et al. 1990). These responses are not 
dependent on the presence of a working endothelium due to PDE3 expression 
in vascular myocytes (Komas, Lugnier & Stoclet 1991). PDE3 inhibition was 
not the same in different vascular beds, with milrinone (PDE3 inhibitor) 
producing a more potent relaxation in coronary than cerebral or renal arteries 
(Polson & Strada 1996). PDE3 inhibition has been assessed as a therapeutic 
target in heart failure, however, chronic administration of milrinone (Primacor) 
and amrinone (imamrinone, Inocor) leads to increased mortality through an 
increase in the incidence of arrhythmias and sudden cardiac death (Maurice 
et al. 2014). A PDE3 inhibitor, cilostazol (Pletal; Otsuka Pharmaceutical), is 
licensed for the treatment of intermittent claudication, an arterial disease 
characterized by ischaemia-induced leg pain, and works by decreasing 
platelet aggregation and directly stimulating arterial vasodilation (De Backer et 
al. 2010). 
PDE4s are expressed in arteries, however inhibition of PDE4 in arteries 
denuded of endothelial cells produces modest relaxation, whereas the 
presence of an intact endothelium significantly increases this response. PDE4 
inhibition caused leftward shifts in relaxation curves to known cAMP 
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dependent vasodilators e.g. Isoprenaline (Maurice et al. 1991; Schoeffter et al. 
1987). Precontraction with different contractile agonists affected the response 
to PDE inhibition, isoproterenol relaxation sensitive to PDE inhibition in 
Prostaglandin F2a (PGF2a) pre-contracted preparations, but not sensitive to 
guanfacine pre-contracted preparations (Lindgren et al. 1990). The need for a 
working endothelium in PDE4 inhibition induced relaxation poses the 
questions to its involvement in healthy vessels; However, increased cGMP 
produced by NO releasing endothelium may inhibit PDE3, “pushing” PDE4 into 
the major cAMP hydrolysing role. This was supported by experiments where, 
after PDE3 inhibition, non-denuded preparations were significantly more 
sensitive to PDE4 inhibition (Lugnier & Komas 1993) (Figure 1.3).  
PDE5 is a cGMP sensitive PDE, and the therapeutic target of sildenafil (Viagra, 
Pfizer) a drug used for erectile dysfunction. PDE5 inhibition in aorta 
preparations initially produced contradictory reports, however this was 
probably due to poor selectivity (Polson & Strada 1996). Saeki et al. (1995) 
produced a highly specific potent inhibitor of PDE5 and showed it produced 
relaxation of porcine coronary artery, which was dependent on endothelium 
and nitric oxide (Saeki et al. 1995).  PDE5 inhibition potentiated nitroglycerin 
(NO donor) mediated relaxations in porcine arteries, while L-NAME inhibited 
PDE5 inhibition mediated relaxations. This relaxation was as a result of a rise 
in cGMP not cAMP (Saeki et al. 1995).  Targeting PDE5 inhibition and the NO-
cGMP pathway may be a possible treatment in stroke, Raynaud’s 
phenomenon, ventilation/perfusion mismatch and heart failure (Ghofrani et al. 
2006). 
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Phillips et al. (2005) reported the presence of PDE 8/9 mRNA in aortic and 
renal artery smooth muscle cells but not in coronary artery smooth muscle 
cells. PDE7 was also present in all vascular smooth muscle cells studied. 
Importantly, these vascular smooth muscle cells in Phillips et al. were in culture 
(Passage 2) and therefore the transition of contractile to synthetic may produce 
a different PDE isoform expression (Phillips et al. 2005). 
 
Figure 1.3- Phosphodiesterase control of cAMP hotspots in the vasculature. Within 
certain cells high concentrations of localised cAMP (hotspots) exist. These hotspots are 
maintained by the presence of localised phosphodiesterases, along with the production 
of cAMP from adenylyl cyclases. PDE3 and PDE4 are the main PDE’s present in the 
vasculature responsible for maintaining cAMP hotspots.  
1.5 cAMP Effectors 
cAMP has four known effector proteins: protein kinase A (PKA); cyclic 
nucleotide-gated (CNG) channels, exchange protein directly activated by 
cAMP (Epac) and PDE10, the cAMP-inhibited phosphodiesterase (Figure 
1.4).  Below three of the effectors are discussed including their structural 
properties. PDE10 is not explored due to the lack of expression in vascular 
preparations (Phillips et al. 2005; de Rooij et al. 1998; Kawasaki et al. 1998; 
Walsh et al. 1968). 
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Figure 1.4- cAMP Effectors and their downstream responses. cAMP has 3 main 
effectors in the vasculature, Epac, PKA and CNGCs. Epac mediates a number of 
signalling pathways including vascular relaxation, insulin secretion and inflammation. 
PKA mediates pathways including gene regulation, glucose metabolism and vascular 
tone. CNGCs have a role within the heart and vascular tone.  
1.5.1 Protein Kinase A 
PKA was first discovered in 1968 by Walsh, Perkins and Krebs (Walsh et al. 
1968). Their discovery that a cAMP-dependent kinase phosphorylated casein 
and protamine has led the way for kinase research over 50 years with PKA still 
thought of as the original and simplest kinase (Walsh et al. 1968). 
1.5.1.1 Structure and Activation of Protein Kinase A 
Protein Kinase A is a tetramer in its inactive state, with two regulatory subunits 
(RI or RII, alpha or beta) forming a complex with two PKA catalytic subunits 
(Kim et al. 2005; Taylor et al. 2012; Zhang et al. 2012). PKA regulatory subunit, 
as the name states, regulates the catalytic region by an inhibitory domain 
towards the N-terminus (Taylor et al. 2012).  
The regulatory subunits of PKA were originally named I (1) and II (2) after the 
order in which they elute from ion exchange chromatography. Further 
isoforms, utilising the names a and b, were discovered due to their different 
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mobility on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). In total there are four genes encoding PKA regulatory subunit isoforms 
(Canaves & Taylor 2002; Taylor et al. 2012). At the N-terminus of the 
regulatory subunits is the dimerization domain responsible for the interaction 
of the two regulatory subunits with one another. This dimerization is produced 
by the anti-parallel arrangement of the two regulatory subunits.  This regulatory 
subunit dimer binds two catalytic subunits to form the tetramer. Each 
regulatory subunit possesses two cAMP binding domains named A and B in 
the carboxyl-terminus. In the inactive state only the cAMP binding domain B is 
accessible to cAMP, and it is after this initial binding of cAMP that the cAMP 
binding domain A is accessible for cAMP binding. cAMP binding to PKA RI at 
only site B in vitro has a reported Kd 0.9 nM. However, Dao et al. (2006) 
showed that cAMP affinity is dramatically affected when PKA is in its 
holoenzyme state (Kd 2.9µM) (Dao et al. 2006).  PKA Type II holoenzymes 
(RIIa2:C2 and RIIb2:C2) have an activation constant of 200-400 nM cAMP, 
compared to 50-100 nM cAMP for PKA Type I holoenzymes (RIa2:C2 and 
RIb2:C2) (Taylor et al. 2012; Zhang et al. 2012). The original text book 
understanding of PKA regulation was that, upon binding of 4 cAMP molecules 
to the regulatory dimer, a conformation change occurs that results in the 
release of the two catalytic domains held in an inactive conformation with the 
regulatory subunits under basal conditions. These catalytic subunits then 
phosphorylate serine and threonine residues on target proteins (Guo et al. 
2012; Rust & Thompson 2011) (Figure 1.5). However, in recent studies it has 
been shown both in vivo and in vitro that at physiological cAMP concentrations, 
regulatory and catalytic subunits remain intact (Smith et al. 2017).  
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Figure 1.5- Regulation and Activation of Protein Kinase A. PKA RII subunits inhibit 
PKA catalytic subunits under basal conditions. Upon cAMP binding the PKA RII subunit, 
inhibition is removed, with PKA catalytic subunits able to phosphorylate downstream 
substrates. 
1.5.2 Cyclic Nucleotide gated ion channels 
Cyclic nucleotide gated channels (CNGCs) are Ca2+-permeable, non-selective 
cation channels expressed in various tissues, including smooth muscle cells 
and vascular endothelial cells (Cheng et al. 2003; Shen et al. 2008; Yao et al. 
1999).  CNGCs have six isoforms, CNGA1 to 4 and CNGB1 and 3; CNGA1/2 
being shown to possess functional effects in the vasculature (Yao et al. 1999; 
K.-T. Cheng et al. 2008; Biel & Michalakis 2002; Cheng et al. 2003; Shen et 
al. 2008). CNGA1 expression is predominately in endothelial cells in guinea 
pig arteries (Yao et al. 1999). CNGA2 is expressed in both smooth muscle and 
endothelial cells, with higher  expression in the vascular smooth muscle layer 
(Cheng et al. 2003). CNGCs are activated by direct binding of cAMP or cGMP, 
with different sensitivities depending on the isoform. They do not desensitize 
to ligand activation (Biel & Michalakis 2002). Contrary to the thought that cyclic 
nucleotides cause relaxation, it has been shown that CNGs are involved in 
thromboxane induced contraction in rat mesenteric arteries (Leung et al. 
2010). Endothelium denuded arteries were susceptible to relaxation upon 
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blockade with selective CNGC blockers such as L-cis-diltiazem in U46619 pre-
contracted arteries (Leung et al. 2010). 
R .S .T  Exchange Protein directly Activated by cAMP 
1.5.3.1 History of Epac 
Exchange protein directly activated by cAMP (Epac) was discovered 
simultaneously by two laboratories in 1998. The laboratory of Johannas Bos, 
discovered Epac based on the PKA-independent Rap1 activation  (de Rooij et 
al. 1998). Activation in response to forskolin showed no difference between 
normal Chinese hamster ovary (CHO) cell lines and CHO cell lines expressing 
a mutant regulatory PKA subunit that rendered PKA inactive. Furthermore, 
Rap1 was activated in the rat fibroblasts (Rat1 cell line) by forskolin, but not 
inhibited by the PKA inhibitor, H89. Epac1 mediated Rap 1 activation was not 
dependent on PKA activation (de Rooij et al. 1998). Epac bound cAMP to a 
similar level as PKA RI subunit, as shown by cAMP-binding assays. This is 
expected as the original search for Epac utilised a gene encompassing a cyclic 
nucleotide binding region and guanine exchange factors for Rap1 and Ras (de 
Rooij et al. 1998). Within the same month an independent laboratory presented 
two proteins, cAMP-GEFI and cAMP-GEFII, which directly activated Rap1 in 
vitro and bound cAMP, shown through cAMP-agarose pull downs (Kawasaki 
et al. 1998). Kawasaki et al. (1998) further explored the expression of both 
cAMP-GEFI and cAMP-GEFII, now known as Epac1 and Epac2, in various 
tissues (Kawasaki et al. 1998). Epac1 was almost ubiquitously expressed with 
predominant heart and kidney expression. Epac2 was shown to be 
predominately expressed in the brain and adrenal glands. Interestingly, they 
showed a difference in mRNA expression between adult and foetal human 
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tissues, with Epac1 and Epac2 expressed in foetal lung tissue but 
undetectable in adult tissue (Kawasaki 1998).  
1.5.3.2 Structure and cAMP binding 
Epac1 (99 kDa) and Epac2 (109 kDa) both possess cyclic nucleotide binding 
domains (CNB), a guanine exchange factor domain (CDC25-HD), Ras-
exchange motif (REM) and a Ras-association domain (RA) along with a 
dishevelled, Egl-10, and Pleckstrin domain (DEP) (Bos 2006; Gloerich & Bos 
2010). Epac1 contains a single cyclic nucleotide binding domain (CNB) termed 
B, with Epac2 possessing an extra CNB, termed A. The CNB-B domain is 
responsible for the auto-inhibition (self inhibition in the absence of cAMP) that 
takes place with both Epac proteins.  This domain possesses a common 
alanine amino acid, which is crucial for the selectivity of cAMP over cGMP, as 
in PKA and CNGCs (Kawasaki 1998; de Rooij et al. 1998). The CNB-A domain 
has a lower cAMP affinity and binding does not relieve auto-inhibition i.e. 
cAMP binding does not produce GEF activity. In fact, binding of cAMP to CNB-
A does not affect Epac2 activity, leading to the idea that this domain is 
redundant (de Rooij et al. 2000).  However, recently an Epac2 splice variant, 
Epac2B, which is without CNB-A was shown to have an increased cytoplasmic 
distribution compared to Epac2 suggesting a possible role of CNB-A in 
localisation of Epac2A (Niimura et al. 2009) (Figure 1.6).  
The DEP domain present in Epac1 and Epac2 is responsible for the 
translocation of Epac to the plasma membrane upon activation. De Rooij et al. 
(1998) and Ponsioen et al. (2004) showed that deletion of the DEP domain 
caused either an increase in the amount of Epac1 in the cytoplasmic fraction 
after activation, assessed by immunoblotting, or a more diffuse cytoplasmic 
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distribution, assessed using Epac-based FRET biosensors (Ponsioen et al. 
2004; de Rooij et al. 2000).  There appears to be a slight difference in what 
effect deletion of the DEP domain has on Rap1 activation, with de Rooij (1998) 
showing a clear Rap1-GTP activation and Ponsioen et al. showing a clear lack 
of Rap1-GTP activation upon DEP deletion. The CDC25 homology domain 
(CDC25-HD) domain present in Epac1, Epac2 and other guanine exchange 
factors (GEFs) is responsible for the exchange of GDP for GTP in small Ras 
superfamily G-proteins (Bos et al. 2007). This CDC25-HD domain works by 
causing a dissociation of the nucleotide from a small GTPase such as Rap1, 
followed by the reuptake of a new nucleotide; with a 50x higher concentration 
of cellular GTP than GDP, there is a higher probability of the small G-protein 
(Rap1/2 in the example of Epac) binding GTP than GDP (Bos et al. 2007). The 
REM is almost always seen adjacent to the CDC25-HD domain in GEFs where 
it stabilises the GEF, allowing CDC25-HD to catalyse the exchange of 
nucleotides (Bos et al. 2007; Gloerich & Bos 2010). The function of the RA in 
Epac1 is still unclear, however Epac2 has been shown to interact with Ras-
GTP through the RA domain, leading to nuclear location (Li et al. 2006).  
cAMP binding to Epac1 through its CNB-B domain has an in vitro Kd of 2.8 µM 
for cAMP and an AC50, the concentration needed for 50% activation, of 50 µM 
(Dao et al. 2006; Poppe et al. 2008).  It was initially thought that Epac is a 
standby/back up cAMP effector to PKA due to PKA R1 subunit have an in vitro 
Kd of 1.3 nM. However, due to the R1 subunit within a holoenzyme having a 
Kd of 2.9 µM for cAMP, some have questioned this secondary role (Dao et al. 
2006). Importantly, in terms of the AC50, Epac1 has a value of 50µM whereas 
the PKA holoenzyme is shown to be below 1µM and therefore would be 
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expected to activate prior to Epac (Dao et al. 2006; Zhang et al. 2012). 
Different in-vitro protocols such as buffer composition may give rise to varying 
Kd/Ac50 values and therefore in-vivo data will be key to establish the order of 
activation and under what stimulus PKA and Epac are activated.  
 
Figure 1.6- Epac1 and Epac 2 Structure and Activation: A) Epac1 and Epac2 have 
similar domains. Epac2 contains a CNB-A domain that binds cAMP with a low affinity. 
DEP domain is responsible for the translocation of Epac to the plasma membrane under 
activation. cAMP binds to CNB-B with a higher affinity than CNB-A of Epac2 and is 
responsible for the auto inhibition of Epac proteins. REM are present in all GEF’s and is 
responsible for stabilisation of the protein to assist the exchange of GDP for GTP which 
is undertaken by the CDC25-HD domain. Epac activation by cAMP produces a 
conformational which allows Rap1 to access the CDC25-HD domain and exchange GDP 
for GTP. B) Inactive Epac in an auto-inhibited state is activated by cAMP formed from 
ATP by adenylyl cyclases, predominately positioned at the membrane. Upon cAMP 
binding, Epac ”unhinges" allowing the small Ras-related G-protein Rap1 to exchange 
GDP to GTP and become activated. Rap1 can be deactivated by GTPase-activating 
proteins (GAPs), which exchange GTP for GDP and inactive the small G-protein. 
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1.5.3.3 Structural basis of Epac activation 
Upon binding of cAMP to the CNB-B domain a cascade of conformational 
changes takes place. The first contact of cAMP is with the phosphate-binding 
cassette (PBC) present in the CNB domain. This interaction causes some 
residues to undergo a conformational change to adapt an optimal docking 
pose. This destabilises the C-terminal hinge-helix and allows the CNB to reach 
the docking position at the REM domain. The cAMP not only activates this 
Epac structure but stabilises the ‘lid and hinge’ to maintain the active 
conformation (Rehmann et al. 2008).  
1.5.3.4 Tool used to study Epac 
Appreciation of the potential functional importance of Epac has come with the 
development of cell-permeant, Epac-specific cAMP analogues. Most 
significant is the Epac “super agonist” 8-pCPT-2’-O-Me-cAMP (8-pCPT), 
which utilises a single difference between the cyclic nucleotide binding 
domains of Epac, compared with CNGCs and PKA (Figure 1.7). A  single 
glutamate residue found only in PKA and CNGCs interacts with the 2-OH 
group of cAMP and is needed for activation of these proteins (Yagura & Miller 
1981; Diller et al. 2001; Enserink et al. 2002). Replacement of this 2-OH group 
in cAMP with 2-OCH3 resulted in selective activation of Epac proteins, as 
indicated by an increased maximal activity (Kmax) (de Rooij et al. 2000) (Epac1 
and Epac2 are both activated by 8-pCPT). This analogue was modified to 
further improve Epac affinity, with the addition of pCPT (4-chlorophenythio) at 
the 8 position. Addition of an AM ester increased permeability in tissue and 
cells (Gloerich & Bos 2010). The AC50 of Epac1 by 8-pCPT in vitro is 1.8µM, 
over 25x lower than cAMP (50 µM) (Rehmann et al. 2003).  8-pCPT-AM not 
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only increases the half maximal concentration, but also increases the Kmax 
(x3.6 compared to cAMP) (Rehmann et al. 2003).  One area of caution is the 
possible inhibition of certain phosphodiesterases by 8-pCPT. Specifically, it 
inhibits PDE1B and 6 with IC50 below 10µM, while it inhibits PDE3 with an IC50 
of ~20 µM. As discussed above, the major PDEs in vascular smooth muscle 
are 1 (A and C), 3, 4 and 5, of which none are inhibited by 8-pCPT at the 5µM 
concentration used by our group (Poppe et al. 2008). 
 
Figure 1.7- Various Tools used to Explore Epac-mediated effects: A) Cyclic 
adenosine monophosphate (cAMP) produced by adenylyl cyclase from ATP is a major 
second messenger within cells. B) 8-pCPT-2´-O-Me-cAMP is a cAMP analogue 
designed to activate Epac without activation PKA or CNGs. Red circle indicates the 
position of the substitution (–OH group to an –OCH3) making 8-pCPT-AM a selective 
Epac agonist. cAMP analogue diagrams were from Holz et al.  (Holz et al. 2006). 
1.6 cAMP signalling in vascular smooth muscle 
1.6.1 cAMP causes quiescence in vascular smooth muscle 
In many cell types including vascular smooth muscle cells cAMP causes an 
inhibition of proliferation in vitro and in vivo (Assender et al. 1992). Since 
discovering the role of cAMP in proliferation, cAMP response element binding 
protein (CREB), a transcription factor, has been shown to be a molecular 
determinant for smooth muscle cell proliferation (Bito et al. 1996). cAMP 
analogues or cAMP increasing compounds increase CREB phosphorylation, 
thereby decreasing proliferation-associated genes that encode endothelin 
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receptors, platelet-derived growth factor receptors and cyclins (Ichiki 2006; 
Klemm et al. 2001). As with numerous cAMP-mediated effects, this inhibition 
of proliferation was thought to be exclusively mediated through PKA. More 
recently skp2, an F-box protein component of SCFskp2 ubiquitin ligase, has 
been shown to be increased in proliferative vascular smooth muscle cells, both 
in culture and in vivo following balloon injury of arteries (Y. J. Wu et al. 2006). 
Skp2 is important in cell cycle regulation, by degrading p27kip1, itself 
responsible for halting the progression of quiescent cells into S phase. cAMP 
analogues decrease skp2 expression, increase p27kip1 expression and inhibit 
focal adhesion kinase activation, which is responsible for skp2 expression (Y. 
J. Wu et al. 2006; Bond et al. 2004). This effect of cAMP is reversed in the 
presence of PKI, an inhibitor peptide of PKA (Cheng et al. 1986). Not 
mentioned specifically in the study showing PKI effects on skp2 expression 
was the level of reversal, with only ~20% (approximate due to estimation of 
the reversal effect from figures) of the original skp2 expression being reversed. 
This is surprising as PKI was used at 40 µM, 1000 fold higher than the IC50 (Y. 
J. Wu et al. 2006). After the discovery of Epac this same group reassessed the 
involvement of Epac in this cAMP-mediated event involving skp2. Using PKA-
specific and Epac-specific activators it demonstrated that PKA and Epac1 work 
synergistically to cause both vascular smooth muscle cell quiescence though 
proliferation studies, and with it a decrease in skp2 expression as shown by 
immunoblots (Hewer et al. 2011). Activation of a single cAMP effector (PKA or 
Epac) did not produce any significant effect (Hewer et al. 2011). Other studies 
have shown a single cAMP effector had an effect, with 8-pCPT increasing the 
level of the transcription factor NR4A1, along with decreasing cell proliferation 
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(Mayer et al. 2011).  The involvement  of Epac in proliferation and migration 
was shown by Epac1 -/- mice, where aortic smooth muscle cells showed 
increased proliferation in response to serum compared to control mice (Kato, 
Yokoyama, Yanai, Ishige, Kurotaki, Umemura, Fujita, Kubota, Okumura, Sata, 
et al. 2015). Epac1-/- mice (from the same animal strain as above) also had 
reduced neointima formation after injury, primarily due to a decrease in cell 
invasion and migration in response to PDGF-BB (Kato, Yokoyama, Yanai, 
Ishige, Kurotaki, Umemura, Fujita, Kubota, Okumura & Sata 2015). 
Interestingly, beraprost (a prostacyclin analogue) activated Epac and inhibited 
migration (the opposite to the Epac1 -/- study), but had no effect on proliferation 
(McKean et al. 2015). The difference in results is yet unexplained but may be 
due to species differences or the role of other receptors present such as EP 
receptors (Orie & Clapp 2011). 
1.6.2 cAMP improves vascular permeability 
cAMP-elevating hormones have long been associated with attenuation of both 
in vitro endothelial cell permeability and ex vivo artery permeability (Langeler 
& van Hinsbergh 1991; Stelzner et al. 1989; Kobayashi et al. 1987). This is not 
the case in all arterial beds, for example the coronary circulation, where cAMP 
increases permeability (Bindewald et al. 2004). Originally, PKA was shown to 
be the cAMP effector responsible for decreasing endothelial permeability, after 
over-expression of the PKA inhibitor gene (PKI) abolished cAMP-mediated 
decreases in permeability (Lum et al. 1999). The potential substrates of PKA 
in endothelial cells are commonly thought of as MLCK and RhoA, both of which 
are involved in the control of MLC phosphorylation, however other substrates 
have been investigated, such as IP3 receptors, filamin and protein 
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phosphatases (Lum et al. 1999). MLC phosphorylation is important in 
endothelial permeability, as contraction of endothelial cells changes 
endothelial cell shape, and with it opens intracellular gaps (Wysolmerski & 
Lagunoff 1990; Yuan et al. 2002). In coronary artery endothelial cells MLC 
phosphorylation and cAMP production are similar to aortic endothelial cells, 
however forskolin treatment produces opposing effects on permeability i.e. 
increases membrane permeability (Bindewald et al. 2004). This opposing 
effect is due to rapid disintegration of cellular adhesion complexes containing 
VE (vascular-endothelial) -cadherin and paxillin (Bindewald et al. 2004). Epac 
has been shown to be involved in both MLC phosphorylation and gap junction 
modulation in the endothelium of arteries.  Cullere et al. (2005) showed that 
Epac activation in human pulmonary artery endothelial cells causes an 
increase in cortical versus stress fibre actin, as well as a continuation of VE-
cadherin staining between cells (Cullere et al. 2005). This continuous VE 
cadherin improves vascular integrity and decreases permeability (Giannotta et 
al. 2013). Thrombin treatment increases RhoA activation and decreases 
continuality of VE-cadherin staining, both of which were reversed by incubation 
with 8-pCPT-AM or by increasing cAMP through forskolin and rolipram (PDE4 
inhibitor) application (Cullere et al. 2005). Epac’s role has been further 
elucidated in endothelial vascular permeability, with a plethora of signaling 
pathways potentially involved. Epac/Rap1 activates Rac1, which strengthens 
adheren junctions (Baumer et al. 2008). Rac1-independent, but Rap1-
dependent, signaling may exist with RhoA activity decreased through a 
multimeric protein complex (Rho GTPase activating protein 29, Radil1 and 
Rasip1) (Post et al. 2013). Rap1-independent Epac-mediated signaling has 
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been shown, with AKAP9 being required for increasing microtubule growth, 
but not for basal vascular permeability (Sehrawat et al. 2011). Further 
confirmation of Epac1 involvement in  vascular permeability has been shown 
where Epac1-/- mice have an increase in microvascular permeability (Kopperud 
et al. 2017).  
1.6.3 Cyclic nucleotide induced relaxation 
Vascular smooth muscle cells in the normal, non-pathophysiological state are 
in a contractile phenotype being quiescent (no cell division) with the role of 
maintaining and controlling blood vessel diameter. cAMP was first explored in 
relation to relaxation, when researchers acknowledged that the increase in 
cAMP seen by b-adrenoceptor activation was accompanied by smooth muscle 
relaxation. For a thorough and complete review on early cAMP studies in the 
vascular see Kramer and Hardman (1980) (Kramer & Hardman 1980). 
1.6.3.1 PKA effect on contractility 
Vascular smooth muscle cell relaxation dependent on cAMP is vascular bed 
specific and difficult to explore due to the potential for cAMP to not only activate 
PKA, but also at high concentrations activate PKG (Morgado et al. 2012). 
However, in general cAMP, produces relaxation through four major routes 
involving the regulation of Ca2+ homeostasis, signaling and cytoplasmic 
contraction apparatus (Murthy 2006; Webb 2003; Beavo & Brunton 2002; 
Hardman 1984; Kramer & Hardman 1980; Roberts & Dart 2014; Morgado et 
al. 2012; Akata 2007a; Akata 2007b): 
1. Decrease in Ca2+ store release: cAMP decreases Ca2+ store release 
through phosphorylation of IP3 receptors, commonly associated with Ca2+ 
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store release. In vitro PKA has been shown to phosphorylate IP3R and 
attenuate Ca2+ release. However in intact rat aorta, PKG was shown to 
mediate IP3 phosphorylation by cAMP increases, presenting it as the 
major kinase for this role through possible (i.e. cAMP activating PKG not 
PKA) (Komalavilas & Lincoln 1996; Narayanan et al. 2012; Murthy & Zhou 
2003). The difference in effect of PKA and PKG may be due to the 
presence of IP3R associated cGMP kinase substrate (IRAG) (Taylor 
2017). 
2. Increase in Ca2+ store reuptake: cAMP working via PKA causes an 
increase in Ca2+ reuptake to the intracellular stores in the sarcoplasmic 
reticulum (Webb & Bhalla 1976; Wegener et al. 1989). The addition of PKA 
catalytic subunit and cAMP to vascular microsomes, showed an increase 
in the level of phosphorylation for a 22kDa protein, as assessed by 
radioactive 32P incorporating experiments (James et al. 1989; Bidlack et 
al. 1982). This protein was later shown to be phospholamban,  which when 
phosphorylated disinhibits the sarco/endoplasmic reticulum Ca2+ ATPase  
(Simmerman & Jones 1998).  
3. Increased efflux of Ca2+ to the extracellular space: The two main 
“escape” routes for Ca2+ from the cytoplasm of smooth muscle cells are 
the plasma membrane Ca2+ ATPase (PMCA) or the Na+/Ca2+ exchanger 
(NCX) (Morgado et al. 2012; Kamishima & McCarron 1998; Oloizia & Paul 
2008). PMCA exchanges 2 H+ ions into the cell in exchange for 1 Ca2+ ion 
out, with ATP needed for this exchange. This ATPase is highly regulated 
by numerous kinases, including Ca2+/calmodulin dependent kinase 
(CaMKII) along with PKA and PKG (Kamishima & McCarron 1998; Oloizia 
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& Paul 2008; Brini & Carafoli 2011). The role of NCX in vascular smooth 
muscle has not fully been elucidated, due to contrasting results, but certain 
groups have shown potentiation of Ca2+ extrusion in response to PKG 
(Brini & Carafoli 2011; Morgado et al. 2012; Kamishima & McCarron 1998; 
Murray 1990).  
4. Decrease in extracellular Ca2+ entry, both directly and through 
membrane potential modulation:  
a. Direct: PKA and its role in direct regulation of Ca2+ entry is 
complex and still not completely understood. For example, T-
type Ca2+ channel activity has been shown to be inhibited by 
PKA in cerebral arterial myocytes. This effect of decreasing Ca2+ 
entry is fitting for a relaxant mechanism, but is paradoxical to the 
potentiation of L-type Ca2+ channels (LTCC) in murine arterial 
myocytes by PKA, which causes vasoconstriction (Nystoriak et 
al. 2017). Enhanced LTCC currents may also produce relaxation 
through activating BKCa channels (Guia et al. 1999). However, 
LTCC currents have also commonly been associated with 
attenuation by PKA (Keef et al. 2001). The varying effects seen 
on LTCCs may be due to “crossover” of cAMP activating PKG 
and vice versa. Due to excessive rundown of LTCC in 
experiments that utilize cell rupture, the majority of experiments 
utilize the perforated patch technique and use specific PKA or 
PKG activators to assess kinase involvement. PKG has been 
shown to reliably inhibit LTCC currents (Ruiz-Velasco et al. 1998; 
Ishikawa et al. 1993; Keef et al. 2001). Inhibition of store-
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operated calcium channels (SOCCs) by PKA and CaMKII takes 
place in rat mesenteric arterial myocytes through inhibition of 
TRPC1 (Transient receptor potential canonical 1)  channel  and 
TRPC5 channel (Albert et al. 2007). SOCCs were also inhibited 
by PKA and PKG in pulmonary artery myocytes (Chen et al. 
2011). Receptor operated calcium channels (ROCC) have been 
subject to a number of experiments to determine their regulation 
by kinases. The consensus is that PKA/PKG inhibit ROCC with 
the TRP channel TRPC6 being inhibited  (Nishioka et al. 2011). 
b. Membrane potential modulation: PKA also decreases Ca2+ 
entry by phosphorylating target proteins that induce 
hyperpolarization of the cell membrane. Positive modulation of 
K+ channels at membrane potentials positive to Ek (K+ reversal 
potential) produce an outward current of K+, which causes a 
hyperpolarization of the cell membrane. This hyperpolarisation 
of the cell membrane attenuates Ca2+ entry via LTCC by 
decreasing the opening probability of LTCC’s and lowering the 
driving for Ca2+. 
i. Voltage-activated K+ channels: Kv channels are 
activated by PKA phosphorylation including endogenous 
Kv currents in smooth muscle cells (Brignell et al. 2015; Y 
Hayabuchi, Standen, et al. 2001).  
ii. ATP-sensitive K+ channels: PKA-mediated 
phosphorylation increases KATP current (Yang et al. 2008; 
Kleppisch & Nelson 1995). 
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iii. Inward-rectifying K+ channels: PKA mediates an 
increase in Kir current induced by  hypoxia  (Park et al. 
2005). 
iv. Large conductance Ca2+-activated K+ channels 
(BKCa): cAMP via PKA or PKG increases open-probability  
(White et al. 2001; Minami et al. 1993; Porter et al. 1998; 
Scornik et al. 1993).  
See Humphries & Dart (2015) for ion channel structure and classifications 
(Humphries & Dart 2015). 
PKA regulation of vascular tone is not only produced by altering available 
cytoplasmic Ca2+, but by regulating the Ca2+ sensitivity of the contractile 
proteins in vascular smooth muscle cells. Phosphorylation at site S695 in the 
MYPT1 subunit of MLCP increases myosin dephosphorylation by inhibiting 
ROCK phosphorylation (Somlyo & Somlyo 2003; Wooldridge et al. 2004). 
Another site, S852, is also phosphorylated, but its effect has not been 
examined (Wooldridge et al. 2004). PKA-mediated inhibition of MLCK has 
been shown in-vitro (Conti & Adelstein 1981), however in-vivo, CaMKII 
appears to play a more physiological role in inhibitory phosphorylation of 
MLCK (Stull et al. 1993). 
A third relaxation pathway dependent on PKA has been shown. In this 
phosphorylation of heat shock protein 20 (HSP20) produces a decrease in the 
interaction between myosin and actin. The exact mechanism is still to be 
elucidated (Figure 1.8) (Beall 1999; Salinthone et al. 2008). 
  
59 
The above mechanisms of relaxation are through PKA-mediated events in 
vascular smooth muscle cells, however PKA also modulates events in 
endothelial cells. Gs-coupled receptors on endothelial cells have been shown 
to increase NO synthase activity by PKA dependent phosphorylation, leading 
to an increase in nitric oxide (NO) a prominent vasodilatory through PKG 
(Ferro et al. 2004; Butt et al. 2000). 
 
Figure 1.8- PKA-dependent relaxation pathways in smooth muscle cells. PKA 
activation produces vasodilatory mechanisms through numerous pathways including a 
direct effect on the contractile machinery and through decreasing available Ca2. The 
contractile machinery is also modulated by decreasing the level of MLC phosphorylation. 
PKA-dependent phosphorylation of HSP20 causes relaxation through actin filament 
regulation. PKA lowers Ca2+ by through phosphorylation of many downstream targets 
such as PMCA, PLB, IP3R, RyR, K+ and Ca2+ channels. 
1.6.3.2 Cyclic Nucleotide gated ion channels in vasodilation 
The cyclic nucleotide gated ion channel encoded by CNGA2 has been recently 
shown to mediate numerous agonist-induced vasorelaxation effects. 
Adenosine and adrenaline-induced relaxations were both attenuated by 
inhibition of CNGCs using L-diltiazem and specific siRNA. CNGCs produces 
relaxation by increasing the Ca2+ current through CNGCs in endothelial cells, 
which produces an activation of the Ca2+-sensitive enzyme, eNOS in 
endothelial cells, and with it increases NO. Indeed, inhibition of NO synthase 
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with L-NAME removed the effect of CNGC inhibition on adenosine 
vasorelaxation (K. T. Cheng et al. 2008). 
1.6.3.3 Epac effect on contractility 
Considerably less is known about the functional role of Epac in regulating 
vascular tone. However, in cardiomyocytes Epac activation has an effect on 
calcium handling by increasing store Ca2+ release, through Ca2+/calmodulin-
dependent kinase II (CaMKII)-dependent phosphorylation of downstream 
targets, including ryanodine-sensitive channels (RyR) and phospholamban 
(PLB). This Ca2+ modulation by Epac is responsible for such effects as chronic 
inotropy, cardiac hypertrophy and arrhythmia (Ruiz-Hurtado et al. 2012; 
Pereira et al. 2013; Pereira et al. 2007). 
Epac activation in the vasculature has been shown to produce relaxation 
through the desensitization of the contractile mechanism to Ca2+. Zieba et al. 
(2011) showed that Epac activation led to Rap1 activation, which suppressed 
RhoA activity and with it ROCK (Zieba et al. 2011). In permeabilised 
preparations of various arteries and smooth muscle preparations, Epac 
activation produced relaxation that was not susceptible to PKA inhibition with 
H89 (Zieba et al. 2011). The lack of dependence on PKA was confirmed 
through Epac1 knockdown, after which no Rap1 activation could be detected 
in response to isoprenaline application (Zieba et al. 2011). The integral 
involvement of Rap1B in aortic vessel tone was further shown through Rap1B 
knock out mice, vessels from which showed an increased susceptibly to 
contraction and a decreased acetylcholine response, due to a decrease in NO 
synthesis (Lakshmikanthan et al. 2014). 
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Recently Stott et al. (2017) showed that Epac activation caused relaxation in 
mesenteric and renal arterial preparations, mediated by Kv7 channel activation 
(Stott et al. 2016). In both these preparations, BKCa channel blockade blunted 
Epac-mediated relaxation. Interestingly, cAMP-mediated relaxation in 
response to isoprenaline was inhibited by the Epac inhibitor, ESI-09, in 
mesenteric artery preparations but not renal (Stott et al. 2016). A concern is 
that ESI-09, a nonspecific inhibitor shown to produce its effect via protein 
degradation, was used at 100nM, whereas the published concentration 
required for 50% inhibition (IC50) of Epac1 and Epac2 is 10.8µM and 4.4µM, 
respectively (Zhu et al. 2015). The same group further explored the effect of 
combining the inhibitors, CE3F4 and HJC0350. Again, CE3F4 was used at 
1µM, whereas its published IC50 is 10.7µM. The Epac2 inhibitor HJC0350 was 
used at 1µM, whereas its published IC50 is 0.3µM (Chen et al. 2013; Courilleau 
et al. 2013). Using these inhibitors at between 10 and 100 fold their IC50 it is 
hard to understand how the effect on relaxation can be attributed to Epac 
inhibition. Secondfold the non-specificity of these inhibitors is of concern, with 
the mechanism of action being general protein instability in one instance 
(Rehmann 2013).  Experiments previously undertaken in our laboratory show 
that ESI-09, when used at a near IC50 concentration inhibits constriction of the 
vessel (Personal Communication. C Dart & T Kamishima).  
While Epac activation has predominately been shown to affect vasodilatory 
mechanism, one intriguing effect would oppose vasodilation. Purves et al. 
(2009) reported that Epac activation in aortic smooth muscle cells inhibited 
KATP current, with the mechanism activating the Ca2+-sensitive protein 
phosphatase, calcineurin. These results are difficult to understand, however 
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they could implicate Epac as a negative feedback effector in conduit arteries 
following excessive cAMP generation, or a possible involvement in 
pathophysiology. Interestingly, stimulating cAMP synthesis with increase 
forskolin produced no inhibition, whereas forskolin treatment in the presence 
of PKA inhibitors reduced pinacidil-evoked KATP currents to the same extent 
as specific Epac activation. (Purves et al. 2009). 
Selective Epac activation in mesenteric artery produces a relaxation that is 
partially endothelium-dependent (Roberts et al. 2013).  Endothelium removal 
or NO synthase produced the same level of inhibition on Epac mediated 
relaxation. NO synthase inhibition was shown by the application of the NOS 
inhibitor, L-NG-Nitroarginine methyl ester (L-NAME). Indeed, Ca2+ imaging in 
endothelial sheets showed a transient increase in [Ca2+]i upon Epac activation. 
Ca2+ transients such as these can activate NO synthesis via Ca2+/calmodulin 
binding to eNOS (Förstermann & Sessa 2012).  
Within smooth muscle cells, Epac activation increased Ca2+ spark frequency, 
but did not change any other parameter of sparks i.e. amplitude/rise 
time/decay half-life (Roberts et al. 2013). As expected this increase in Ca2+ 
spark frequency translated to an increase in STOC frequency under Epac 
activation (Figure 1.9). In the same cells STOC amplitude was increased, due 
to an increase in the probability of larger STOCs. Confirmation of recorded 
currents being STOCs (i.e. activated by Ca2+ sparks) was shown by both 
ryanodine and iberiotoxin (a BKCa channel blocker) inhibiting the currents. This 
increase in STOCs caused hyperpolarization of the cell membrane, confirmed 
by current-clamp recordings. It is important to note that selective Epac 
activation was confirmed in mesenteric artery smooth muscle cells by 
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assessing both the level vasodilatory-associated stimulated phosphoprotein 
(VASP) phosphorylation by immunoblotting, a well know PKA phosphorylation 
substrate, and with electrophysiological experiments being undertaken in the 
presence of the selective PKA inhibitor, PKI-(Myr-14-22)-amide (Roberts et al. 
2013) therefore negating PKA activation in cells.  
 
Figure 1.9- Epac activation increases Ca2+ spark frequency and STOC frequency. 
Epac activation using the specific Epac activation 8-pCPT-AM increases Ca2+ spark 
frequency. Ca2+ sparks are localised, high concentrated (>10µM) releases of Ca2+ from 
ryanodine receptors (so called due to being sensitive to ryanodine). This release of Ca2+ 
causes activation of BKca channels, or Ca2+ activated K+ channels producing a transient 
outward current of potassium. This current causes a decrease in the membrane potential 
and decreases/inhibits voltage dependent Ca2+ entry, thereby causing relaxation of the 
vascular smooth muscle cell. 
1.7 Aims 
The aim of this thesis is to further elucidate Epac-mediated signaling that lends 
to vasodilation in mesenteric artery smooth muscle cells. Using both 
biochemical and electrophysiological techniques I aim to elucidate the 
signaling pathway by which Epac increases STOCs in freshly isolated 
mesenteric artery smooth muscle cells.  Our starting hypothesis is that, similar 
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to cardiomyocytes, Epac activation leads to activation of CaMKII, with this 
leading to phosphorylation of downstream signaling components.  
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2 Materials and Methods 
2.1 Animals 
Tissues were obtained from adult male Wistar rats (175-225g; Charles River 
Laboratories, Wilmington, USA) and wild-type, CaMKIIδ and CaMKIIγ 
knockout mice (C57B/6 background; provided by Dr Tim Curtis, Queens 
University, Belfast, UK). Wild-type mice were littermates of the homozygous 
knockouts. All animals were euthanized by a rising concentration of CO2 
followed by cervical dislocation. The care and euthanasia of animals 
conformed to the requirements of the UK Animals (Scientific Procedures) Act 
1986, and were approved by the University of Liverpool and Queens 
University, Belfast local ethics committee.  
2.2 Chemicals 
2-[N-(2-hidroxyethyl)-N-(4-methoxy-benzenesulfonyl)]-amino-N-(4-chloro- 
cinnamyl)-N-methylbenzylamine (KN-93), 2-[N-(4'- Methoxybenzenesulfonyl)] 
amino-N-(4'-chlorophenyl)-2-propenyl-N-methylbenzylamine (KN-92), 
carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-
dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester, monomethanesulfonate (BIM 
IX) (Cambridge Bioscience, Cambridge, UK), KN93 and KN92 were prepared 
as 500µM stocks in 100% DMSO (Final DMSO 0.1%). BIM-IX was prepared 
in DMSO at a stock concentration of 500µM (Final DMSO 0.05%) 8-(4-
chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate-AM (8-
pCPT-2'-O-Me-cAMP-AM; Biolog Life Science Institute, Bremen, Germany) 
was prepared as a 5mM stock in DMSO (stored at -80 oC). Thapsigargin 
(Merck (Calbiochem), Darmstadt, Germany) stock was made up in DMSO. All 
other chemicals were purchased from Sigma Aldrich (St.Louis, USA). 
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2.3 Cell Isolation 
Proximal first-order branches of rat superior mesenteric arteries were 
dissected and placed in low Ca2+ buffer containing (in mM): 134 NaCl, 6 KCl, 
0.42 Na2HPO4, 0.44 NaH2PO4, 10 HEPES, 10 glucose, 1.0 MgCl2, 0.1 CaCl2  
(pH 7.4) at 35 oC for 10 minutes.  After incubation, branches were moved to 
the first stage digestion buffer consisting of low Ca2+ buffer containing papain 
(1.4mg/ml; P4762 Papain from Papaya Latex), 4-dithioerythritol (0.9 mg/ml 
A7030 fatty acid free) and bovine serum albumin (BSA; 0.9mg/ml) for 8 to10 
minutes at 35 oC. Branches were then washed 3 times in pre-warmed, low Ca2+ 
buffer and transferred to second stage digestion buffer, consisting of low Ca2+ 
buffer containing hyaluronidase (0.9mg/ml ), collagenase (1.4 mg/ml) and BSA 
(0.9mg/ml) at 35 oC.  The incubation period for second stage digestion varied 
from 8 to 12 minutes. Branches were subsequently transferred to fresh ice-
cold, low Ca2+ buffer and carefully washed before dispersion of cells by gentle 
trituration of the tissue through a heat-polished glass pipette.  Dispersed rat 
mesenteric artery smooth muscle cells (RMASMCs) were stored in low Ca2+ 
buffer on ice and used in experiments between 1 and 8 hours after digestion. 
All chemicals were from Sigma-Aldrich. 
2.4 Cell Culture 
Chinese hamster ovary (CHO) cells were grown in Dulbecco’s Minimum 
Essential Medium containing 10% (v/v) foetal bovine serum and 4% (v/v) non-
essential amino acids supplemented with 50U/ml penicillin and streptomycin 
(Thermo Fisher Scientific (Invitrogen), Carlsbad, USA). Cells were kept at 37 
oC in 5% CO2 humidified atmosphere and passaged at a 1 in 8 dilution into 
fresh media when ~ 90% confluent.  
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2.5 Electrophysiology 
Spontaneous transient outward currents (STOCs) were recorded from single 
freshly isolated RMASMCs using the whole-cell configuration with an Axopatch 
200B amplifier (Molecular Devices, Sunnyvale, USA) as previously described 
(Roberts et al. 2013). Currents were filtered at 5 kHz and digitized at 10 kHz 
using a Digidata 1320A interface (Molecular Devices, Sunnyvale, USA) after 
which they were stored on a HP desktop PC. The pipette-filling solution 
contained (in mM): 140 KCl, 3 MgCl2, 0.2 EGTA, 10 HEPES, 3 Na2ATP, pH 
7.2 with KOH. Extracellular recording solutions contained (in mM): 6 KCl, 134 
NaCl, 1 MgCl2, 2 CaCl2, 10 HEPES, pH 7.4 with NaOH. STOCs were recorded 
at a holding potential of -20 mV and defined as events deviating from the 
baseline by a factor of 4 standard deviations above baseline noise. For 
experiments using the CamKII inhibitor peptide, Autoinhibitory-2-related 
peptide (1µM) was placed in the intracellular solution and allowed to dialyse 
into the cell for 5 minutes before the start of recording.  
2.6 Ca2+ Fluorometry: Measurement of SR Ca2+ content 
Transient Ca2+ release from the SR was triggered by pulse applications of the 
RyR activator caffeine, in single freshly-isolated. voltage-clamped and fura-2-
dialyzed RMASMCs, as previously described (Kamishima & McCarron 1996).  
Fura-2-pentapotassium was purchased from Thermo Fisher Scientific 
(Invitrogen, Carlsbad, USA).  Cells were suspended in low Ca2+ extracellular 
solution containing (in mM): 145 NaCl, 6 KCl, 1 MgCl2, 0.1 CaCl2, 10 HEPES 
and 10 glucose (pH 7.4 with NaOH) and placed in a perspex perfusion 
chamber with size 0 glass coverslip as a base. The cell was illuminated 
alternately with 340 and 380 nm light (bandpass 5 nm) using a PTI DeltaRAM 
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Illuminator (Horiba Scientific, Canada), and the emission signal was detected 
at 510 nm (40 nm bandpass). Background fluorescence counts for dual 
excitation wavelengths were taken after establishing a giga seal but before 
achieving the whole-cell clamp configuration.  On achieving the whole-cell 
configuration, the cell was dialyzed with pipette-filling solution containing (in 
mM): 145 CsCl, 3 MgCl2, 3 Na2ATP, 10 HEPES and 0.05 fura-2 
pentapotassium (pH 7.2 with CsOH).  The cell membrane potential was held 
at -60 mV. Cells were superfused with extracellular solution, in which CaCl2 
has been raised to 3 mM. Changes in photon counts were measured, 
background counts subtracted, and the ratio 340:380 obtained at 50 Hz.  
Fluorescence signals and cell membrane potentials were acquired using PTI 
Computer Software FelixGX (Horiba Scientific, Kyoto, Japan). RyRs were 
activated by rapid application of 5 mM caffeine using a U tube superfusion 
system.  Caffeine was applied for 100 ms by closing a solenoid valve placed 
downstream of the U tube ejection hole.  Valve closure was triggered by the 
patch clamp software producing a transient hyperpolarisation to -90mV 
(pCLAMP, version 10.2, Molecular Devices, Sunnyvale, USA).  Caffeine 
application was terminated by restoration of the membrane potential to -60 mV 
(i.e. holding potential), which causes a closure of the valve.  The brief 
membrane hyperpolarization thus served to accurately mark the duration of 
caffeine exposure on the fluorescence recording.  Valve closure was normally 
triggered once every 60 seconds with cells superfused in normal Ca2+ 
extracellular solution. After the 3rd or 4th caffeine application, the extracellular 
solution was switched to 3mM Ca2+  containing solution containing either 
vehicle control (DMSO) or 8-pCPT-AM (5μM), whilst caffeine transients were 
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continuously triggered at regular intervals. To convert the fluorescence ratio to 
cytoplasmic calcium concentration [Ca2+]i, in vitro calibration was carried out 
using EGTA-buffered intracellular solutions containing a range of free [Ca2]. 
The free [Ca2+] was calculated with MAXchelator (#46 v8;standford.edu). the 
fluorescence ratio in the absence of added CaCl2 (Rmin) and in the presence 
of saturating Ca2+ (Rmax) were decreased by 15% to account for viscosity 
(Poenie 1990), and the Kd of fura-2 was determined as 160 nM using the 
equation –  
!"#$ = &'	×	*	×(, − ,./0)(,.23 − ,) 	 
b = the ratio of fluorescent count at 340 nm / 380 nm. 
R= ratio at specific calcium concentration 
To profile Ca2+ transients, three parameters were examined: amplitude, 
duration and rate of cytosolic Ca2+ increase.  Amplitude was measured as the 
[Ca2+]i difference between resting and peak [Ca2+]i.  Duration was determined 
as the time that [Ca2+]i remained above half amplitude.  To examine the early 
stage of the cytosolic Ca2+ rise, data points from baseline to [Ca2+]i of 200 nM 
were fit with a third order polynomial using Sigmaplot 13 (Systat Software, San 
Jose, USA). The rate of Ca2+ increase was determined as the time taken to 
reach a [Ca2+]i of 100 nM.  For each parameter, the value of the 3rd Ca2+ 
transient after switching to the test solution was measured relative to that of 
the Ca2+ transient immediately before solution change. 
2.7 1D-gel electrophoresis & Immunoblotting 
First- or second-order branches of rat superior mesenteric arteries 
(approximately 5-8 branches) were homogenized in a pre-cooled hand-held 
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homogenizer, using 100-500 µL of ice-cold lysis buffer of composition (in mM): 
20 Tris-HCl; 250 NaCl, 3 EDTA, 3 EGTA, 0.5% (v/v) Triton-X 100, pH 7.6, 1% 
(v/v) mammalian protease inhibitor cocktail (Sigma Aldrich, St Louis, USA) and 
1X PhosSTOP (Roche, Basel, Switzerland). Resultant lysates were placed on 
ice for 10 minutes then centrifuged at 16,100 x g for 10 minutes at 4 oC . 
Supernatants were removed and mixed 1:3 (v/v) with 4 times sodium dodecyl 
sulfate (SDS) sample buffer (2% SDS final concentration), before heating to 
98 oC for 10 minutes.  Lysates for RyR, PLB and Epac1 immunoblots utilised 
RIPA buffer (in mM) 50 Tris-HCl (pH 7.4 at 21oC ), 150 NaCl, 0.1% SDS, 1% 
NP-40, 1% protease inhibitor or 1x SDS sample buffer to maximise 
phosphorylation preservation and increase protein solubilisation. RIPA lysates 
were then mixed 1:3 with 4 times sample buffer as with Triton X-100 based 
lysates. Samples were kept at -20 oC until use. Proteins within the lysates were 
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on either 5%, 10% or 15% polyacrylamide-Tris-glycine gels (dependent 
on the protein of interest, and transferred electrophoretically onto nitrocellulose 
membranes (Hybond ECL, GE Healthcare (Amersham), Little Chalfont, UK). 
When immunoblotting for either phospholamban or RyR, proteins were 
transferred to 0.22µm or 0.44µm PVDF membrane, respectively. 
Immunoblotting was performed as previously described (Purves et al. 2009). 
Where indicated, membranes were stripped at room temperature for 1 hour in 
50mM Tris (pH 6.8 at 21oC), 1% SDS or using Abcam’s recommended mild 
stripping buffer (1.5g glycine, 0.1g SDS, 1ml Tween per 100mL; pH 2.2). 
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2.8 2D-gel electrophoresis  
Seven cm, pH 3-10 immobilised pH Gradient (IPG) strips were used to 
separate proteins based on their Pi (BioRad, Hercules, USA) as per the BIO-
RAD ReadyStripTM IPG strip instruction manual.  IPG strips were rehydrated 
overnight in 135 µL rehydration buffer (8 M urea, 5 % (v/v) beta-
mecaptoethanol, 2% NP-40, 0.2 % (v/v) ampholytes (IPG) and a few grains of 
bromophenol blue (approx. 5mg). Samples were cup-loaded (10 µL) at the 
cathode end of the IPG strip. The electrophoresis run was a linear ramp preset 
method.  Parameters for the S1-conditioning step were 250 V for 15 minutes; 
for S2-voltage ramping step the voltage increased towards a maximum of 
4,000 V using linear ramping. The S3-final focusing step continued with a 
voltage step to a maximum voltage of 4,000V by rapid ramping (the limiting 
factor is current per strip set at 50µA). Focusing was stopped once approx. 
16,000 Vh had been reached. IPG strips were then removed from the cup 
loading tray, drained, and transferred into a 15 ml tube where the strips were 
equilibrated in SDS-containing buffers.  First the IPG strips were placed in 
equilibration buffer (6 M urea, 2 % (w/v) SDS, 50mM Tris-HCl, 10 % (v/v) 
glycerol and a few grains of bromophenol blue) with 10 mg/ml dithiothreitol 
(DTT) for 15 minutes and placed on an orbital shaker. Strips were then drained 
and placed in equilibration buffer with 30 mg/ml iodoacetamide (IAA) and 
gently shaken for a further 15 minutes.  IPG strips were run in the second 
dimension on 10 % SDS-PAGE gels (as per immunoblots) at 150 V (max 40 
mA per gel) until the dye front reached the end of the gel. Gels were then 
stained with  colloidal or silver staining, or transferred to nitrocellulose 
membranes as described in Immunoblot section (Section 2.7). 
  
72 
2.9 Colloidal/ Coomassie Staining 
Depending on the quantity of sample loaded, one or two staining methods 
were used, standard Coomassie staining or colloidal Coomassie staining 
(standard being used first, after which colloidal was used). Standard 
Coomassie staining was undertaken on gels as follows. SDS-PAGE gels were 
removed from the running cassette and rinsed in MilliQ water, quickly followed 
by immersion in staining solution (0.1% (w/v) Coomassie (R-250), 7% acetic 
acid, 50% methanol) and stained, with agitation, for 1 hour. Gels were then 
rinsed in MilliQ water and placed in de-staining solution (50% methanol, 10% 
acetic acid, 40% MilliQ water), with agitation until the background was clear. 
Colloidal Coomassie staining was undertaken as described in Kang et al. 
(2002). SDS-PAGE gels were twice rinsed in MilliQ water to remove SDS 
followed by overnight incubation, with agitation in staining buffer (0.02% (w/v) 
colloidal brilliant blue (G-250), 5% w/v aluminium sulphate, 10% v/v ethanol 
and 2% phosphoric acid). Gels were de-stained in 10% v/v ethanol and 2% 
phosphoric acid until the background was removed. 
2.10 Silver Staining 
Silver staining was undertaken using the ProteoSilver Plus Silver Stain Kit 
(Sigma Aldrich, St Louis, USA). After complete de-staining of Coomassie gels, 
SDS-PAGE gels were fixed in 50% (v/v) ethanol, 40% (v/v) MilliQ water and 
10% (v/v) acetic acid for between 40 mins and overnight. Gels were then 
transferred to 30% (v/v) ethanol for 10 minutes, washed in MilliQ water for 10 
minutes and placed in sensitisation buffer for 10 minutes. Gels were then 
washed twice for 10 minutes in MilliQ water, followed by a 10 minute incubation 
in silver staining solution. A short rinse for less than 1 minute in water followed 
by incubation in Developing Buffer (kit). Development of gels took approx. 5 
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minutes, after which it was terminated using Stop Buffer. The gel were then 
rinsed and imaged by a standard PC scanner (Epson, Hemel Hempstead, UK). 
All solutions compositions are proprietary and undisclosed by the provider 
Sigma-Aldrich. 
2.11 Immunoprecipitation  
Tissue was homogenised in modified immunoprecipitation (IP) buffer (in mM) 
50 Tris-HCl (pH 7.4 at 21oC), 150 NaCl, 1% (v/v) Triton X-100, 1% (v/v) 
protease inhibitor unless otherwise stated, followed by end-over-end 
incubation at 4 oC for 1 hour. Homogenates were spun at 16,100 x g for 10 
minutes after which homogenates were equally split (approx. 250µl per IP 
condition), with approx. 10% of total homogenate retained as an input 
reference. Homogenates were then incubated overnight on an end-over-end 
rotator with 2 µg of antibody or same species IgG control. 25 µL per sample of 
protein A/G agarose slurry (Thermo Fisher Scientific (Pierce), Carlsbad, USA) 
was prepared the following morning by 3 washes in IP buffer. Following 
washing, beads were suspended in IP buffer and divided equally between 
samples, followed by 2 hours incubation at 4 oC. Following this final incubation, 
beads were spun and washed three times in 1ml wash buffer containing (in 
mM) 50 Tris-HCl (pH 7.4), 150 NaCl , 0.1% (v/v) Triton X-100  with 5 minutes 
agitation between washes. After the final wash, beads were pelleted and two 
times sample buffer (final concentration 2% SDS) was added, followed by 10 
minutes heating at 98 oC. Samples were then loaded on SDS-PAGE for either 
immunoblotting or Coomassie/colloidal/silver staining. Proteins expected at 
~55kDa and ~25kDa used immunoprecipitation specific secondary antibodies. 
This eliminates the cross reaction of secondary antibodies with the IgG heavy 
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and light chains from antibodies used to pull down the protein of interest during 
the IP.  
2.12 Antibodies 
For immunoblotting, the primary antibodies used were phospho-CaMKII T286 
(D21E4; 1 in 1000), phospholamban (D9W8M; 1:500) and phospho-
serine/threonine (9631), all from Cell Signaling Technology (Danvers, USA).  
CaMKIId (EPR13095; 1:2500) and CaMKII (pan; EP1829Y; 1:2500) antibodies 
were from Abcam (Cambridge, UK). The phospho-phospholamban (T17: A010-
13; 1 in 5000) antibody was from Badrilla (Leeds, UK). Anti-BKca (APC-021; 
1:250) was from Chemicon International (Merck, Darmstadt, Germany). Anti-
PKA Regulatory II (ab75993) was from Abcam (Cambridge, UK).  Anti-Epac1 
antibodies used were as follows: Abcam (EPR6172; Cambridge, UK), Cell 
Signalling Technology (5D3; Danvers, USA) and Santa Cruz Biotechnology 
(A-5; Dallas, USA). Figure legends indicate which antibody was used. The 
secondary antibodies used were anti-mouse IgG (H+L) HRP conjugated 
polyclonal antibody and anti-rabbit IgG (H+L) HRP conjugated polyclonal 
antibody (Stratech Scientific Ltd., Newmarket, U.K.). For immunoprecipitation 
samples, secondary antibodies were: Veriblot for IP mouse (Abcam) and 
mouse anti-rabbit (conformational; Cell Signaling Technology). 
2.13 Expression of GST-RalGDS-RBD 
GST-RalGDS-RBD fusion protein, consisting of glutathione S-transferase 
(GST) fused to the Rap binding domain (RBD) of Ral guanine nucleotide 
dissociation stimulator (RalGDS); was expressed from the pGEX4T3-GST-
RalGDS-RBD plasmid, kindly provided by Prof. Johannes Bos (University 
Medical Centre, Utrecht, the Netherlands), in the BL21 strain of Escherichia 
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coli as described previously (Van Triest et al. 2001). Following induction cells 
were spun down and placed overnight at -20 oC to aid lysis, followed by 3 bouts 
of sonication for 30 seconds in lysis buffer containing (in mM) 150 NaCl, 1% 
(v/v) Triton X-100, 50 Tris (pH 7.5 at 21oC) and 1% (v/v) protease inhibitor 
(Sigma Aldrich, St.Louis, USA).  Lysates were spun to remove insoluble 
material before incubation at 4 oC for 1 hour with 1ml glutathione-coated 
sepharose bead slurry (GE Healthcare, Little Chalfont, UK). The bead/lysate 
mixture was then poured into an empty PD-10 column followed by 30mL 
phosphate-buffered saline (PBS). Bound GST-RalGDS-RBD fusion protein 
was eluted using elution buffer containing (in mM) 50 Tris-HCl pH 8.0, 10 
reduced glutathione. Elutants containing GST-RalGDS-RBD were pooled, 
followed by buffer exchange with a solution containing (in mM) 50 Tris-HCl (pH 
7.2 at 21oC), 150 NaCl, 0.5% (v/v) Triton X-100, 5 MgCl2, 1 dithiothreitol (DTT), 
1% protease inhibitors and 10% glycerol using a P10 column (Thermo Fisher 
Scientific (Pierce), Carlsbad, USA). 
2.14 Expression of PKA Regulatory IIa (His Tagged) 
PKA RIIa-His fusion protein, consisting of protein kinase A (PKA) RIIa subunits 
possessing a his-tag, was expressed from the PET280-PKAR2a plasmid 
(kindly provided by John Scott (University of Washington), in the pLysS strain 
of Escherichia coli. A starter culture of 50ml Luria-Bertani (LB) 
w/chloramphenicol (35 µg/ml) + kanamycin (50 µg/ml) (LB+Chl/Kan) was 
grown overnight and 5ml was used to inoculate 750ml LB +Chl/Kan. This 
culture was grown until an optical density at 600nm (OD600) of 0.6. Cells were 
then induced overnight with 0.5mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) at 18 oC. Cells were pelleted (10 mins at 5000 x g) followed by 
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resuspension in 40ml ice cold lysis buffer containing (in mM) 50 Tris-HCl 
(pH7.4 @ 21 oC), 300 NaCl, 1 DTT, 10% (v/v) glycerol, 10 imidazole, 0.1 
EDTA, 0.1 EGTA and 1% (v/v) protease inhibitor.  Lysis by sonication with five 
15 second bursts was undertaken followed by filtration of the lysate through a 
0.45 µM filter. Filtered lysates were spun at 8000 x g for 1 hour at 4 oC before 
the supernatant was mixed with Ni-NTA agarose beads (Qiagen, Hilden, 
Germany) for 1 hour at 4 oC. Beads were sedimented on a column then 
washed with 30 ml of binding buffer containing (in mM) 50 Tris-HCl pH 7.4, 
500 NaCl, 10% (v/v) glycerol and 20 imidazole. PKA RIIa was eluted in 0.5 ml 
fractions with elution buffer (in mM) 50 Tris-HCl (pH7.4 @ oC), 300 NaCl, 10% 
(v/v) glycerol and 500 imidazole. Fractions were assessed by SDS-PAGE 
before pooling of PKA RIIa containing fractions, followed by protein 
concentration determination by bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific (Pierce), Carlsbad, USA). 
2.15 Rap1-GTP pull-down assay  
50 µL of Glutathione-sepharose 4B beads (Thermo Fisher Scientific (Pierce), 
Carlsbad, USA) at 10% (v/v) in PBS (GE Healthcare), were washed three 
times in wash/lysis/binding buffer (Thermo Fisher Scientific (Pierce), Carlsbad, 
USA) followed by incubation with 20 µg GST-RalGDS-RBD fusion protein for 
1 hour at 4 °C. First-order proximal rat superior mesenteric arteries were 
incubated with 5 μM 8-pCPT-2'-O-Me-cAMP-AM in extracellular 
electrophysiology recording solution (2mM Ca2+) at room temperature (18–22 
oC) or the equivalent volume of vehicle (dimethyl sulfoxide, DMSO) for 5 
minutes, homogenised in 300 μl of ice-cold lysis buffer per artery and 
centrifuged at 16,100 x g for 10 minutes at 4°C.  One-tenth of the supernatant 
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was removed and heated at 98 oC for 5 minutes after mixing 3:1 with 4 times 
SDS sample buffer for later assessment of total Rap1 levels.  The remaining 
supernatant was mixed with washed GST-RalGDS-RBD-bound sepharose 
beads for 1 hour at 4 oC.  After washing the beads four times in ice-cold 
lysis/binding/wash buffer, proteins were eluted in two times SDS sample buffer 
and heated at 98 oC for 5 minutes.  Proteins were resolved by SDS-PAGE 
followed by immunoblotting as described above. 
2.16 8-AHA-2’-O-Me-cAMP-Agarose Pulldowns 
After homogenisation, lysates were mixed end-over-end at 4 oC for 1 hour, 
followed by centrifugation at 16,100 x g for 10 minutes. 8-AHA-2’-O-Me-cAMP 
agarose beads (Biolog, Bremen, Germany) were prepared by washing 3 times 
in lysis buffer. Lysate supernatant and beads were combined and mixed at 4 
oC overnight (18 hours). Beads were pelleted and washed three times in 1ml 
lysis buffer with 5 minutes agitation between washes. After the final wash 
beads were pelleted and suspended in two times sample buffer and heated at 
98 oC for 10 minutes. 
2.17 Total RNA extraction and reverse transcription 
Total RNA was extracted and purified from first- or second-order branches of 
rat superior mesenteric arteries using an RNeasy Mini Kit® (Qiagen, Hilden, 
Germany), as per the manufacturer’s instructions. Extracted RNA was treated 
with DNase I by incubating total RNA with 10x DNase I buffer and  DNase I (1 
U/µl; Invitrogen) at room temperature to 15 minutes. EDTA (25 mM) was then 
added and the reaction heated to 65 oC for 10 minutes. First strand cDNA was 
synthesized using SuperScript® III reverse transcriptase (Thermo Fisher 
Scientific (Invitrogen), Carlsbad, USA).  In brief for each reaction, 1 Oligo (dT), 
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total DNase I-treated RNA, dNTPs (10 mM each) and nuclease free H2O were 
heated at 65 oC for 5 minutes. Reaction tubes were quickly chilled on ice before 
the addition of five times reaction  buffer, dithiothreitol (0.1 M) and  RNase Out 
(40U/µl). The samples were then incubated at 42 oC for 2 minutes. 
SuperScript® III reverse transcriptase (200 U/µl) was added to the reaction 
tubes, then incubated at 50 oC for 50 minutes. Reverse transcriptase was 
inactivated by heating at 85 oC for 15 minutes. The purity and concentration of 
the resulting cDNA template was determined by measuring absorbance at 260 
and 280 nm using a NanoDrop spectrophotometer, with a 1.8 ratio indicating 
pure DNA with minimal protein contaminants (Thermo Fisher Scientific, 
Carlsbad, USA). 
2.18 Polymerase Chain Reaction (PCR) 
Touchdown PCR (decreasing the annealing temperature per PCR cycle from 
high to low) was carried out using HotStarTaq Master Mix Plus (Qiagen, 
Hilden, Germany), following the manufacturer’s instructions.  Primers used to 
amplify specific CaMKII isoforms were:  
CaMKIId  
• Forward (5-GCATGTGGCGTCATCCTCTA-3)  
• Reverse (5-TCCTTTACCCCATCCGGTT-3)  
CaMKIIg 
• Forward (5-CATCCACCAGCATGACATCG-3)  
• Reverse (5-CTTTCCTCAAGACCTCAGG-3).  
CaMKIId Splice Variation  
• Forward (5- CGGAAATTGAAGGGTGCCATC-3) 
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• Reverse (5-CCCTACCAGGTGTACGTGAG-3)  
CaMKIIg Splice Variation  
• Forward (5-GAAGGGTGCCATCCTCACAA-3)  
• Reverse (5-GTTACCAAGGGCTTCTGGCT-3) 
Following an initial 5 minute denaturing step at 95 oC, each reaction went 
through the following touchdown PCR protocol for 15 cycles: 94 oC for 1 
minute, annealing temperature (ranging from 65 to 50 oC – decreasing by 1 oC 
each cycle) for 30 seconds, extension at 72 oC for 1 minute.  After the 
touchdown element 25 cycles at the lowest annealing temperature took place. 
At the end of the cycles, final extension was at 72 oC for 5 minutes. Products 
were analysed by running on a 3 % (w/v) agarose gel containing Midori Green 
(1:10,000; GC Biotech, Alphen aan den Rijn, Netherlands) for ~1 hour at 80 V. 
A 100 bp DNA ladder (New England Biolabs, Ipswich, USA) was used Gels 
were viewed under ultraviolet (UV) light and analysed using Quality 4.6.4 and 
ChemDoc software (Bio-Rad, Hercules, USA).  Bands were excised under UV 
light and products purified using a QIAquick Gel Extraction kit (Qiagen, Hilden, 
Germany) as per the manufacturer’s instructions. Briefly, bands were weighed 
and Buffer QC was added at a 1:6 ratio, after which bands were dissolved at 
50 oC for 10 minutes.  Isopropanol was added at a 1:1 weight of band to volume 
of isopropanol. The dissolved gel was then bound to a QIAquick column using 
centrifugation (10,000g). The column was washed with 750 µl Buffer PE and 
centrifuged (10,000g), before being left to dry for 2 minutes. DNA was eluted 
using 30µl water. Products were verified by sequencing (GATC Biotech, 
Germany). 
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2.19 IP3 Competitive ELISA Assay 
An IP3 rat ELISA assay was purchased from Bluegene Biotech (Shanghai, 
China), all buffers used were included with the kit. One whole aortae, or one 
mesenteric bed, was homogenised in 150 µL ice-cold PBS containing (in mM) 
137 NaCl, 2.7 KCl, 10 Na2PO4,1.8 K2PO4 (pH7.4 @ 21 oC), followed by 2 
rounds of sonication. Homogenates were centrifuged at 1500 x g for 15 
minutes at 4 oC. After pelleting cell debris, the supernatant was incubated in 
pre-coated anti-IP3 wells along with 10 µL Balance Solution and 50 µL 
Conjugate Solution for 1 hour at 37 oC. This was followed by 3 washes with 
wash buffer, then a final drying of the wells by inverting the wells onto a paper 
towel. To dry wells, 50 µL of Solution A and 50 µL of Solution B were added 
and the wells mixed, followed by incubation for 30 minutes at 37 oC Stop 
Solution was then added, wells were mixed well and the optical density at 450 
nm (O.D450)  was measured on a spectrophotometer. Known concentration 
standards were also treated as the samples apart from the addition of balance 
solution. These were used to produce a standard curve to quantify IP3 levels 
in tissue lysates. 
2.20  Statistical Analysis 
Results are expressed as the mean ± S.E.M. Intergroup differences were 
analysed using repeated measures  ANOVA followed by Newman-Keuls post-
hoc test for experiments where a single cell was exposed to three treatments, 
or Student’s t-test for simple comparisons between two groups; levels of 
significance were * p < 0.05, **p < 0.01. All data was tested for normality using 
a Shapiro-Wilk normality test. 
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Results 
3 Epac activates Ca2+/calmodulin-dependent kinase 2 
(CaMKII) in arterial smooth muscle  
3.1 Introduction 
Following the identification of Epac as a downstream target of cAMP, 
much research has been undertaken to explore it’s involvement in a number 
of cAMP-mediated signalling pathways (de Rooij et al. 1998; Kawasaki et al. 
1998). Our group has previously explored the role of Epac in vasculature, 
showing Epac activation produces relaxation of rat mesenteric arteries 
(Roberts et al. 2013). Epac specifically modulates Ca2+ sparks in vascular 
smooth muscle cells, but the mechanism by how it does this is unknown. In 
line with the aims of this thesis, we explored possible mechanisms by how 
Epac increases Ca2+ sparks, and with it STOCs. Very little research has been 
undertaken on Ca2+ spark modulation in smooth muscle, however an abundant 
amount of research exists on Ca2+ spark modulation in cardiomyocytes. 
Indeed, a protein commonly shown to modulate Ca2+ sparks in cardiomyocytes 
is calcium/calmodulin-dependent protein kinase II (CaMKII), which has been 
shown downstream on Epac activation in cardiomyocytes (Oestreich et al. 
2007; Pereira et al. 2007). 
3.1.1 Ca2+/calmodulin-dependent kinase 2 (CaMKII) 
CaMKII, one of the 74 kinases within the Serine/Threonine Ca2+/CaM-
dependent kinase family, is a large multifunctional kinase that is made up of 
12 subunits that stack in 2 hexameric rings (Rellos et al. 2010; Manning et al. 
2002). CaMKII is produced from 4 closely-related genes (a, b, g and d) that 
produce 4 isoforms (Swulius & Waxham 2013). In addition, CaMKII genes 
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undergo numerous alternative splicing events, giving rise to a number of 
different variants 50-68kDa (Swulius & Waxham 2013; Toussaint et al. 2016). 
Each subunit of the CaMKII holoenzyme consists of 3 domains, an N-terminal 
catalytic region, an autoregulatory domain and a C-terminal association 
domain responsible for forming the dodecameric structure (Hoelz et al. 2003; 
Hudmon & Schulman 2002) (Figure 3.1). 
 
Figure 3.1– CaMKII Structure. A) CaMKII consists of three domains, catalytic, 
autoregulatory and association. B) Schematic of CaMKII forming a hexameric ring. C) 
Two hexameric rings form to produce the dodecameric CaMKII holoenzyme. 
Under resting conditions, the autoregulatory domain inhibits the activity of the 
catalytic region through tight affinity interactions (Soderling & Stull 2001; 
Payne et al. 1988).  Binding of Ca2+/CaM “opens up” the structure and 
disinhibits CaMKII (Payne et al. 1988). Upon this activation, a single CaMKII 
subunit can phosphorylate a neighbouring CaMKII subunit at a threonine 
residue T286/7, known as autophosphorylation (Meyer et al. 1992). Threonine 
286 (287 in the b,g,d isoform) is conserved in all four a, b, g and d. This 
phosphorylation produces autonomous activity, where the removal of 
Ca2+/CaM does not reduce activation. This autonomous activity is due to the 
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position of the phospho-threonine, which inhibits interactions between the 
catalytic and the regulatory domains and thus reformation of the 
closed/inactive state. This activation continues until the phosphate is removed 
by a phosphatase (Erickson 2014).  This gives the kinase so-called ‘memory’ 
of previous Ca2+ events. See Coultrap and Bayer (2012) for an in-depth review 
on CaMKII (Coultrap & Bayer 2012).  
In differentiated vascular smooth muscle, which relies on complex patterns of 
Ca2+ signalling, surprisingly little is known about the functional role of this Ca2+-
sensing enzyme.  The main CaMKII holoenzymes found in vascular smooth 
muscle form from splice products of CaMKIIg and CaMKIId genes  (Singer 
2012). CaMKIIg expression dominates in contractile smooth muscle, with  
CaMKIId expressed as a relatively minor isoform (Kim et al. 2000; Marganski 
et al. 2005). CaMKIId is up-regulated in synthetic/proliferating  smooth muscle 
and is required for injury-induced neointima formation, largely through its 
regulation of the expression and activity of cell cycle activators (Li et al. 2011). 
In large blood vessels (ferret aortae and pig carotid artery) CaMKII is activated 
in response to contractile stimuli, with activation maintained throughout tonic 
contraction (Kim et al. 2000; Rokolya & Singer 2000) . However, in mesenteric 
arteries, CaMKII deletion has no effect on vascular tone in response to high 
extracellular K+, angiotensin II, or phenylephrine (Prasad et al. 2013). Instead, 
CaMKII supports intracellular Ca2+ homeostasis by phosphorylating and 
maintaining the activity of voltage-dependent Ca2+ channels and 
phospholamban (Prasad et al. 2013). 
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3.2 Aim 
The aim of this part of the study was to: 
1. Determine the expression of CaMKII isoforms within mesenteric artery;  
2. Assess isoform-selective activation by Epac;  
3. Establish the role of CaMKII activation in Epac-induced STOC activity 
in rat mesenteric artery smooth muscle cells.  
3.3 Results 
3.3.1 Epac1 is widely expressed in vascular beds 
As a starting experiment, we first assessed the relative expression of Epac in 
a range of vascular beds, including aorta, cerebral, femoral, mesenteric and 
renal beds, using immunoblot analysis (Figure 3.2).  Immunoblots of arterial 
lysates, using antibodies against Epac1,  produced an immunoreactive doublet 
at ~100 kDa, the predicted molecular weight for Epac1 (Kawasaki et al. 1998). 
Epac1, the product of the RAPGEF3 gene, possesses several splice variants 
explaining the visualisation of a doublet (Isoform 1- 104kDa, Isoform 2 – 100 
kDa (Uniprot Database (Q9Z1C8). Immunoblots using antibodies against 
Epac2 produced no immunoreactive bands for arterial lysates, however the 
positive control (rat ventricular tissue) produced a clear doublet at ~120 kDa, 
the predicted molecular weight for Epac2 (Purves et al. 2009). Expression 
levels of Epac1 varied between different vascular beds, with the highest 
expression found in cerebral arteries and the lowest in femoral arteries (Figure 
3.2; equal protein loading 20 µg per lane). 
Previous work from our lab using a combination of myography, Ca2+ imaging 
and electrophysiology has shown that selective activation of Epac in rat 
mesenteric artery induces vasorelaxation, by increasing Ca2+ spark and STOC 
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activity (Roberts et al. 2013). Since we have significant background 
information in this artery, and the mesenteric bed provides relatively large 
amounts of tissue (compared to for example cerebral arteries), we chose to 
conduct subsequent studies on these resistance vessels. 
 
Figure 3.2- Epac1 is not equally expressed throughout the arterial vasculature. A) 
Proteins within lysates from different vascular beds (lysates equalized for protein 
content; 20 µg per lane) were separated on 8% polyacrylamide gels. Membranes probed 
using anti-Epac1 (Cell Signaling Technology 1:1000) showed variation in Epac1 
expression in different vascular beds. B) Summary of relative Epac expression in various 
artery beds, with cerebral lysates being given a value of 1 due to the highest intensity. 
 
3.3.2 mRNAs for multiple splice variants of CaMKII exist in the 
vasculature 
We next assessed the expression of CaMKII within different vascular beds. 
Reverse transcription-PCR, using cDNA derived from arterial lysates as a 
template and primers designed to detect CaMKII isoforms, showed clear d and 
g isoform expression in all vascular beds (Figure 3.3A). CaMKIIb was also 
present. This isoform is predominantly expressed in neuronal and endothelial 
tissue, as assessed by immunocytochemistry and immunoblotting (Soderling 
& Stull 2001; Toussaint et al. 2015). Whole arterial lysates contain a 
combination of different cell types, and we believe that the presence of the b 
isoform likely represents the presence of cDNA originating from nerve and 
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endothelial cell-derived mRNA.    Primers designed to amplify Von Willeband 
factor, an endothelial cell marker, also produced clear PCR products, 
confirming the presence of cDNA originating from the endothelium within our 
cDNA library.  Alternative splicing of the d and g genes produces numerous 
splice variants (Toussaint et al. 2016). Thus, we next designed PCR primers 
to detect d and g splice variants. These splice variant primers were designed 
so that different splice variants produced different sized PCR products. This 
was confirmed by amplifying numerous variants from other tissues (Figure 
3.3C). 
RT-PCR using splice variant-specific primers confirmed the presence of 
mRNA for at least two g variants and two d variants in mesenteric arteries 
(Figure 3.3B).  Sequencing of these products revealed them to be g predicted 
isoforms X18 and X16, and d isoforms 2 and/or 3. 
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Figure 3.3– Mesenteric artery cDNA library contains numerous CaMKII Isoforms and 
Splice Variants. A) Mesenteric artery cDNA library was examined for CaMKII b, d and 
g expression. Primers designed to amplify Von Willeband Factor (endothelial cell marker) and 
smooth muscle a actin (smooth muscle marker) were also used. PCR products were 
separated on a 1.5% agarose gel B) The same cDNA library as in A was used to examine 
which b, d and g splice variants were expressed. Following PCR, 3% agarose gels were used 
to allow separation of products C) Numerous rat tissues cDNA libraries were examined to 
confirm that splice variant primers detect multiple variants. PCR products were separated on 
3% agarose gels.  
 
3.3.3 Multiple splice variants of CaMKII are expressed in the vasculature 
Consistent with the expression of multiple CaMKII mRNA isoforms, 
immunoblots of arterial lysates using pan-specific CaMKII antibodies, which 
bind all four isoforms of CaMKII, produced three or four distinct 
immunoreactive bands (Figure 3.4). Interestingly, different arterial beds 
appeared to produce different banding patterns in relation to the relative 
density between certain bands. Aortic preparations possessed a more intense 
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lower molecular weight (MW) band in contrast to cerebral, in which the higher 
MW band was prominent (Figure 3.4C).  
3.3.4 Selective Epac activation causes autophosphorylation of specific 
CaMKII isoforms in rat mesenteric artery 
To assess the effect of Epac activation on CaMKII activity, we incubated 
arteries in the selective Epac activator 8-pCPT-2`-O-Me-cAMP (8-pCPT; 
10µM) or vehicle control (DMSO). As a positive control, we also incubated 
mesenteric arteries in the Ca2+ ionophore A23187 (12.5µM), which would be 
expected to globally raise intracellular [Ca2+] and activate CaMKII. Immunoblot 
analysis of 8-pCPT-treated arterial lysates indicated phosphorylation of 
CaMKII at pThr286, an autophosphorylation site that indicates CaMKII 
activation, following 8-pCPT exposure (n=3; Figure 3.4).  Of the three or four 
immunoreactive bands detected by pan-specific anti-CaMKII, one band 
(second from bottom) strongly bound phospho-CaMKII antibodies against 
pThr286/7 following 8-pCPT-AM treatment.  Exposure to A23187 induced 
phosphorylation of all immunoreactive bands detected by pan-specific anti-
CaMKII (Figure 3.4).     
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Figure 3.4- Epac activation induces autophosphorylation of CaMKII. A) 
Representative immunoblots of CaMKII activation in aorta, renal, cerebral and 
mesenteric vasculature in response to 8-pCPT. B) Histogram of CaMKII pT286/Pan ratio 
in vascular beds in control and stimulated vessels (n=3 animals). C) The two major 
CaMKII bands present in the vasculature are expressed at different proportions in 
various vascular beds.  
 
3.3.5 Selective Epac activation causes autophosphorylation of 
predominantly CaMKII g isoforms 
To identify the CaMKII isoform/s differentially phosphorylated by Epac 
activation, we used immunoblotting to analyse arterial tissue obtained from 
mice in which the gene encoding either CaMKIId or CaMKIIg had been globally 
knocked out (Backs et al. 2009; Backs et al. 2010). Immunoblots of arterial 
lysates from wildtype mice using CaMKII antibodies showed a similar pattern 
of three/four immunoreactive bands as observed in rat tissue (Figure 3.5).  In 
arterial lysates obtained from CaMKIId knockout animals, the lowest molecular 
weight band was absent. In contrast, in CaMKIIg knockout lysates, the lower 
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band remained but the higher molecular weight bands were missing (Figure 
3.5)
 
Figure 3.5–Arterial lysates from knockout mice map immunoreactive bands to 
CaMKIId and g isoforms. A) Representative immunoblots of mesenteric artery lysates 
from wildtype mice, CaMKIId and CaMKIIg knockout mice. B) Representative 
immunoblots of renal artery lysates from wildtype mice, CaMKIId and g knockout mice 
C) Simplified diagram showing which isoform is responsible for each band in CaMKII 
immunoblots. 
 
The potential involvement of CaMKIId downstream of Epac activation was 
confirmed by 2D western blot, which separated isoforms on that basis of 
isoelectric point (PI; 3-10 IPG Strip) and molecular weight (Figure 3.6). 
Immunoblots for CaMKII (pT286) and CaMKIId showed that the highest intensity 
“dot” when probed with CaMKII (pT286) was the same “dot” as that when 
probed with an anti-CaMKIId antibody (Figure 3.6). Knock out (KO) animals 
were not used for functional studies as d and g isoforms are known to 
functionally compensate for each other (Kreusser et al. 2014). 
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Figure 3.6- CaMKIId cannot be ruled out of Epac mediated CaMKII activation. Shown 
is an immunoblot of 8-pCPT-AM stimulated rat mesenteric arterial lysates separated 
using 2D electrophoresis and western blotting. During 2D electrophoresis proteins are 
simultaneously separated by molecular weight and isoelectric point. Proteins were 
subsequently immunoblotted against CaMKIId and CaMKII (pT286). Bottom is a 
schematic of the observed CaMKII immunoblots. Circled in red is the protein “dot” which 
is present in both immunoblots and overlaps in both immunoblots.  
 
3.3.6 Inhibition of CaMKII attenuates the increase in STOC frequency 
mediated by Epac in rat mesenteric myocytes 
Selective activation of Epac with 8-pCPT-AM induces vasorelaxation by 
increasing both the frequency and amplitude of STOCs in rat mesenteric beds 
(Figure 3.7)  (Roberts et al. 2013).  
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Figure 3.7- Epac activation with 8-pCPT-AM produces an increase in STOC 
frequency and a higher probability of larger STOCs. A) Representative trace of a 
freshly isolated rat mesenteric artery smooth muscle cell in whole cell configuration. 8-
pCPT-AM was applied before wash out B) Frequency histogram of the representative 
cell above. C) STOC amplitude probability in basal and 8-pCPT-AM incubated 
conditions. 
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Several parameters were explored in basal and stimulated (8-pCPT-AM) 
conditions: frequency, STOC duration, STOC rise time (baseline to peak), 
STOC decay time (peak to return of baseline), charge per STOC, total outward 
charge per analysed segment and average STOC amplitude. Decay and rise 
rate were also obtained by dividing amplitude by rise or decay time. No 
difference was seen in STOC duration, rise time, decay time. This is in line 
with the Ca2+ sparks analysed by Roberts et al.  (2013) who saw no difference 
in decay rate. An increase in charge was expected as it is this charge that 
produces the hyperpolarisation of the cell, as seen by Roberts et al. 2013. 
Epac mediated STOCs are larger in amplitude under Epac activation 
compared to control (Table 3.1). 
Parameter Control 8-pCPT-AM P-value 
Frequency (s-1) 0.62 ± 0.11 1.71 ±0.22 0.013 
Amplitude (pA) 19.24 ±1.92 25.52 ± 1.72 0.043 
Duration (s) 0.031 ± 0.003 0.036 ± 0.003 ns 
Duration/Amplitude (s/pA) 0.0017 ± 0.0001 0.0014 ± 0.00007 0.0326 
Rise Time (s) 0.013 ± 0.001 0.015 ± 0.001 ns 
Decay Time (s) 0.018 ± 0.002 0.021 ± 0.003 ns 
Rise Rate (pA/s) 1637 ± 183.5 2241 ± 191.7 ns (0.073) 
Decay Rate (pA/s) 1404 ± 201.4 1629 ± 113.7 Ns 
Charge- Sum 2.30 ± 0.68 8.59 ± 1.46 0.023 
Charge- per STOC 0.46 ± 0.07 0.66 ± 0.06 Ns (0.077) 
Table 3.1– Table summarising the effects of Epac activation on STOC kinetics: 
Epac activation significantly effects Frequency, Amplitude, Duration/Amplitude and 
Charge per cell condition. Epac activation does no significantly affect other parameters 
such as total duration, rise/decay time, rise/decay rate and charge per STOC
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Furthermore, 8-pCPT-AM-induced STOCs were inhibited by pre-incubation of 
cells in the RyR inhibitor, ryanodine, confirming that they are triggered by 
underlying RyR/Ca2+ spark activity. In other experiments STOC frequency was 
significantly attenuated by the application of ryanodine after 8-pCPT-AM 
induced STOCs were activated (2.54 ±  0.59 STOCs s-1 vs. 0.58 ± 0.18 STOCs 
s-1, mean ± SEM, p<0.05, paired t-test, n=4 (Figure 3.8).  
 
Figure 3.8– Epac activation produces its effects through ryanodine receptors in 
RMASMCs. A) STOCs recorded in a freshly isolated rat mesenteric artery smooth 
muscle cell under whole-cell configuration. Application of ryanodine reversed the 
increase in STOC frequency and amplitude induced by 8-pCPT-AM.  B) In cells pre-
incubated in ryanodine (15 μM), application of 8-pCPT-AM does not increase STOC 
activity (n = 3). C) Summary of STOC frequency for experiments shown in (A). D) 
Summary of STOC frequency for experiments shown in (B). 
To assess whether 8-pCPT-induced activation of CaMKII is involved in the 
activation of STOC activity, we used the whole-cell recording technique to 
record STOCs in mesenteric artery myocytes following activation of Epac in 
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the presence and absence of pharmacological inhibitors of CaMKII. 
Application of the CaMKII inhibitor KN-93 (500nM) reversed the increase in 
STOC frequency (1.71 ± 0.22 STOCs s-1 to 0.61 ± 0.18 STOCs s-1; mean ± 
SEM) induced by 8-pCPT-AM (5 µM; p<0.05; n=5; paired t-test; Figure 3.9). 
The mean amplitude of STOCs in the presence of 8-pCPT-AM was 
significantly different to the mean amplitude in the presence of 8-pCPT-AM + 
KN93 (32.6  ± 3.00 pA vs. 25.86 ± 2.43 pA, mean ± SEM, p<0.01, paired t-
test, n=5). To further assess and confirm it is the inhibition of CaMKII that 
reverts STOC frequency to baseline, KN-92, the inactive analogue of KN-93, 
was used. 
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Figure 3.9– Epac-mediated increase in STOCs are attenuated by CaMKII inhibition 
(KN-93). A)  Representative trace of a freshly isolated rat mesenteric artery smooth 
muscle in whole cell configuration exposed to 8-pCPT-AM (5 µM), followed by addition 
of the CaMKII inhibitor, KN-93 (500 nM). 25 second inserts highlight analysed areas. 
Bar indicated 20 pA. B) Summary of STOC frequency for experiments as in A (n=5) C) 
STOC frequency histogram of A. D) Probability frequency histogram of the STOC 
amplitude from A. 
 
Unlike KN-93, addition of KN-92 (500 nM) did not reverse the increase in 
STOC frequency induced by 8-pCPT-AM back to basal STOC frequency (1.05 
± 0.36 STOCs s-1 vs. 1.61 ± 0.38 STOCs s-1, mean ± SEM, p>0.05, paired t-
test, n=3) (Figure 3.10). To further confirm the involvement of CaMKII, we also 
undertook experiments using autocamtide-2-inhibitory peptide (AIP), a highly 
specific peptide inhibitor of CaMKII that corresponds to its autoinhibitory 
domain (Ishida et al. 1995).
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Figure 3.10- Epac-mediated increase in STOCs are not affected by KN-92, the inactive 
analogue of KN93. A) Representative trace of a freshly isolated rat mesenteric artery smooth 
muscle cell in whole-cell configuration exposed to 8-pCPT-AM (5 µM), followed by addition of 
KN-92 (500 nM), an inactive analogue of KN-93. Inserts highlight analysed areas. Bar 
indicates 20 pA. B) Summary of STOC frequency for experiments shown in A (n=3) C) 
Frequency histogram of the above representative trace against time. D) Probability frequency 
histogram of STOC amplitude of the cell in A. 
 
Inclusion of this peptide in the pipette-filling solution (1µM), followed by an 
incubation to allow cell dialysis, prevented Epac-mediated STOC frequency 
increases (1.08 ± 0.23 STOCs s-1 vs. 0.59 ± 0.12 STOCs s-1, mean ± SEM, 
p<0.05, paired t-test, n=4; Figure 3.11). The statistical analysis in-fact showed 
a decrease in STOC frequency in the presence of Epac activation with 
inclusion of AIP. This we believe is due to delayed inhibition of basal CaMKII 
activity by AIP during the experiment. This basal CamKII activation can be 
seen with a degree of CamKII autophosphorylation in control arteries (Figure 
3.4). 
 
Figure 3.11– CaMKII inhibition by an intracellular blocking peptide inhibits Epac 
mediated STOC increases. A) Representative trace of a freshly isolated rat mesenteric 
artery smooth muscle cell in whole-cell configuration exposed to 8-pCPT-AM (5µM) after 
dialysis of autocamtide inhibitory peptide (1µM), the CaMKII inhibitor peptide. B) 
Summary of STOC frequency from experiments as in A (n=4). C) Frequency histogram 
of the above representative trace. 
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3.4 Discussion 
The key findings of this chapter are: 
1. Vascular tissue expresses several different isoforms of CaMKII that 
may vary in relative levels between different vascular beds; 
2. Selective activation of Epac causes autophosphorylation (activation) of 
CaMKII, primarily the g isoforms; 
3. Activation of CaMKII is required to mediate Epac-driven increases in 
STOC activity. 
The main downstream targets for CaMKII phosphorylation in the heart are 
RyRs, a major class of Ca2+ release channel on the SR, and phospholamban, 
a protein that controls the activity of the SERCA pump. CaMKII 
phosphorylation of these targets increases store Ca2+ release by increasing 
both cardiac RyR2 Ca2+ sensitivity and Ca2+ content of the store (Grimm et al. 
2015; Ai et al. 2005; X. H.T. Wehrens et al. 2004).  
The main CaMKII holoenzymes found in vascular smooth muscle form 
from splice products from CaMKIIg and CaMKIId genes (Singer 2012).  
Consistent with this we found messenger RNA encoding at least two CaMKIIg 
variants and two CaMKIId variants in rat mesenteric artery.  The expression of 
multiple CaMKII isoforms in this tissue was confirmed by immunoblots of 
arterial lysates using pan-specific CaMKII antibodies that produce three or four 
immunoreactive bands, only one of which was significantly phosphorylated 
following Epac activation. By immunoblotting arterial tissue obtained from mice 
in which the gene encoding either CaMKIId or CaMKIIg had been globally 
deleted (Backs et al. 2010; Backs et al. 2009), we were able to determine that 
Epac activation predominantly induced phosphorylation of CaMKIIg variants. 
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This is consistent with the finding that CaMKIIg is the most abundant isoform 
in differentiated smooth muscle. Studies in ferret aortae suggest it regulates 
contractile pathways (Kim et al. 2000; Marganski et al. 2005). We cannot 
entirely rule out the possibility that d variants made up a minor component of 
the band that strongly bound phospho-CaMKII antibodies following 8-pCPT-
AM treatment.  Faint anti-CaMKII immunoreactive bands persisted at this 
molecular weight (approx. 50kDa) in CaMKIIg knockout lysates, and it is 
possible that d and g subunits exist together in the functional holoenzyme 
complex. A CaMKIIg specific antibody was not used due to cross-detection of 
CaMKII isoforms from all commercially available CaMKIIg antibodies.  Using 
2D electrophoresis to further separate CaMKII isoforms, based on isolectric 
point and molecular weight (Rabilloud & Lelong 2011), we also saw an overlap 
between CaMKIId and CaMKII pT286 2D immunoblots.  Interestingly, the two 
major PCR products we detected using primers designed to amplify 
CaMKIIg isoforms are predicted splice variants of the CaMKIIg gene, whose 
expression has never been reported. Thus, the CaMKII isoforms involved in 
this pathway may be novel. 
Since these biochemical experiments were conducted in whole arteries 
we cannot fully distinguish whether the isoforms were detected in smooth 
muscle cells, endothelial cells or innervating nerves. Involvement of CaMKII in 
Epac-mediated STOCs was therefore confirmed using patch-clamp 
electrophysiology on single isolated arterial myocytes. Epac activation 
increased STOC frequency and amplitude in freshly isolated mesenteric artery 
smooth muscle cells, which was attenuated to baseline by addition of the 
CaMKII inhibitor KN-93.  KN-93 inhibits CaMKII by competitively blocking CaM 
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binding to the kinase (Pellicena & Schulman 2014), but can produce off-target 
effects, mostly notably on voltage-gated K+ channels and Ica  (L-type calcium 
current from ventricular cardiomyocytes) (Anderson et al. 1998; Rezazadeh et 
al. 2006) . Important to note is that the use of 500 nM KN-93, along with a -
20mV holding potential minimised these off-target effects (Pellicena & 
Schulman 2014; Anderson et al. 1998).  KN-92, the inactive analogue of KN-
93, did not attenuate Epac-mediated STOCs, while intracellular inclusion of 
the CaMKII inhibitor peptide, autocamtide related peptide 2 (AIP) prevented 
Epac-mediated STOC frequency increases.    
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4 CaMKII activation by Epac is mediated through IP3 
dependent Ca2+ release 
4.1 Introduction 
CaMKII is activated by the binding of Ca2+/calmodulin to the regulatory domain 
of the enzyme. CaMKII possesses a KCaM (concentration of CaM needed to 
half activate CaMKII) of ~25 nM at saturating Ca2+ concentrations. A half 
maximal activation is produced at 0.5-1 µM Ca2+ in non-saturating conditions  
(Soderling & Stull 2001; Hudmon & Schulman 2002). In vitro application of 
ATP allowing CamKII activation, and with it autophosphorylation, reduces this 
half maximal activation to 150pM (Hudmon & Schulman 2002). This reduction 
in half maximal activation allows prolongation of activation, commonly also 
called activation memory. The [Ca2+] elevations responsible for activation of 
CaMKII are produced through Ca2+ release from localised subcellular stores, 
such as the nucleus and sarcoplasmic reticulum (X. Wu et al. 2006; Mishra et 
al. 2011) or potentially through a novel extracellular Ca2+ influx (Chandra & 
Angle 2005).  
4.1.1 Epac activation by CaMKII in Cardiomyocytes 
Two models currently exist. One proposes that Epac-mediated CaMKII 
activation is activated by inositol trisphosphate (IP3) -mediated Ca2+ release 
(Ruiz-Hurtado et al. 2013; Pereira et al. 2012), the second proposes that 
CaMKII is activated in a Ca2+-independent manner, through phosphorylation 
by protein kinase C (PKC), possibly increasing CaMKII Ca2+ sensitivity by 
phosphorylation of pT286/7 (Oestreich et al. 2009).  Both models place the 
enzyme phospholipase C (PLC) upstream of CaMKII activation, since PLC 
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forms both IP3 and diacylglycerol (DAG), which subsequently activates PKC 
(Katan 2005).  
A role for IP3 was proposed as CaMKII activation could not be produced by 
Epac activation in the presence of 2-aminoethoxydiphenylborate (2APB), an 
IP3 receptor antagonist (Pereira et al. 2007). Protein kinase C has also been 
shown, in vitro and in vivo, to activate CaMKII (Waxham & Aronowski 1993; 
Oestreich et al. 2007), however Pereira et al. saw no inhibition of Epac 
mediated Ca2+ spark activity in the presence of chelerythrine, a PKC inhibitor, 
suggesting no role of PKC in Epac mediated spark modulation. 
In opposing results, Oestreich et al. (2009) showed that 8-pCPT addition 
increased electrically-evoked Ca2+ transients in cardiomyocytes, which could 
be inhibited by bisindolylmaleimide IX, a PKC inhibitor. Unlike Pereira et al., 
Oestreich et al. saw no effect of 2-APB on the Ca2+ transient evoked by Epac 
activation (Oestreich et al. 2009) (Figure 4.1). 
4.1.2 Phospholipase C involvement in Epac-mediated signalling 
Upstream in both models lies the IP3 and DAG-producing enzyme, 
phospholipase C. The phospholipase C family is a class of membrane-
associated enzymes that cleave phosphatidyl 4,-5 inositol bisphosphate (PIP2) 
to release IP3 (the head group), and diacylglycerol (DAG). There are thirteen 
kinds of mammalian phospholipase C that are classified into six isotypes (β, γ, 
δ, ε, ζ, η) according to structure (Katan 2005).     PLCe contains a PIP2 catalytic 
domain, a CDC25-HD domain and a Ras Association (RA) domain (Song et 
al. 2001; Kelley et al. 2001). The PIP2 catalytic domain is responsible for the 
cleavage of PIP2 to IP3 and DAG, responsible for Ca2+ release through IP3 
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receptors and PKC activation, respectively. PLCe is an unusual PLC isoform 
in that it possesses an N-terminal Ras GEF domain and two C-terminal Ras-
binding domains (Kelley et al. 2001). PLCe can be activated by Rap1 and Ras 
when they are active (i.e. GTP bound), through its RA domain. The CDC25 
domain of PLCe appears however to be specific for Rap1 activation, with other 
small G proteins such as Rap2 and Ha-Ras not activated by PLCe (Jin et al. 
2001).   
IP3 produced by PLC hydrolysis of PIP2 activates IP3 receptors present on 
numerous Ca2+ stores such as the sarcoplasmic reticulum, with IP3R1 being 
the predominant receptor isoform in mesenteric vascular smooth muscle cells 
(Narayanan et al. 2012). This IP3-mediated Ca2+ release can activate CaMKII 
through Ca2+/calmodulin binding. 
Protein Kinase C isoforms reside predominately within the cytoplasm at rest, 
with most isoforms translocating to the membrane fraction upon activation 
(Morgan & Claypool 2010). Certain isoforms reside within the perinuclear 
region, entering the nucleus under activation (Khalil & Morgan 1991). The PKC 
isoforms predominating in the vasculature are a, b, d, e, q, h µ and g. In 
vascular smooth muscle, they have been shown to be involved in both 
contraction and relaxation. 
• Contraction - PKC phosphorylates and inhibits K+ channels, KATP 
(Sampson et al. 2007; Y. Hayabuchi et al. 2001; Kubo et al. 1997) , BKCa 
(Barman et al. 2004) and Kv channels (Y Hayabuchi, Standen, et al. 
2001; Aiello et al. 1996), which are involved in generating 
hyperpolarizing membrane currents. It also phosphorylates  and 
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activates the 17-kDa PKC potentiated inhibitor protein (CPI-17), which 
inhibits MLCP (Somlyo & Somlyo 2003).   
• Relaxation. PKC phosphorylates MLCK and PMCA (responsible for 
transient contraction by PKC) (Inagaki et al. 1987; Khalil 2010). 
PKC isoforms a,b,g known as classical isoforms, are activated by 
diacylglycerol and phosphatidylserine. Activation is dependent on Ca2+, with 
Ca2+ increasing the affinity for negatively charged lipids (however Ca2+ 
produces minimal activation on its own). Novel isoforms d, e, q, h, µ do not 
require Ca2+    (Newton 1995).  Atypical PKC isoforms l and z do not bind DAG, 
but PIP3  and ceramide (Steinberg 2008).  While CaMKII has been shown to 
be phosphorylated in vitro by PKC, little in vivo mechanistic data is available 
(Waxham & Aronowski 1993; O-Uchi et al. 2008). However, Oestreich et al. 
(2009) showed a clear decrease in Epac-mediated CaMKII 
autophosphorylation under PKC inhibition, as shown by CaMKII immunoblots 
(Oestreich et al. 2009) (summarised in Figure 4.1).  
 
Figure 4.1- Comparison of Epac mediated CaMKII activation. Schematic comparison 
of two signalling pathways, which both activate CaMKII following Epac activation.  
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4.2 Aim 
The aim of this part of the study was to assess the upstream signalling pathway 
responsible for Epac-induced activation of CaMKII in rat mesenteric vascular 
smooth muscle. This involved determining: 
1. The involvement of PLC;  
2. The role of IP3-mediated Ca2+ release;  
3. The role of PKC. 
4.3 Results 
4.3.1 Phospholipase C-mediated feedback is essential for sustained 
Epac-induced Rap activity 
To assess PLC involvement in Epac signalling in the vasculature, we utilised 
a Rap1 activation assay. Epac directly activates Rap1, which in turn can 
activate PLCε.  Activated PLCε has two roles, further activation of Rap1 
through its unusual GEF activity and phosphoinositol hydrolysis to produce IP3 
and DAG (Oestreich et al. 2007). Active Rap levels were determined by 
incubating arterial lysates with fusion proteins comprising glutathione-S-
transferase and the Rap-binding domain of Ral-guanine nucleotide-
dissociation stimulator (GST-RalGDS-RBD), which only bind the active GTP-
bound form of Rap1. Glutathione-sepharose beads were then used to 
specifically pull-down Rap1-GTP from arteries preincubated with or without 8-
pCPT-AM (5 minutes) and the PLC inhibitor, U73122 (10 minutes).  Levels of 
captured Rap1-GTP were then quantified by immunoblot analysis (Figure 4.2). 
8-pCPT-AM increased active Rap1 (Rap1-GTP), which was inhibited by PLC 
inhibition using U73122. 
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Figure 4.2- Inhibition of PLC inhibits Epac-mediated Rap1 activation in rat 
mesenteric artery. A) SDS-PAGE gel showing various stages of RBD-RalGDS-GST 
purification B) Representative immunoblot of active Rap 1 (top) and total Rap1 levels 
(bottom) following exposure to 8-pCPT-AM and U73122 (PLC inhibitor). C) Histogram of 
Active Rap1/Total Rap1 following exposure to 8-pCPT-AM and U73122 (n=2). 
4.3.2 Protein kinase C is not involved in Epac-mediated changes in 
STOC activity 
In cardiomyocytes, CaMKII may be activated by Ca2+/calmodulin or via 
phosphorylation by PKC in a Ca2+ independent manner (Oestreich et al. 2009; 
Pereira et al. 2012). We therefore explored the role of PKC in Epac-mediated 
STOC frequency increases.  PKC was inhibited with the potent PKC inhibitor, 
bisindolylmaleimide IX (BIM IX), also known as RO 31-8220, which has a Ki 
for PKC isoforms ranging from 5 to 28 nM (Wilkinson et al. 1993). Application 
of 8-pCPT-AM to freshly isolated, voltage-clamped rat mesenteric artery 
myocytes increased STOC frequency, which application of BIM IX (500nM) did 
not attenuate (1.91 ± 0.25 STOCs s-1 vs. 2.05 ± 0.11 STOCs s-1, mean ± SEM, 
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paired t-test, p>0.05, n=3; Figure 4.3). STOC amplitude was also not affected 
by PKC inhibition (47.13 ± 15.01 pA vs. 43.2 ±12.47 pA, mean ± SEM, paired 
t-test, p>0.05, n=3).  
 
Figure 4.3- Inhibition of PKC does not attenuate Epac-mediated STOC increases. 
A) Representative trace of a freshly isolated rat mesenteric artery smooth muscle cell in 
whole-cell configuration exposed to 8-pCPT-AM (5 µM), followed by addition of BIM IX 
(250nM), a PKC inhibitor. Inserts: Highlight analysed areas (25 seconds). Bar indicates 
20 pA. B) Histogram summarising STOC frequency (n=3). D) Probability frequency 
histogram of STOC amplitude from A. 
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4.3.3 Inhibition of IP3 receptors blocks Epac-mediated CaMKII activation 
and increases in STOC activity 
Since our data suggest the upstream involvement of the IP3-generating 
enzyme PLC, we next assessed whether Ca2+ from IP3-releasable stores could 
activate CaMKII to affect STOC activity. Epac activation with 8-pCPT-AM (5 
µM), was unable to increase STOC activity in rat mesenteric artery myocytes 
pre-incubated in 2-aminoethoxydiphenyl borate (2-APB; 100 µM), an IP3 
receptor (IP3R) inhibitor. It was noted during experiments that 2-APB 
application alone caused a rapid increase in STOC activity that declined to 
baseline under prolonged application.  Importantly however, after return to 
basal STOC frequency, application of 8-pCPT-AM produced no effect on 
STOCs (Figure. 4.4). 
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Figure 4.4- Activation of Epac does not increase STOC activity following inhibition 
of IP3Rs: A) Representative trace of a freshly isolated rat mesenteric artery smooth 
muscle cell in whole cell recording exposed to 8-pCPT-AM (5µM) following 2-APB 
(100µM) pre-incubation.  B) Representative trace of a freshly isolated rat mesenteric 
artery smooth muscle cell in whole-cell recording configuration exposed to IP3R block 
with 2-APB (100 µM). C) Histogram summarising STOC frequency. The effect of 2-APB 
was measured at 1 minute and 6 minutes after initial application. D) STOC frequency 
histogram for cell B.  
 
Consistent with these data, 2-APB application following STOC activation with 
8-pCPT-AM caused an initial rapid increase in STOC frequency, followed by a 
decline to levels significantly below those measured in 8-pCPT-AM alone (from 
1.72 ± 0.27 STOCs s-1 to 0.83 ± 0.23 STOCs s-1; mean ± SEM, p<0.05; paired 
t-test; n=6; Figure 4.5).  
Figure 4.5- Inhibition of IP3R attenuates Epac-mediated STOC increases. A) 
Representative trace of a freshly isolated rat mesenteric artery smooth muscle cell in 
whole cell configuration exposed to 8-pCPT-AM (5 µM), followed by addition of 2-APB 
(100 µM) an IP3 receptor antagonist. Inserts highlight analysed areas. Bar indicates 20 
pA. B) Histogram summarising STOC frequency (n=6) D) Probability frequency 
histogram of STOCs from the above representative cell. 
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To directly link the effects of 2-APB to CaMKII activity, we stimulated rat 
mesenteric arteries with 8-pCPT-AM (5 µM) in the presence and absence of 2-
APB (100µM). Then homogenised the tissue and quantified the changes in 
CaMKII phosphorylation by immunoblot analysis, using phospho-specific 
antibodies against the CaMKII Thr286/7 autophosphorylation site.  In the presence 
of 2-APB, 8-pCPT-AM was unable to induce phosphorylation at Thr286/7 (Figure 
4.6, n=3).  Consistent with the idea that store Ca2+ is needed to activate CaMKII, 
pre-treatment with thapsigargin (500nM), which depletes intracellular Ca2+ stores 
by blocking Ca2+ uptake via SERCA, also abolished 8-pCPT-AM-induced 
phosphorylation of CaMKII at Thr286/7 (Figure 4.6, n=3).   Thapsigargin was not 
used for STOC electrophysiology experiments since store depletion with this drug 
automatically inhibits Ca2+ sparks and thus STOCs (Nelson et al. 1995). 
 
Figure 4.6- Intracellular stores are vital for Epac-mediated CaMKII activation. A) Prior 
to homogenisation branches of rat mesenteric artery were incubated with vehicle control 
(DMSO) or 8-pCPT-AM (5 µM) for 5 min, or incubated with 8-pCPT-AM (5 µM) for 5 min 
following prior application of 2-APB (100 µM) for 15 min. Proteins were separated on 10% 
polyacrylamide-Tris gels and probed using CaMKII pT286 and CaMKII (pan) antibodies B) 
Representative immunoblot of Epac activation in the presence of thapsigargin. As in A) 
branches were incubated with 8-pCPT-AM in the absence or presence of thapsigargin, 
followed by separation and immunoblotting. Histogram summarising the level of CamKII 
activity in experiments A) and B) 
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Having demonstrated that Epac is likely activated by Ca2+ released from IP3 
receptors, we aimed to quantify the level of Epac-induced IP3 in vascular smooth 
muscle. An IP3 ELISA was used, however the concentration of global IP3 induced 
by the application of 8-pCPT-AM was below the sensitivity of the ELISA (Figure 
4.7). 
 
 
Figure 4.7- IP3 concentrations in rat mesenteric artery beds under basal and 
stimulated conditions are below the sensitivity of ELISA detection. A) Illustration of 
competitive ELISA, where a high endogenous IP3 concentration causes a low absorbance 
due to less labelled IP3 binding to the well. The opposite is the case for low endogenous 
IP3 levels. After addition of IP3 wells were incubated in an acidic substrate to allow 
development of the colour B) 0ng/ml, 2.5ng/ml and 5ng/ml produced reproducible standard 
curves. Control and 8-pCPT-AM stimulated arteries had IP3 levels below the sensitivity of 
the ELISA (2.5ng/ml). To note between DMSO and 8-pCPT a paired t-test shows p>0.05. 
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4.4 Discussion 
Our data suggest that CaMKII activity in vascular smooth muscle is triggered by 
Epac-induced Ca2+ efflux through IP3Rs.    Epac’s immediate downstream target 
is the small-Ras-related G-protein Rap1.  We propose that following activation, 
Rap interacts with the C-terminal Ras binding domains of PLCε (Kelley et al. 
2001).  Subsequent activation of PLCε results in two separate events: 
phosphoinositol hydrolysis leading to the formation of IP3, and further activation 
of Rap through PLCε’s N-terminal Ras GEF domain. Consistent with this model, 
the PLC inhibitor U73122 significantly reduced the ability of the selective Epac 
activator, 8-pCPT-AM, to induce sustained activation of Rap1.  Indeed, the 
abolition of 8-pCPT-AM-induced Rap activation by U73122 suggests that 
potentially as in cardiomyocytes, a PLC-mediated feedback mechanism is 
essential for sustained Rap activation in vascular smooth muscle. Further 
investigation downstream of PLC using U73122 (i.e. its effect on Epac-induced 
STOCs) was not undertaken due to U73122’s known side effect of 
phospholamban inhibition (Macmillan & McCarron 2010). We also found that in 
the presence of the IP3 receptor inhibitor 2-APB, 8-pCPT-AM is unable to induce 
phosphorylation of CaMKII at Thr286/7, or increase STOC frequency/amplitude, 
which would be consistent with IP3-released Ca2+ being essential for activation of 
the CaMKII holoenzyme.  Pre-treatment with thapsigargin, which depletes 
intracellular Ca2+ stores by blocking Ca2+ uptake via SERCA, also abolished 8-
pCPT-AM-induced CaMKII phosphorylation.  During experiments, we noticed 
that 2-APB application following STOC activation with 8-pCPT-AM had a bi-
phasic effect on STOC activity, causing an initial rapid increase in STOC 
frequency followed by a decline to levels significantly below those measured in 
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8-pCPT-AM alone.  Further experiments showed application of 2-APB alone 
caused a transient increase in basal STOC frequency, which may indicate a 
constant Ca2+ leak from a common Ca2+ store via IP3Rs which, when blocked, 
alters store content and RyR activity (Figure 4.8).  We see some evidence of 
basal phosphorylation of CaMKII in immunoblots, which may be consistent with 
this idea of basal leak through IP3 receptors activating CaMKII.  
 
Figure 4.8- IP3R inhibition hypothesis. Under IP3R inhibition in electrophysiological 
recordings we observe an increase in STOC frequency. We hypothesis that this IP3R 
inhibition limits basal IP3-mediated calcium release, increasing the store content and 
therefore increasing leak mediated through RyRs. 
In Pereira et al. and this thesis the use of 2-APB as an IP3 receptor inhibitor could 
be problematic as this compound has been shown to be a promiscuous blocker 
of many Ca2+-related ion channels, such as TRPCs and store operated Ca2+ entry 
(SOCE) pathways (Missiaen et al. 2001). Controls for the application of 2-APB 
using STOC recordings showed a transient increase in STOCs, which we 
hypothesise is due to a “push” towards RyR dependent Ca2+ leak. The possibility 
of CaMKII being directly activated by 2-APB dependent Ca2+ leak exists 
(Lievremont et al. 2005). However, after 8-pCPT-AM addition in STOC 
recordings, at which point we propose CaMKII is activated due to the effects of 
KN-93 addition and immunoblots, we still see a transient increase in STOCs by 
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2-APB followed by reversal. Due to this we favour the theory of pushing Ca2+ leak 
to RyR dependent pathways, however we cannot rule out 2-APB directly further 
activating CaMKII in this transient increase period. Further experiments in rat 
cardiomyocytes utilising the novel CaMKII FRET-biosensor, Camui,  showed that 
2-APB inhibition of Ca2+ sparks were due to CaMKII inhibition by 2-APB, not a 
possible off-target effect, such as 2-APB mediated calcium store leak (Pereira et 
al. 2015).  
In our experiments, specific inhibition of PKC with BIM IX produced no significant 
decrease in STOCs induced by Epac activation, suggesting that PKC does not 
play a significant role in the Epac-STOC pathway in VSMCs. Thapsigargin 
inhibited CaMKII activation as assessed by immunoblot of mesenteric arterial 
lysates, showing a dependency on intracellular calcium stores, such as IP3-
mediated release.  
While Ca2+ efflux from IP3-releasable stores is the likely mechanism for Epac-
mediated CaMKII activation we cannot rule out other possible regulators of 
CaMKII.  Recently CaMKII autonomous activity, whereby CaMKII activity is 
maintained in the absence of Ca2+/CaM, has been shown to be produced through 
various translational modifications, such as oxidation, nitrosylation and O-
GlcNAcylation (Toussaint et al. 2016; Erickson et al. 2015; Erickson et al. 2013). 
Therefore, while we use CaMKII T286 phosphorylation as an indicator of CaMKII 
activity, assessing the proportion of autonomous and total CaMKII activity 
through radioactive experiments may prove insightful. Here, CaMKII activity 
would be assessed by phosphorylation of CaMKII substrates to explore total and 
autonomous activity, in the presence or absence of Ca2+. Indeed, Epac signalling 
via Akt has recently been shown to activate nitric oxide synthase type 1 (NOS1), 
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causing an increase in autonomous CaMKII activity by S-nitrosylation of CaMKII 
(Pereira et al. 2017).  This NOS1 activation is required for b-adrenergic-spark 
responses in cardiomyocytes (Curran et al. 2014). The site responsible for this 
CaMKII autonomous activity is cysteine 290. Interestingly, pre-incubation with an 
NO donor inhibited this autonomous activity. The nitrosylation must be after the 
initial activation of CaMKII by Ca2+/calmodulin. The site responsible for the 
inhibition of CaMKII is cysteine 273 (Erickson et al. 2015; Pereira et al. 2017). 
NOS1 and 3, as with CaMKII, require Ca2+/CaM for activation and therefore the 
potential arises for an elevation of Ca2+/CaM to produce NOS1/3 activation and 
CaMKII simultaneously. An alternative modulator of CaMKII is glucose, which 
increases CaMKII autonomous activity by addition of O-linked N-
acetylglucosamine on CaMKII at site S279 (Erickson et al. 2013). Inhibition of 
GlyNAc inhibitors (i.e. increasing glycosylation) increased Ca2+ spark frequency 
in cardiomyocytes (Erickson et al. 2013). This effect of glucose could be a reason 
why autophosphorylation is seen in control lysates, as all buffers used contained 
glucose. Oxidation, another post translation modification affecting CaMKII 
activity, has not been specifically explored in vascular smooth muscle. However, 
X-ROS (Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
produced reactive oxygen species (ROS)) increased STOCs in cerebral 
vasculature (Pritchard et al. 2016). Inhibition of O2- produced by NADPH oxidase 
(NOX), in response to such events as angiotensin II application, vascular 
pressure increase and hypoxia, attenuated STOCs (Griendling et al. 1994; 
Rathore et al. 2008; Vecchione et al. 2009). Could this ROS activate CaMKII and 
produce its effects on sparks/STOCs via CaMKII as part of a negative feedback 
mechanism to contraction? 
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While block of IP3Rs inhibited CaMKII initial activation, the possible role of other 
post-translation modifications on the prolonged effect (autonomous CaMKII 
activity) of Epac-mediated STOCs is still to be elucidated. Indeed recently two 
pathways both of which increase Ca2+ sparks, involving Epac/CaMKII/Sparks and 
Akt/NOS/CaMKII/Sparks, have been shown to work together in a merged 
signalling cascade. Experimental data from this pathway showed no 
autophosphorylation of CaMKII without O-Nitrosylation of CaMKII, showing a 
clear need for post-translation modifications in Ca2+ signalling pathways (Pereira 
et al. 2007; Curran et al. 2014). Assessing the involvement of Akt in smooth 
muscle using phospho-Akt antibodies in immunoblots, along with the use of an 
Akt inhibitor in electrophysiological studies will provide further knowledge. 
4.5 Conclusion 
Epac-induced CaMKII activation is likely initiated by IP3-mobilized Ca2+: 8-pCPT-
AM failed to induce CaMKII activation following intracellular Ca2+ store depletion, 
and inhibition of IP3 receptors blocked both 8-pCPT-AM-mediated CaMKII 
phosphorylation and STOC activity. 
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5 Downstream targets of Epac-activated CaMKII   
5.1 Introduction 
Within smooth muscle cells changes in STOC frequency or amplitude can arise 
from direct changes in the behaviour of BKCa channels, or indirectly from changes 
in the behaviour of the underlying RyRs. Both of these routes can be modulated 
by CaMKII.  RyRs respond to changes in both cytosolic and luminal SR Ca2+ 
levels (Zhuge et al. 2002).  Increases in RyR activity can in turn come about either 
through enhancement of their Ca2+ sensitivity, or through an increase in the 
content of the RyR-accessible Ca2+ store (Van Petegem 2012).  Primary targets 
downstream of Epac-induced CaMKII activation are therefore BKCa channels, 
RyRs, and/or proteins that modify Ca2+ uptake into the SR. 
5.1.1 Large conductance Ca2+ activated K+ (BKCa) channels 
BKCa channels are formed from four, seven transmembrane domain a subunits 
along with b subunits, responsible for modulation of the channel (Humphries & 
Dart 2015). Like voltage-dependent K+ channels, BKCa channels possess a 
voltage-sensor in the a subunit S4 transmembrane segment, in addition to a 
“Ca2+ bowl” at the C terminus. These are responsible for voltage and Ca2+ 
regulation, respectively (Humphries & Dart 2015). BKCa channels open in 
response to depolarising membrane potentials, with activation at lower 
membrane potentials in the presence of Ca2+ (Humphries & Dart 2015) . CaMKII 
phosphorylation of BKCa channels has been previously explored in glomerular 
mesangial and neuronal cells (van Welie & du Lac 2011; Sansom et al. 2000). In 
neurones, CaMKII phosphorylation of BKCa channels has been shown to increase 
their open probability, by shifting their voltage dependence towards more 
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hyperpolarized membrane potentials (van Welie & du Lac 2011). In contrast it 
has been shown that somatostatin produces its effect of increased BKCa activity 
by dephosphorylating BKCa  channels (White et al. 1991). Over 20 possible 
phosphorylation sites have been identified on BKCa channel subunits (Yan et al. 
2008) and temporal patterns of phosphorylation are likely to be important, since 
effects of PKA on BKCa activity are dependent on previous PKC phosphorylation 
(Zhou et al. 2010; Yan et al. 2008). 
5.1.2 Ryanodine Receptors (RyRs) 
Ryanodine receptors coded by RYR1-3 are one of the largest known ion 
channels, with a single subunit at ~565 kDa forming a homotetramer >2MDa 
(Lanner et al. 2010). Ryanodine receptors (RyR1-3) are expressed in 
cardiomyocytes, skeletal tissue, vascular smooth muscle and various non-
muscle cells, such as neurones (Lanner et al. 2010). In the vasculature, 
specifically the cerebral vasculature, all RyR isoforms are expressed, with RyR2 
being the predominant isoform, and importantly the most common isoform found 
at subplasmalemma localisations (Vaithianathan et al. 2010) . Interestingly, 
although RyR3 has been shown by Vaithianathan et al. (2010) to be minimally 
expressed in the subplasmalemma SR membrane, they still appear to play a 
pivotal role in spark and STOC formation, as shown by RyR3 KO mice (Löhn et 
al. 2001). RyRs are susceptible to numerous post-translational modifications and 
possess multiple phosphorylation sites (Ozawa 2010). In cardiac muscle, PKA 
can phosphorylate RyR at serine 2808/9 and serine 2030, located in cytoplasmic 
region of RyR, while CaMKII can phosphorylate the same proteins at ser2808/9 
and ser2814/5 (Van Petegem 2012).  
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Phosphorylation of RyR by PKA at ser2808/9 causes dissociation of FK506 
binding protein (FKBP12.6, also known as calstabin 2) from a RyR/FKBP12.6 
complex. FKBP12.6 is responsible for regulating RyRs, therefore this loss of 
FKBP 12.6 causes an increase in open probability (Marx et al. 2000; Ondrias et 
al. 1994). CaMKII phosphorylation of this site is controversial, however the weight 
of evidence now suggests that Ser2808/9 can be phosphorylated by CaMKII 
(Rodriguez et al. 2003; Camors & Valdivia 2014). It is important to note that the 
effect of PKA phosphorylation and phosphorylation at 2808/9 is still under debate, 
with a wide range of responses to p2808/9 phosphomimetic knock-in mice. For a 
full report of the conflicts and contrasting results see Camors and Valdivia (2014), 
while Dobrev and Wehrens (2014) present some possible technical reasons that 
may cause discrepancies (Camors & Valdivia 2014; Dobrev & Wehrens 2014). 
The effect of phosphorylation of Ser2030 is still unknown, with no effect on the 
Ca2+ sensitivity of RyR induced by phosphomimetic mutation (Xiao et al. 2005). 
CaMKII-dependent phosphorylation of RyR at serine 2814/5, produces (by 
general consensus) an activation of RyR as an increase in open probability 
(Xander H T Wehrens et al. 2004). This phosphorylation site is commonly 
associated with heart failure: ablation of the phospho site, or inhibition of CaMKII, 
reduces heart failure from transverse aortic constriction induced cardiac 
hypertrophy (Respress et al. 2012; Ling et al. 2009). This is proposed to be due 
to an increased diastolic Ca2+ leak and decreased Ca2+ store content, both 
mediated by CaMKII phosphorylation (Ai et al. 2005). This phosphorylation site 
has less phosphorylation under basal condition compared to p2808/9 (15% vs. 
69%) as shown by Li et al. 2013. 
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5.1.3 Phospholamban (PLB)  
Another key Ca2+ handling protein involved in STOC production is 
phospholamban (PLB) (Cheranov & Jaggar 2002). PLB is a 5/6 kDa pentamer 
(25-30 kDa) present on the sarcoplasmic reticulum membrane, where its role is 
that of inhibiting the sarco/endoplasmic reticulum ATPase (SERCA) (Hagemann 
& Xiao 2002). Phosphorylation of PLB disinhibits its control on SERCA, therefore 
leading to an increase in reuptake of Ca2+ from the cytosol, by lowering the KCa 
(half maximal activation of Ca2+ transport) of SERCA by 50% (Simmerman & 
Jones 1998). CaMKII and PKA phosphorylate PLB at T17 and S16, respectively 
(Hagemann & Xiao 2002). 
5.1.4 Ca2+ Modulation/The SR effect 
Ca2+ store levels within smooth muscle cells play a pivotal role in Ca2+ spark 
formation, whereas there is less dependency in cardiomyocytes (Essin et al. 
2007). In cardiomyocytes, Ca2+ enters through Ca2+ channels and activates RyR 
to release more Ca2+. Each opening of an L-type Ca2+ channel produces a Ca2+ 
spark, which leads to a twitch response. Vascular smooth muscle in contrast 
lacks tight coupling between LTCC and RyRs. In vascular smooth muscle cells 
not every L-type Ca2+ channel opening produces a Ca2+ spark, indeed it is the 
net inward flux of Ca2+ that regulates Ca2+ sparks  (Collier et al. 2000; Essin & 
Gollasch 2009; Essin et al. 2007). In murine arterial smooth muscle cells, ablation 
of the Cav1.2 a subunit (a major Ca2+ entry route) has been shown to reduce 
spark frequency, due to a decrease in the [Ca2+]i causing a decrease in 
intracellular store calcium levels. Reversal of this decrease in cytoplasmic Ca2+ 
by increasing Ca2+ influx led to an increase in store content, which restored 
calcium spark frequency in KO mice (Essin et al. 2007).  
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5.2 Aims 
In this part of the study I aimed to assess: 
1. Epac-induced post-translational modifications to RyRs;  
2. Epac-induced post-translational modifications to PLB which reverse its 
inhibition of SERCA; 
3. Epac-induced changes in Ca2+ store uptake and store content; 
4. Epac-induced changes in the activation and phosphorylation of BKCa 
channels. 
5.3 Results 
Epac and subsequent CaMKII activation likely induce changes in RyR activity 
through phosphorylation of the release channel itself, its associated regulatory 
proteins, or the SERCA pump regulator PLB. We assessed the effects of Epac 
activation on each of these targets. 
5.3.1 PLB undergoes a post-translational modification in response to Epac 
activation 
To assess the effects of Epac activation on PLB, arteries were incubated in 8-
pCPT-AM, lysed and proteins within the lysates analysed by SDS-PAGE and 
immunoblotting with antibodies against PLB and phosphorylated PLB (phospho-
specific antibodies against the CaMKII site Thr17). We detected some evidence 
of phosphorylation at Thr17 in response to 8-pCPT-AM (Figure 5.1A). A faint 
immunoreactive band is detected by the phospho-antibody (upper panel) and a 
slightly heavier species of PLB is detected by the pan-PLB antibody (lower 
panel). 
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Serendipitously, it was observed that control (DMSO treated) arteries produced 
a stronger immunoreactive band than both forskolin and 8-pCPT-AM incubated 
arterial lysates when probed with a PLB (pan) antibody which detects all forms of 
PLB, phosphorylated and non-phosphorylated (Figure 5.1C). Further analysis 
using a-actin as a loading control showed this not to be a loading error, but due 
to a decrease in PLB in the soluble fraction of the lysate upon stimulation with 
forskolin or 8-pCPT-AM.  Post translation modification of PLB, such as 
phosphorylation, has previously been reported to change its susceptibility to 
detergent extraction from membranes (Bidlack et al. 1982). Indeed, further pan 
PLB immunoblots, using RIPA buffer for lysis, showed 8-pCPT-AM-mediated 
changes in PLB mobility within gels, which may indicate PLB phosphorylation 
following Epac activation (Figure 5.1B). 
 
Figure 5.1– Epac activation produces possible post-translational modifications on 
the Ca2+ reuptake protein PLB. A) Immunoblot of rat mesenteric arteries stimulated by 8-
pCPT-AM before lysis. PLB (pan) and PLB (T17) antibodies were used to probe membranes 
B) Pan PLB immunoblots of mesenteric artery lysates, lysed in RIPA buffer separated on 
15% SDS-PAGE gels C) Left: Positive control Heart lysate used to show pentamer and 
monomer separation on 15% SDS-PAGE immunoblots. Right: Rat mesenteric arteries 
stimulated with forskolin or 8-pCPT-AM before lysis, followed by separation on SDS-PAGE 
gels and immunoblotted for PLB. Smooth muscle alpha actin shown as a loading control. 
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5.3.2 RyR is not detectable via biochemical techniques in a single rat 
mesenteric artery bed 
We next attempted to assess both total RyR and phosphorylated RyR levels in 
response to 8-pCPT-AM exposure. Firstly, total RyR was assessed by 
immunoblotting arterial lysates using a commercially available RyR (34C) 
antibody (Thermo Scientific) and a custom antibody (#2160 RyR(pan)) provided 
by Prof Tony Lai (University of Cardiff, Wales). Neither antibody produced a clear 
immunoreactive band from rat mesenteric lysates (Figure 5.2). Positive controls, 
such as the SR fraction of heart tissue and RyR immunoprecipitation from heart 
lysates, were used and showed a clear band at ~500kDa, consistent with the 
expression of RyR (Van Petegem 2012). A phospho-specific antibody against the 
CaMKII site (ser2808/9) did not detect any band at ~500 kDa. 
 
Figure 5.2– RyR is undetectable by immunoblotting in mesenteric arterial lysates. A) 
Immunoblot of rat tissues using the anti-RyR 34C (Developmental studies Hybridoma 
Bank). B) Immunoblot of rat tissues (as in A) using the anti-RyR antibody #2160 kindly 
provided by Prof. Tony Lai (Cardiff, Wales). Tissues are: Lane 1–Heart IP using anti-RyR 
34C, Lane 2–Heart IP using anti–RyR #2160, Lane 4–enriched sarcoplasmic reticulum 
(Heart), Lane 5–enriched sarcoplasmic reticulum (Mesenteric), Lane 6–Mesenteric Heart 
IP using anti-RyR 34C, Lane 7–Mesenteric IP using anti –RyR #2160, Lane 8–Mesenteric 
artery lysed in 10% SDS containing lysis buffer.  
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Since our results suggest possible Epac/CaMKII effects on PLB we investigated 
whether Epac activation alters the Ca2+ content of the RyR-accessible Ca2+ store.  
We therefore measured the effect of Epac activation on Ca2+ store content and 
the rate of Ca2+ clearance from the cytosol. Transient Ca2+ release from the SR 
was induced using pulsed applications of the RyR activator caffeine, in voltage-
clamped and fura-2-dialyzed myocytes. Prior to experiments, fura-2 calibration 
was undertaken to provide accurate Ca2+ concentrations within the cytosol, rather 
than relative fluorescent intensity changes.  
5.3.3 In-vitro fura-2 calibration and optimisation of caffeine-induced Ca2+ 
release 
Fura-2, a ratiometric Ca2+ indicator was used to assess Ca2+ concentrations in 
the cytosol. A non-membrane-permeant version was used to avoid both leakage 
out of the cell and the loading of fura-2 into intracellular organelles during 
experiments (10-15 mins). Fura-2 is a dual excitation dye that allows ratiometric 
measurements. Ca2+-bound fura-2 absorbs at approx 340nm, free unbound fura-
2 absorbs at approx. 380nm. Excitation at both these wavelengths emits light at 
~510nm, therefore allowing a ratio of bound to free indicator that is independent 
of dye contraction/cell size to be recorded.  
A range of calibration solutions buffered with 10 mM EGTA and containing free 
Ca2+ concentrations of 15nM, 40nM, 100nM, 225nM, 250nM, 600nM, 1.35µM 
and 20mM were used. A minimum free Ca2+ solution was produced by using a 
10mM EGTA, with no CaCl2 added. Experiments were firstly undertaken without 
image masking, which delineates a small area of recording to minimise 
background; However, this produced dissociation constant (Kd) values of 
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~300nM  that are high compared to previously published values (Grynkiewicz et 
al. 1985). It was also noted that the b values (ratio of the photon count with Rmin 
and Rmax solutions at 380 nm) were lower than expected and varied (Grynkiewicz 
et al. 1985). A single rat mesenteric artery smooth muscle cell occupies a fraction 
of the viewing field and therefore the interference by background will be 
substantial. Kd values were therefore obtained with image masking. For this the 
area of measuring is decreased to only surround the cell of interest. This is 
undertaken as it is not possible to draw a region of interest using a PTI system. 
These results allowed us to determine the Kd for fura-2 in our specific set up i.e. 
temperature/solutions/imaging system. This was averaged from two separate 
recordings of 183nM and 136nM, therefore 160nM was our average Kd 
(Grynkiewicz et al. 1985) (Figure 5.3).  This value is as expected with the level 
of free Mg2+ present in the intracellular solution.  
 
Figure 5.3– Fura-2 In-Vitro Calibration. A) Initial experiments were undertaken without 
image masking, however produced high Kd values and low b-values. Graphs were produced 
by plotting R-Rmin/Ca2+ Concentration vs. R-Rmin B) Experiments with image masking 
  
 
130 
produced lower Kd values, higher b-values and showed maximal Rmax compared to previous 
experiments. Graphs were plotted as in A. Kd values are in nM. 
Following accurate dissociation constant evaluation, which gave measured 
resting state [Ca2+]i that was close to previously published concentrations 
(Kamishima & McCarron 1998), preliminary experiments were undertaken to 
assess the concentration of caffeine needed to evoke multiple Ca2+ release 
events. Initial experiments showed that while 10mM caffeine evoked transients, 
Ca2+ handling was not reliable over the time of the experiment, leading to altered 
transient shape and cell death during the experiment (Figure 5.4). In contrast, 1 
and 3mM caffeine produced tolerable transients i.e. reliable transient shape/Ca2+ 
handling but did not consistently evoke Ca2+ release. Therefore, it was decided 
to use 5 mM caffeine as the Ca2+ release stimulant, with this concentration 
producing tolerable and consistent release events. Initial experiments further 
showed that allowing an incubation period following drug application, in which no 
transients were produce, reverted the steady decrease in transient amplitude 
seen with repetitive stimulations. This was not reliable, with transient recovering 
being varied, while transient amplitude rundown was reliable when evoked every 
1 minute. Therefore, it was decided to constantly evoke transients by application 
of caffeine at regular intervals (60 seconds). 
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Figure 5.4- Optimisation of Caffeine induced Ca2+ transients. A) Repetitive application 
of 1mM caffeine application produced inconsistent transients. B) Using 3mM caffeine 
produced inconsistent transients as in A. C) The use of 10mM caffeine produced transients 
that were not tolerated by rat mesenteric artery smooth muscle cells. This was seen through 
altered calcium handling through experiments as seen in C. Upper deflections along x-axis 
indicate caffeine application. Experiments were undertaken by Dr. Tomoko Kamishima. 
 
  
 
132 
5.3.4 Epac activation affects SR kinetics with no effect on store Ca2+ load 
Caffeine activates RyRs and induces a bulk release of store Ca2+ into the cytosol. 
This Ca2+ is subsequently cleared from the cytosol by uptake and extrusion 
pumps (Kamishima & McCarron 1998).  The effects of 8-pCPT-AM and DMSO 
(control) on 3 parameters of caffeine-induced Ca2+ release events were 
assessed: transient amplitude, transient duration (50% to 50%) and initial rise 
time (baseline to 200nM cytosolic Ca2+; Figure 5.5). 
• Transient amplitude reflects Ca2+ SR content where SR containing higher 
levels of Ca2+ produce a larger initial transient. We assessed whether 
Epac activation modulated SR content in the positive or negative direction. 
• Duration (50% to 50%) assesses possible Epac involvement in Ca2+ 
clearance mechanisms. Phosphorylation of PLB, for example, would be 
expected to increase the activity of SERCA, increase Ca2+ reuptake into 
stores and shorten the duration of transients. 
• Initial rise time was used to assess if Epac activation altered RyR 
activation kinetics. This was calculated using a third order polynomial fit of 
Ca2+ rise between baseline and 200nM. Using this fit we calculated the 
time to 100nM from baseline. Use of fitted data avoided any bias because 
of a delay in Ca2+ rise due to the application of caffeine or specific cellular 
effects.  
 
All Ca2+ transient data is normalised to the last control transient of the recording 
(i.e. before DMSO or 8-pCPT-AM application), with this transient given a value of 
1 in respect to all measurements. This was undertaken due to the highly variable 
Ca2+ transient profile we observed in rat mesenteric artery smooth muscle cells. 
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Figure 5.5– Caffeine-induced Ca2+ Transient Parameters. Amplitude indicative of SR 
content is assessed from baseline to peak. Duration upon elevate Ca2+ of 50% caffeine 
peak is 50% to 50% duration. Baseline to 100nM [Ca2+]I as indicated by the silver circle. 
Repeated 100ms application of caffeine (5mM; indicated by circles) at 60 
second intervals triggered a train of Ca2+ release transients (Figure 5.6A).   
At the point indicated by the bar above the trace, the extracellular superfusing 
solution was switched to test solutions containing either vehicle control (DMSO; 
upper panel) or 8-pCPT-AM (5 µM; lower panel).  In both cases, the amplitude of 
the caffeine-induced Ca2+ transients decreased during the course of the 
experiment, suggesting that the SR Ca2+ is being slowly depleted.  Epac 
activation with 8-pCPT-AM had no significant effect on Ca2+ transient amplitude, 
amplitude for DMSO-treated cells 0.68 ± 0.07 and for 8-pCPT-AM treated cells 
0.80 ± 0.03, n=5, 4 respectively; p>0.05; unpaired t-test; Figure 5.6Cii).  There 
was however a significant shortening of the relative duration of the transient 
following Epac activation (DMSO treated cells 1.39 ± 0.15 and 8-pCPT-AM 
treated cells 0.98 ± 0.08, n=5, 4 respectively; p<0.05; unpaired t-test; Figure 
5.6Ciii). 
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During the experiments, it was noted that the initial upward deflection of the 
Ca2+ transient appeared slower following 8-pCPT-AM application.  Thus, the early 
period of [Ca2+]i increase in response to caffeine was more closely examined.  
The initial rate of Ca2+ rise (from baseline to a [Ca2+]i of 100 nM) was virtually 
indistinguishable before and after DMSO application, despite the latter Ca2+ 
transients being smaller in amplitude (Figure 5.6Bi). The initial Ca2+ rise was 
however considerably slower after application of 8-pCPT-AM (5 μM; Figure 
5.6Bii).  The relative initial Ca2+ rise was 1.17 ± 0.07 and 2.00 ± 0.41 for DMSO 
and 8-pCPT-AM treated cells respectively (n=4, 5; p<0.05, unpaired t-test; 
Figure 5.6Ci).  These results suggest that Epac activation has no significant 
effect upon store content, although may affect the kinetic behaviour of the RyR 
release channels. 
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Figure 5.6– Epac activation modulates Ca2+ release kinetics, however does not affect 
Ca2+ store content. A) Representative traces of caffeine-induced Ca2+ release transients. 
5mM caffeine was transiently applied to rat mesenteric artery smooth muscle cells to evoke 
Ca2+ release B) Initial Ca2+ rise 200nM Ca2+ was fit using a third-order polynomial equation. 
The rise of Ca2+ in the last transient before DMSO or 8-pCPT-AM was fit (control), 
compared to the rise of Ca2+ in the third transient of drug application (DMSO or 8-pCPT-
AM). C) Summary of Epac activation on i) initial Ca2+ rise, ii) store content (transient 
amplitude) and iii) transient duration. Initial Ca2+ rise and transient duration were both 
significantly different, DMSO vs 8-pCPT-AM (n=5,4). Experiments were undertaken by Dr. 
Tomoko Kamishima. 
5.3.5 Epac activation does not directly activate BKCa channels 
In neurones, CaMKII phosphorylation of BKCa channels has been shown to 
increase their open probability by shifting their voltage dependence towards more 
hyperpolarized membrane potentials (van Welie & du Lac 2011). We therefore 
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investigated whether a component of the 8-pCPT-AM effect on STOC activity 
could originate from direct effects on BKCa channels.  In whole-cell recordings 
from isolated mesenteric artery myocytes with ryanodine (15µM) and Ca2+ 
(300nM) included in the pipette-filling solution, application of 8-pCPT-AM (5µM) 
failed to increase BKCa channel activity (Figure 5.7; n=3). Under these conditions 
Ca2+ release via RyRs will be blocked, but BKCa channels will still be available for 
activation. This is demonstrated by the subsequent addition of the selective BKCa 
channel activator NS11021 (10 µM), which induced a large outward current 
(Figure 5.7).   
 
Figure 5.7– Epac activation does not directly activate BKCa channels. Freshly isolated 
rat mesenteric artery smooth muscles in the whole cell configuration were perfused with 8-
pCPT-AM. Intracellular solution contained Ryanodine (15µM) and 300nM Ca2+. To confirm 
BKCa channel expression the opener/Ca2+ sensitizer NS11021 was applied. 
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Using an antibody against phospho-serine/phospho-threonine residues to 
immunoprecipitate phosphorylated proteins, followed by immunoblotting for BKCa 
channels, we aimed to assess the level of BKCa channel phosphorylation 
following Epac activation. BKCa phosphorylation upon Epac activation were 
varied and showed no consistent trend as seen in Figure 5.8. 
 
Figure 5.8- Phosphorylation of BKCa channels following Epac activation. Shown are 
five individual immunoblots using anti-BKCa antibodies. Immunoprecipitations were 
undertaken using phospho Ser/Thr antibodies on freshly lysed rat mesenteric arteries pre-
treated in DMSO or 8-pCPT-AM. 
5.4 Discussion 
To increase STOC activity, Epac may affect Ca2+ sparks by directly modulating 
RyR behaviour, or indirectly by increasing the content of intracellular Ca2+ stores. 
The sarcoplasmic reticulum (SR) in smooth muscle cells contains a large amount 
of Ca2+, predominantly bound to Ca2+ binding proteins such as calreticulin (Akata 
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2007a). This Ca2+ store is involved in IP3-mediated Ca2+ release producing 
contraction and relaxation through Ca2+ spark production, and therefore is pivotal 
to the generation of force in smooth muscle, and with it vascular tone (Nelson et 
al. 1995; Khalil 2010).  Epac activation significantly slowed the initial global rise 
in [Ca2+]i in response to caffeine, but had no effect on the relative transient 
amplitude.  This suggests that Epac activation does not affect store content, but 
may affect kinetics of the RyR response to caffeine.  
A possible explanation for the slowing of the initial global rise in [Ca2+]i in 
response to caffeine, could be that the rapid and synchronized opening of RyRs 
is compromised by Epac activation. CaMKII likely induces changes in RyR 
activity through phosphorylation of the release channel itself or associated 
regulatory proteins (Van Petegem 2012).   RyR1, 2 and 3 have been reported to 
be expressed in vascular smooth muscle, with RyR1 and 2 shown to be 
modulated by post-translational modifications, such as phosphorylation. In 
cardiomyocytes this phosphorylation via PKA or CaMKII has been associated 
with an increase in RyR open probability (Li et al. 1997; Marx et al. 2000). 
Therefore, we assessed whether similar post-translational modifications took 
place in the vasculature upon Epac activation. We could not assess RyR 
phosphorylation due to technical limitations, where RyR was not detected in 
arterial lysates using immunoblot. Every attempt was made to detect RyR, 
including testing whole tissue lysates, SR fractionation and RyR 
immunoprecipitations, all of which were confirmed to be technically acceptable in 
heart tissue, used as a positive control. Immunoblots and immunoprecipitations 
were performed with two antibodies to exhaust all avenues of detection. #2160 
RyR (pan) kindly gifted by Prof. Tony Lai reacts with all RyR isoforms, while 34C 
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preferentially reacts with RyR2, therefore both were tested to not miss RyR1/3 
expression. CaMKII may also directly or indirectly modify the behaviour of 
regulatory proteins associated with RyR, such as FK-506 binding protein (FKBP). 
Phosphorylation at ser2808/9 on RyR causes dissocation of the RyR/FKBP 
complex (Marx et al. 2000).  FKBP functions to synchronize the activity of RyRs 
by coupling the opening and closure of  neighbouring channels (Marx et al. 1998).  
Loss of the ability to simultaneously open in response to caffeine would account 
for our Epac-mediated slowing of the global [Ca2+]i rise. 
While our data suggest that the Ca2+ store content is not affected by Epac 
activation, we cannot rule out an increase in uptake that balances the increased 
store leak (spark activity).  An analogy for this would be that if the bucket empties 
as quickly as it fills, the bucket is always full to the same level. Indeed, we show 
that in the presence of 8-pCPT-AM caffeine-induced Ca2+ transients are shorter 
in duration, which would be consistent with an increase in released Ca2+ 
clearance rates from the cytosol. Within vascular smooth muscle cells and 
cardiomyocytes there are numerous Ca2+ reuptake and extrusion mechanisms 
(plasma Na+/Ca2+ exchanger, SERCA, PMCA and mitochondrial Ca2+ reuptake) 
(Kamishima & McCarron 1998). Kamishima and McCarron (1998) showed, using 
various inhibitors (SERCA inhibitors and mitochondrial ionophores) and different 
buffer compositions (removal of Na+), that the Na+/Ca2+ exchanger is not 
responsible for the decay of Ca2+ transients at any time point in cerebral 
myocytes (Kamishima & McCarron 1998; Kamishima et al. 2000). While we could 
not reliably detect phosphorylation of the SERCA pump regulator PLB at Thr17, a 
key CaMKII target in the heart, we did see that 8-pCPT-AM-mediated changes in 
both PLB mobility within gels and susceptibility to detergent extraction from 
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membranes, which may indicate protein modification such as phosphorylation 
following Epac activation (Bidlack et al. 1982). Together, these results suggest 
that possible modification of PLB changes Ca2+ reuptake in to stores and 
decreases the duration of the caffeine-induced Ca2+ transient. 
CaMKII activation has been shown to increase the probability of BKCa channel 
opening, as has the application of the adenylyl cyclase activator, forskolin, to 
arterial myocytes (Porter et al. 1998). In contrast, dephosphorylation of BKCa 
channels has been shown in pituitary tumour cells to increase their open 
probability (White et al. 1991).  In whole-cell voltage-clamp experiments, we 
inhibited Ca2+ sparks by including ryanodine in the pipette-filling solution to clamp 
the Ca2+ present at the BKCa channel. The pipette-filling solution contained 300 
nM free Ca2+ to allow activation of BKCa channels. Under these conditions, we 
saw no significant BKCa channel activation by 8-pCPT-AM, even though BKCa 
channels was still susceptible to activation by NS11021. This is in-line with BKCa 
Ca2+ sensitivity not being altered, as STOC length was no longer in the presence 
of 8-pCPT-AM. A longer STOC would be expected if BKCa channels activated 
faster to Ca2+ and deactivated more slowly. Biochemical analysis of BKCa channel 
phosphorylation provided variable results, with both increases and decreases in 
total phosphorylation seen following Epac activation.  Importantly, our functional 
data suggest that these variable Epac-induced changes in phosphorylation, if 
real, do not translate directly in to changes in channel activity. Overall these 
results are in line with those in Chapter 3 where Epac-mediated STOCs were 
inhibited by ryanodine. This suggests that STOC activity results from changes in 
the underlying RyR activity, as opposed to direct changes in BKCa behaviour.  
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Acknowledgement: Within this chapter all caffeine evoked transient 
experiments were undertaken by Dr. Tomoko Kamishima using cells isolated by 
myself. All other work was undertaken by myself. 
6 Insights into Epac-based signalosomes 
6.1 Introduction 
With cAMP being a common second messenger for several vasoactive 
transmitters the question quite often posed is, why do not all cAMP elevating 
coupled receptors (Gas) produce the same physiological response? This was first 
shown in cardiomyocytes, where activation of b-adrenergic receptors by 
isoprenaline produced cAMP increases and PKA activation to a similar level as 
prostaglandin, acting on PGE1 receptors. However, only isoprenaline produced 
inotropic effects in myocytes (Lefkimmiatis & Zaccolo 2014). This phenomenon 
was shown in whole tissue by Hayes et al. (1980) and in cell preparations by 
Buxton & Brunton (1983) (Hayes et al. 1980; Buxton & Brunton 1983). However, 
nearly 20 years went by before protein-based probes such as ICUE1 (indicator 
for cAMP based on EPAC) and AKAR1 (a PKA activity biosensor) were 
developed and cAMP compartmentalisation was confirmed (DiPilato et al. 2004; 
Zhang et al. 2001). Studies with these proposed that signalling specificity is 
maintained by distinct pools of cAMP (controlled by barriers of 
phosphodiesterases) and/or compartmentalization of signalling molecules by 
protein scaffolds. Zaccolo & Pozzan (2002) used neonatal cardiomyocytes 
transfected with fluorescently-labelled catalytic and regulatory subunits of PKA 
(YFP-PKA catalytic and CFP-PKA RII). With these they showed that treatment 
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with IBMX, the broad-spectrum phosphodiesterase inhibitor, or Ht-31, a AKAP-
PKA RII disruptor peptide, produced a generalized spread of cAMP throughout 
the cell i.e abolishing discrete microdomains with high concentration of cAMP 
(Zaccolo & Pozzan 2002). 
6.1.1 AKAPs 
A-Kinase anchoring proteins (AKAPs) are a large family (~50 members) of 
scaffolding proteins expressed in various tissues/cells with differing intracellular 
localisations (Beene & Scott 2007; Esseltine & Scott 2013; Scott & Santana 
2010). AKAPs act as scaffolding proteins that control the localization of PKA and 
other signalling proteins within the cell. These signalling complexes often contain 
the cAMP-destroying PDE enzymes, thus producing highly-defined cAMP 
gradients around the signalosome (Appendix. 1, Section 8.1). AKAPs are 
structurally diverse, but have in common a 14-18 residue amphipathic helix that 
predominately binds RII domains via a hydrophobic groove produced by the two 
anti-parallel  PKA RII subunits (Welch et al. 2010). RI selective AKAPs and 
AKAPs that interact with both RI and RII have also been discovered, such as 
sphingosine kinase interacting protein (SKIP) and AKAP1 (Eggers et al. 2009; 
Means et al. 2011). Further analysis of AKAP specificity using various cAMP 
analogue-bound agarose beads showed that AKAP9,11,7,5,14 and MAP2 were 
RII specific, AKAP3,4,12,2,1 and 10 were dual specific in that they bound both 
RI and RII (Aye et al. 2009). 
6.1.2 Epac: Involvement in signalosomes 
Epac has been explored in a number of signalosomes, predominately in relation 
to the migration of endothelial cells (Sehrawat et al. 2011; Rampersad et al. 2010; 
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Wilson et al. 2011). Importantly, most of this work was conducted in cell lines and 
very little research on ex-vivo tissue has been undertaken, possibly due to the 
numerous cell types present with tissues and limitations on tissue/protein 
amount. Indeed, immunoprecipitations generally require highly concentrated 
protein lysates. A number of Epac signalosomes are shown in Table 6.1. Epac 
complexes shown in HEK293 cells only are not shown in the table. 
 
Table 6.1- Epac involving Signalosomes 
Proteins Involved Proposed Function Cell line Citation 
Epac1/PDE3B/p84-
p110y 
Inhibit HAEC 
migration leading to 
angiogenesis 
Human Aortic 
endothelial cell 
(Wilson et 
al. 2011) 
Epac1/PDE4D/b-
cateninin/PKARII/ 
PKAC/VECAD/Rap1 
Vascular 
permeability  
Human arterial 
endothelial cells 
(Rampersad 
et al. 2010) 
Epac1/PKA/mAKAP/ 
PDE4D3/ERK5 Hypertrophy 
Ventricular 
myocytes/heart tissue 
(Dodge et 
al. 2001) 
Epac1/Importin b1 Neuronal outgrowth N2A cells (Baameur et al. 2016) 
Epac1/ HSP70 or 
HSP71 or HSP90 
N/A (Mass Spec 
Hits) N/A 
(Baameur et 
al. 2016) 
Epac1/Ran Nucleus Rap1 activation HEK293 
(Liu et al. 
2010) 
Epac1/GRK2 Pain (hyperalgesia) Neuronal cells 
(Singhmar 
et al. 2016; 
Singhmar et 
al. 2014) 
Epac1/b-arrestin/CamK Beta adrenergic signalling Heart/HEK293 
(Mangmool 
et al. 2010) 
Epac1/AKAP9 Microvascular Permeability HUVECs 
(Sehrawat 
et al. 2011) 
Epac1/2 with SUR1/2 Insulin/Vascular 
Pancreatic B-cells 
Vascular smooth 
muscle 
(Purves et 
al. 2009; 
Kang et al. 
2006) 
Epac1/ERM Signalling localisation ACHN Cells 
(Gloerich et 
al. 2010) 
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Importantly, to our knowledge there is no research presenting Epac-containing 
signalosomes in vascular smooth muscle. 
6.1.3 Signalosomes in smooth muscle 
In smooth muscle, AKAP5, also known as AKAP79 (human) and AKAP150 
(rodent), is the most researched. AKAP150 has been shown to be involved in the 
formation of Ca2+ sparklets. Sparklets in vascular smooth muscle cells, which are 
local [Ca2+] increases, are mediated through voltage-dependent Ca2+ channels 
(Cav1.2) or TRPV4 ion channels, with Cav1.2 sparklets smaller in amplitude than 
TRPV4 but possessing a higher frequency. This higher frequency means Cav1.2 
sparklets control global Ca2+ within the cell, whereas TRPV4 sparklets produce 
localised increases (Mercado et al. 2014). When not colocalised with PKCa 
sparklets through Cav1.2 channels are in “low-activity” mode, where rare 
stochastic openings of channels takes place. When colocalised with PKCa Ca2+ 
sparklets are in “high activity” mode, through sustained channel opening. This 
sustained activation places Ca2+ sparklets as a major Ca2+ entry route into cells 
when PKCa is activated (Navedo et al. 2008; Navedo et al. 2006).  Deletion of 
AKAP150 disrupts PKC recruitment to Cav1.2 channels, resulting in a lower Ica 
in AKAP150 -/- myocytes (Navedo et al. 2008). Pressurised artery experiments 
showed smooth muscle cells in  AKAP150 -/- vessels have a lower [Ca2+]i and 
tone compared to WT, along with a decreased response to the vasoconstrictor, 
angiotensin II (Navedo et al. 2008; Navedo & Amberg 2013).  
To add another level of complexity to Ca2+ handling and the regulation of 
contraction in smooth muscle, AKAP150 has been shown to be involved in both. 
Endothelium denuded cerebral arteries from TRPV4-/-  KO mice are more 
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sensitive than WT to angiotensin II induced contraction (Mercado et al. 2014). 
This relaxant pathway through TRPV4 could merge with earlier work by Earley et 
al. 2005 , who showed that TRPV4/BKca form a novel signalling complex capable 
of causing hyperpolarisation. TRPV4-mediated relaxation by  
epoxyeicosatrienoic acids (EETs) was  50% dependent on BKca channel 
activation in smooth muscle cells and 50% dependent on endothelium cells 
(Earley et al. 2005; Earley et al. 2009). 
Further studies to explore the endothelium dependent relaxation showed a small 
number of TRPV4 channels producing Ca2+ sparklets were capable of activating 
IKCa and SKCa channels, to produce maximal vasodilation of small mouse 
mesenteric arteries (Sonkusare et al. 2012). This activation of TRPV4 by 
acetylcholine was dependent on AKAP150, where it localises PKC to 
myoendothelial projections (MEPs) containing IKCa/TRPV4/AKAP150/PKC.  
In rat arterial smooth muscle cells, AKAP involvement in the regulation of KATP 
currents has been explored. Here Ht-31, the AKAP-PKA disruptor reduced 
cAMP-mediated KATP activation, along with calcitonin-gene related peptide 
mediated KATP activation (Y Hayabuchi, Dart, et al. 2001). Together these 
experiments show a major role for AKAP150 in vascular smooth muscle and 
endothelial cells, with rather contradictory roles (i.e. contraction vs. relaxation) in 
Cav1.2 vs TRPV4-mediated sparklets, respectively.  
Therefore, exploring this tight spatial regulation is of increasing importance to 
understanding cAMP-mediated vascular smooth muscle signalling; even more so 
with the recent work showing PKA catalytic subunit remains localised even after 
activation (Smith et al. 2017). 
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6.2 Aim 
The aim of this part of the study was to optimise conditions that would allow us: 
1) To assess the potential complex partners of Epac1 in the vasculature via 
immunoprecipitation 
2) To explore possible AKAP expression in the vasculature and its 
involvement in Epac-mediated signalling 
3) To investigate the recruitment of proteins to Epac1-mediated complexes 
when Epac1 is active. 
6.3 Results 
6.3.1 Testing efficiency of Epac1 antibodies for immunoprecipitation 
Optimisation of antibodies and lysis conditions for immunoprecipitation of Epac 
(and potential complex partners) was initially undertaken by transiently 
transfecting CHO cells with Epac. The Epac expression construct used was H21, 
a first-generation biosensor where full-length Epac is tagged with fluorescent 
proteins (CFP – Epac1 –YFP). A clear band at ~150 kDa, the expected size of 
H21 can be seen when using anti-Epac1 (EPR6172; Abcam) compared to the 
control lanes containing Epac1 Ab (Abcam) with no lysate or Epac1 Ab (Abcam) 
only (hashed box). Using anti-Epac1 (SCBT) produced no clear band with silver 
staining. Immunoblotting for Epac with anti-Epac1 (CST) showed strong efficient 
precipitation of H21 by anti-Epac1 (Abcam) (Figure 6.1).  
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Figure 6.1- Validation of Epac immunoprecipitation using H21 transiently expressed 
in CHO Cells. A) Immunoblot using an Anti-Epac (CST) antibody on immunoprecipitations 
from H21 expressing CHO cell lysates. Immunoprecipitations were undertaken using either 
Abcam or SCBT anti-Epac1 antibodies and seperated by SDS-PAGE. H21 expressing cells 
were lysed at 0,24 and 48 hours. B) The same lysates as in A were run on a SDS-PAGE 
gel followed by silver staining. 
 
6.3.2 Optimising Epac1 immunoprecipitations in arterial homogenates 
Having established possible antibody combinations we undertook pilot 
experiments in rat brain tissue, due to abundant material, to optimise 
endogenous Epac1 immunoprecipitation. Due to initial lysates producing lower 
than expected levels of Epac pulldown, we undertook a buffer screen to improve 
efficiency of protein extraction (Figure 6.2). 
RIPA Buffer (in mM): 10 Tris pH 7.4, 150 NaCl, 0.1% SDS, 1% Triton X-100, 
1% Sodium Deoxycholate, 5 EDTA 
Triton Based (in mM) : 150 NaCl pH7.4, 50 Tris, 1% Triton X-100, 1 EDTA 
NP-40 Based (in mM): 50 Tris pH7.4, 100 NaCl, 1% NP-40, 10% Glycerol 
Gloerich (Gloerich et al. 2010) (in mM): 20 Tris pH7.4, 1% Triton X-100, 0.5% 
Sodium Deoxycholate, 10 EDTA, 150 NaCl  
NOTE: All buffers contained protease inhibitors (Sigma) at a 1 in 100 dilution 
(final concentration one times). 
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In rat brain tissue RIPA buffer produced the highest amount of Epac1 
immunoprecipitation. 
 
Figure 6.2- Optimisation of Immuoprecipitation buffer. A) Brain lysate (25mg of tissue) 
was homogenized in various buffers due to poor immunoprecipitation using CHO buffer in 
tissue. Epac1 was immunoprecipitated by Anti-Epac1 (Abcam) and immunoblotted with 
Anti-Epac1 (CST). Rabbit IgG at 1ug (same as Anti-Epac1) was included to establish 
specificity. B) As A except using SCBT Epac to immunoprecipitate Epac1. 
 
6.3.3 Considerations: Dynamic recruitment to a signalosome 
Epac is a dynamic signalling molecule that undergoes possible translocation to 
the membrane to activate Rap1 (Ponsioen et al. 2009). To counter the possibility 
that Epac1 may only being present in a signalosome when under activation we 
utilised 8-AHA-2’-Me-O-cAMP agarose beads. This allows pull-downs of 
activated Epac since 8-AHA-2’-Me-O-cAMP (8-AHA) is an Epac agonist similar 
to 8-pCPT. In brain homogenates, used for optimisation due to high protein 
content and known Epac1 expression, the Triton X-100 based buffer produced 
the strongest Epac1 band as detected by immunoblotting. Harsher buffers such 
as RIPA (used for IP) were not used, due to possible denaturation of Epac under 
such conditions leading to a lack of Epac activation by 8-AHA-cAMP beads. EtOH 
beads were used as negative controls with them possessing no bound cAMP 
analogue. In aortic homogenates CaMKII was pulled down by 8-AHA-cAMP 
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beads, however confirmation of Epac1 presence in agarose pull down was not 
possible (Figure 6.3). 
 
Figure 6.3- Optimisation of Active Epac Pull Downs Using 8-AHA-2´-O-Me-cAMP 
agarose beads. Aortic or Brain homogenates in appropriate lysis buffer were incubated 
with 8-AHA-2’-O-Me-cAMP agarose beads to pull down active Epac, which may be recruited 
to complexes. Pellets (pulldown) were eluted and immunoblotted with anti-Epac1 (CST) or 
anti-CaMKII. 
 
In a different technical approach to explore active Epac1 involving signalosomes 
we utilised post activation cross-linking experiments. After addition of 8-pCPT-
AM for 5 minutes, tissues were placed in 1% paraformaldehyde (in PBS) to fix 
protein to protein interactions. Epac1 was shown to immunoprecipitate from 
mesenteric artery smooth muscle cells using anti-Epac1 (Abcam) (Figure 6.4). 
 
Figure 6.4- Epac1 Immunoprecipitation after PFA (1%) fixation. Mesenteric arteries 
were fixed post 8-pCPT-AM application followed by RIPA buffer lysis and IP with anti-Epac1 
or Mouse IgG. Pellets were immunoblotted with anti-Epac1. 
 
  
 
150 
6.3.4 Possible Involvement of AKAPs in Epac1 containing Signalosomes 
cAMP/PKA/Epac signalling involves a high degree of localisation, with much of 
cAMP localisation involving A kinase anchoring proteins (AKAPs). To assess 
AKAP expression we undertook a far western, also called PKA RII overlay 
(Hausken et al. 1998). Recombinant PKA RII was expressed in E.coli followed 
by purification using nickel agarose beads (Figure 6.5A). Tissue lysates were 
run as per a normal immunoblot and transferred to nitrocellulose, followed by 
blocking. AKAPs present in lysates, specifically their amphipathic helix, are 
resistant to denaturation and therefore maintain the ability to interact with PKA 
RI/II (Hausken et al. 1998). Recombinant PKA RII was then incubated with the 
membrane overnight, followed by washing. Anti-PKA RII (Abcam) was then 
incubated at room temperature for two hours, followed by standard secondary 
antibody protocols. Heart SR fraction produced clear bands at both the predicted 
size of PKA, as expected, but also a clear band at ~18 kDa possibly indicating 
evidence of AKAP7, known to be expressed in cardiac SR membranes. However, 
recognition of AKAPs based on size cannot be used as a true evaluation, due to 
AKAP7g (AKAP18g) being approx. 40 kDa (Lygren et al. 2007). A positive control 
in the form of AKAP79 (truncated mutant) which binds to PKA RII was used to 
show an interaction between AKAP and PKA RII. A strong band (at the AKAP 
truncant MW) can be seen, corresponding to clear evidence that our recombinant 
PKA RII binds to AKAPs via this far-western method (Figure 6.5B). Aortic lysates 
produced numerous potential bands at 60,100,150 kDa (Figure 6.5B/C). 
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Figure 6.5- Optimisation of PKA Reg II far western. A) Recombinant PKA RII was 
expressed in E.coli followed by lysis and purification. Coomassie staining showed 
overexpressed of a 50kDa protein as expected for PKA RII B) Brain, Heart and recombinant 
AKAP79 show clear strong staining, whereas vascular lysates appear fainter. Due to 
possible overloading Lane 6 was ½ the amount loaded in Lane 1 C) Inset from B) 
Mesenteric lysate produced no clear bands, however faint similar banding to Aortic lysate 
can be seen. Banding in the Aorta lane is at 50 – 100 kDa, with a faint band at 150 kDa. 
6.4 Discussion 
Endogenous Epac1 has proved incredibly difficult to immunoprecipitate in a 
number of studies by other authors, either due to the availability of suitable 
antibodies, problems with extracting Epac from cells and/or the low copy number 
of Epac proteins (Gupta & Yarwood 2005; Zhao 2006; Gloerich et al. 2010). We 
show here that, after optimisation, endogenous Epac1 can be 
immunoprecipitated from arterial lysates. However, the conditions required for 
immunoprecipitation are harsh and could possibly cause dissociation of transient 
complexes, while they were also snapshots of complexes at varying Epac 
activation states, due to currently undetermined levels of Epac activity under rest 
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in specific arteries (Vasilescu et al. 2004). The lack of known complex partners 
for Epac1 in the vascular smooth muscle makes it difficult to confirm that 
complexes are difficult. Potential complex partners, as identified from the 
signalling pathway elucidated in previous chapters of this study, are CaMKII, 
phospholamban, IP3R, PLCe and RyR.  Using these optimised (i.e. using RIPA 
buffer) conditions, we could not identify phospholamban or RyR in Epac-
precipitated lysates (data not shown). Interestingly, immunoprecipitation with 
RyR2 antibodies (validated in Chapter 5) produced a faint doublet at 100 kDa 
using anti-Epac1 (CST) for immunoblotting, potentially consistent with the co-
precipitation of Epac (Appendix 2).  Detection of CaMKII via IP is difficult due to 
CaMKII being similar weight to IgG heavy chain. Also, only active CaMKII 
(autophosphorylated) may be recruited to a signalosome requiring prolonged IP 
of phosphorylated CaMKII. 
Epac translocates from the cytoplasm to the plasma membrane under activation 
and therefore may only form functional complexes when active (Consonni et al. 
2012). To assess this we utilised two methods. Firstly, we utilised 8-AHA-2’-O-
Me-cAMP agarose beads, allowing pull-down of active Epac1 in complexes. 
However, 8-AHA-2’-O-Me-cAMP also binds PKARI, therefore PKARI is pulled-
down, potentially limiting the use of this technique for investigating exclusively 
Epac-based signalosomes (Aye et al. 2009).  
We recently explored the possible use of paraformaldehyde as an in-vivo 
crosslinker of protein-protein interactions, prior to standard immunoprecipitation. 
The use of a crosslinker allows “freezing” or fixation of potential dynamic and 
transient complexes, both of which we expect such signalling cascades to use. 
This method produces a snapshot of the intact complex, allowing possible 
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downstream identification of complex partners using immunoblot and mass 
spectrometry. The possible modification of paraformaldehyde is of concern for 
mass spectrometry analysis, due to the addition of a 12 Da modifications, 
however it has been shown that reversal of crosslinking by SDS-PAGE sample 
buffer is adequate to remove this (Vasilescu et al. 2004; Toews et al. 2008).  
AKAPs are commonly involved in cAMP signalling and we provide some 
evidence of AKAP expression in arterial beds. Previous studies on AKAPs in a 
number of tissue/cell preparations have been shown (Table 6.1). Validation of 
the exact products are required, however MW can sometimes be used as a 
possible indicator. In aortic tissue there appears to be bands at 80 kDa, 150 kDa 
and numerous between 45 and 60 kDa, potentially corresponding to AKAP100, 
AKAP150 and PKA RII (due to its expression in lysates and the use of anti-PKA 
RII antibody for detection). Certain AKAPs, such as AKAP100 and AKAP18, have 
been shown to have sarcoplasmic reticulum localisation (Lygren et al. 2007; 
McCartney et al. 1995). Further analysis utilising the PKARII/AKAP disruptor 
peptide HT-31 and its inactive analogue HT-31P, which contains two proline 
substitutions are needed, as is further AKAP identity validation (Carr et al. 1991).   
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7 General Discussion 
7.1 Overview 
A common feature of vasorelaxant pathways is the use of the second messenger 
cAMP to convey the relaxant signal from cell-surface receptors to downstream 
effectors.   In the vasculature, cAMP has three known effector proteins: PKA, 
CNGCs and Epac (Morgado et al. 2012).  Over the years, the relaxant effects of 
cAMP have been largely attributed to the activation of PKA and phosphorylation 
of downstream targets (de Rooij et al. 1998; Gloerich & Bos 2010).  More 
recently, reports show additional roles for Epac as a potent vasodilator and 
suggest an important vasorelaxant pathway that is distinct from the more 
traditional cyclic AMP-PKA axis (Stott et al. 2016; Zieba et al. 2011; Roberts et 
al. 2013).  Previous work from our lab has shown that Epac relaxes vascular 
smooth muscle by activating STOCs that hyperpolarize the cell membrane and 
reduce voltage-dependent Ca2+ influx (Roberts et al. 2013). How Epac activates 
STOCs is unknown and the central aim of this thesis was to define the signalling 
pathway by which Epac modulates STOC activity. 
Key novel findings discussed in this thesis include (Figure 7.1): 
(i) Epac increased STOC frequency and amplitude in rat mesenteric 
artery smooth muscle cells in a manner dependent upon the activation 
of CaMKII (Chapter 3);  
(ii) Epac activation preferentially induced auto-phosphorylation of specific 
CaMKII g isoform/s (Chapter 3);  
(iii) Epac-induced CaMKII activation was likely initiated by IP3-mobilized 
Ca2+ (Chapter 4);  
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(iv) Epac activation had little effect on intracellular Ca2+ store content, but 
it affected caffeine-induced store release, possibly due to changes in 
the kinetic behaviour or synchronous opening of RyRs (Chapter 5). 
 
Figure 7.1- Summary of the mechanism by which Epac activates STOCs in RMASMCs: 
A) Shown is the mechanism proposed by Roberts et al. (Roberts et al. 2013), in which 
Epac1 produces an increase in Ca2+ sparks and STOCs. B) Proposed mechanism by which 
Epac induces an increase in STOCs including data shown in this thesis. 
 
7.2 Physiological context & implications 
Within cells the major second messenger cAMP produces a number of 
physiological effects. These cellular effects are produced by the complex 
integration of 9 adenylyl cyclases, producing cAMP that is tightly controlled by 11 
cAMP destroying phosphodiesterases. This control produces cAMP hotspots 
within the cell, rather than the global cell-wide increase that would be seen due 
to a diffusion rate of 330 – 970 µm2/s (Agarwal et al. 2016). This 
compartmentalized cAMP then activates potentially four different effectors, each 
giving rise to varied downstream signalling pathways (Maurice et al. 2014). This 
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highly complex signalling mechanism allows extracellular messages to give rise 
to different and highly reproducible physiological events. Within vascular smooth 
muscle, cAMP regulates 3 cAMP effectors, PKA, Epac and CNGs. Differences 
between the in vitro cAMP concentration for activation of PKA and Epac (1µM vs 
50µM) has led some to predict that Epac signalling may represent a negative 
feedback mechanism that comes into effect at high cAMP levels, while others 
have shown that PKA and Epac work synergistically (Christensen et al. 2003; 
Poppe et al. 2008; Purves et al. 2009; Hewer et al. 2011). There is also the 
possibility that PKA and Epac are present in differing cAMP microdomains within 
cells, each with different concentrations of cAMP and therefore different levels of 
Epac/PKA activation.  Our pilot data presented in Appendix 2 (Section 8.2) 
suggests that Epac may indeed exist in multiprotein complexes that include 
RyRs. Future work will hopefully establish other partners and define whether 
these are distinct from PKA.   Epac signalosomes proved difficult to assess. We 
showed that immunoprecipitation of Epac1 with RIPA lysis buffer produced the 
largest amount of immunoprecipitated Epac1, possibly due to the increased 
power to lyse membranes/SR microsomes where Epac1 is present, as seen 
using crude fractionation by centrifugation (data not shown). However, such 
harsh lysis buffers, including detergents such as SDS, may easily dissociate 
transient, dynamic complexes. Further optimisation of cross-linking experiments 
may be required to explore the highly spatially regulated cAMP signalosome. 
The involvement of CaMKII in our pathways is also particularly interesting due to 
prior experiments showing CaMKII involvement in vascular smooth muscle 
contraction  (Kim et al. 2000; Rokolya & Singer 2000). The ability for CaMKII to 
mediate both relaxation and contraction either means that this enzyme has 
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different functional roles in different vascular beds, or that distinct pools of CaMKII 
exist that are activated by different stimuli.  CaMKII autonomous activity, whereby 
CaMKII activity is maintained in the absence of Ca2+/CaM, can be produced 
through various translational modifications, such as oxidation, nitrosylation and 
O-GlcNAcylation (Toussaint et al. 2016; Erickson et al. 2015; Erickson et al. 
2013).  Most important physiologically, in terms of vasorelaxation, may be 
regulation of CaMKII by NO. NO is a common mediator of relaxation in the 
vasculature, with it mediating the classical endothelium-dependent relaxation 
method. In cardiomyocytes and in vitro, CaMKII has been shown to be activated 
and inhibited by NO. I hypothesise that CaMKII that is activated to induce 
relaxation in cells may be potentiated by NO, whereas the CaMKII involved in 
contraction may be inhibited by NO, due to no prior activation of CaMKII. 
7.3 Limitations of the work 
A limitation of this work is the use of cAMP analogues to specifically activate 
Epac. This allows identification of downstream Epac signalling, but does not allow 
identification of endogenous hormones utilising Epac-dependent pathways. 
Follow on studies to this project should assess STOC activation by endogenous 
vasodilators in the presence of selective PKA inhibition. This must not be limited 
to a single vasodilator, as physiological Epac-mediated STOC effects may be 
due to a specific pool of cAMP, activated by a specific receptor type. 
While we do not show the physiological relevance of Epac, other studies have 
utilised either PKA inhibition or Epac inhibition in response to endogenous 
vasodilators to show Epac involvement. In different vascular beds, b-adrenergic 
and prostacyclin-induced elevation of cAMP changes the sensitivity of the 
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contractile proteins through Rap-initiated alteration of myosin light chain 
phosphorylation  (Roscioni et al. 2011; Zieba et al. 2011; Sukhanova et al. 2006). 
Epac knockout has been shown to affect vascular permeability, both basally and 
upon treatment with atrial naturetic peptide (ANP), which increases permeability 
(Cullere et al. 2005; Kopperud et al. 2017; Birukova et al. 2008).  Knockout 
studies have also shown Epac to be physiologically relevant within the heart, 
involved in b-adrenergic-mediated hypertrophy (Epac1) and modulation of Ca2+ 
spark /proarrhythmic events (Epac2) (Pereira et al. 2015; Pereira et al. 2013; 
Oestreich et al. 2009; Ruiz-Hurtado et al. 2013; Pereira et al. 2007).  
All of the work presented in this thesis is undertaken in rat or mouse vascular 
tissue, and therefore further research of this mechanism in human tissue/cells to 
identify the potential as a therapeutic target is needed. To this end, we initially 
explored the possible use of human coronary artery smooth muscle cells. 
However, under normal cell culture conditions no STOCs were present, nor could 
they be induced by cell culture medium manipulation (such as serum deprivation) 
that increased contractile markers (Humphries 2013). This suggests that 
phenotypic and morphological changes associated with placing smooth muscle 
cells in culture disrupts the intricate intracellular architecture required to maintain 
spark/STOC coupling. 
7.4 Therapeutic Possibilities 
With Epac expression being shown in tissues such as the pancreas, heart and 
vasculature, global activation of Epac will most probably lead to off-target effects 
in the form of abnormal glucose regulation and sinus rhythm. Recently, targeting 
the interaction of Epac with complex partners (particularly PDEs) has been 
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utilised as an alternative strategy  (Wilson et al. 2011; Maurice et al. 2014; 
Rampersad et al. 2010). As seen in many cAMP signalosomes there are 
commonly AKAPs, cAMP effectors and  PDEs, which degrades the cAMP signal; 
targeting the activity of the PDE is seen as a therapeutic target to maintain or 
increase activation of a specific cAMP effector within the signalosome. Currently, 
two PDE-Epac interaction inhibitors have been shown to increase Epac 
activation, and with it increase endothelial tube formation and increase 
endothelial barrier integrity (Wilson et al. 2011; Rampersad et al. 2010). Further 
work is needed to assess the viability of Epac-PDE disruption in vivo and in 
pathophysiological situations, but this project holds real promise. These 
disruptors both rely on peptide-based disruption, which while adequate in 
preliminary basic biomedical research, may not translate to the clinic due to poor 
permeability and poor bioavailability (Maurice et al. 2014). Other cAMP 
signalosomes have been targeted involving the interaction of PKA to AKAPs, 
including non-peptide based small molecule disruptors (Christian et al. 2011).  
7.5 Remaining Questions and Future work 
Important remaining questions that lead on from this project are: 
• Does post-translational modifications of CaMKII such as oxidation, s-
nitrosylation or glycosylation affect Epac-mediated CaMKII activation? 
• Within vascular smooth muscle is Epac within a dynamic signalling 
complex? If so, what are the protein complex partners? 
• Does Epac activation take place under basal (myogenic tone) or under 
vasodilatory agonists? If so what are the roles in both the endothelial and 
smooth muscle in regard to each vasodilatory agonist? 
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• Is the modulation of Epac1 in vascular smooth muscle a potential 
therapeutic target for arterial diseases such as idiopathic hypertension or 
secondary hypertension? 
• Finally, and perhaps most fundamentally, what is the physiological 
relationship between Epac and PKA? 
This final point highlights the apparent complexity of cAMP signalling whereby 
two cAMP effectors produce opposing and synergistic effects in numerous cells, 
including vascular smooth muscle and endothelial cells. Understanding this 
interaction between the two and elucidating their roles may prove vital for 
treatment of arterial disease, and numerous other diseases involving cAMP 
signalling. 
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8.1 Appendix 1 – Smooth Muscle AKAPs 
Table 8.1- Smooth Muscle AKAPs 
Name Alias Localisation 
Smooth 
muscle 
expression? 
Dual 
AKAP Action Refs 
AKAP1 
AKAP149, 
AKAP121 
(human) 
AKAP82 
(Rat) 
D-AKAP1 
ER 
Mitochondria 
Yes 
(mRNA) 
(Horvat et al. 
2012) 
Yes 
Binds PP1, Tubulin, AMY1, PPD1, mRNA, 
VEGFR, 
Cardiac hypoxic response by inhibiting 
dephosphorisation of DRP1. 
Knockdown produced cardiac hypertrophy 
 
(Ma & Taylor 
2008; Horvat et 
al. 2012; Kim et 
al. 2011) 
AKAP10 D-AKAP2 Mitochondria No Yes Endocytosis via Rab4 and Rab11. (Eggers et al. 2009) 
AKAP2 AKAP220 Cancers 
Yes 
(Horvat et al. 
2012) 
Yes 
Calcitonin mediated cancer cell tumourisity 
and metastatic ability. 
Involved in developmental processes 
(Li et al. 
2016)(Thakkar et al. 
2016) 
AKAP3 AKAP110 Testis Cancers 
Yes 
(Horvat et al. 
2012) 
Yes 
Expressed in normal testis only 
Biomarker for triple negative breast 
cancer/ovarian cancer. 
Sperm mobility through tyrosine 
phosphorylation of AKAP3. 
(Esmaeili et al. 
2015; Sharma et al. 
2016; Xu & Qi 2014; 
Luconi 2005; Horvat 
et al. 2012) 
AKAP4 AKAP82 Testis Cancers No No 
Colon cancer cell line proliferation, migration, 
invasion & apoptosis. 
Biomarker for breast cancer 
Sperm motility 
(Saini et al. 
2013; Jagadish et al. 
2015; Miki et al. 
2002) 
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AKAP5 
AKAP75 
AKAP79 
(humans) 
AKAP150 
(rodents) 
Neurones 
(dendritic 
compartments) 
Smooth 
muscle cells 
Cardiomyocy
tes 
Yes 
(Horvat et al. 
2012) 
No 
Neuronal electrophysiology causing 
behavioural changes. 
Interacts:PP2A,PSD95,AC5/6,LTCC,b-
adrenergic receptors & Cav-3. 
b-adrenoceptor Ca2+ handling & ECC KO mice 
caused cardiac hypertrophy. 
AKAP150/TRPV4 involvement in endothelial 
dependent relaxation. 
Hyperglycaemic BKCa channel suppression via 
calcineruin. 
Form a complex with Cav1.2 (LTCC) and 
BKca. 
PKB/Akt regulation in neurones 
Diabetes/Glucose regulation by binding of 
calcineurin. 
(Nichols et al. 
2010; Weisenhaus et 
al. 2010; Li et al. 
2014; Sonkusare et 
al. 2014; Nystoriak et 
al. 2013; Nijholt et al. 
2008; Liu et al. 2004) 
AKAP6 mAKAP AKAP100 
Heart 
Skeletal 
Muscle 
Brain 
No No 
Skeletal muscle differentiation and repair. 
Involved in cardiac hypertrophy via a 
Epac1,PKA, PDE4D3 containing complex. 
Involved in the hypoxic response mediated by 
HIF-1a 
(Dodge-Kafka et 
al. 2005; Lee et al. 
2015; Wong et al. 
2008) 
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8.2 Appendix 2 – Possible interaction between RyR and 
Epac1 
 
 
Figure 8.1- Epac1 possibly co-immunoprecipitates with RyR in mesenteric 
arteries. RyR immunoprecipitation using RyR (34C) was used as in cardiac tissue to 
immunoprecipitate RyR. Immunoblots using Epac1 (CST) showed a possible co-
immunoprecipitation of RyR and Epac.  
 
 
 
 
 
 
 
 
 
 
 
